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3Three years after the last global assessment of Amphetamine-Type Stimulants (ATS), the manufacture and trafficking 
of these drugs remains a serious and constantly evolving challenge. The 2011 Global ATS Assessment shines a pow-
erful light on ATS helping governments to better understand this important phenomenon.
Once viewed as purely a cottage industry, ATS manufacture and trafficking has undergone its own industrial revolu-
tion. After cannabis, ATS are the second most widely used drugs across the globe outstripping the use of heroin or 
cocaine. ATS are now manufactured and marketed with organized crime groups involved throughout the production 
and supply chain. 
Until recently, the ATS trade was sometimes ignored in favour of the traditional focus on heroin and cocaine. But 
there is growing recognition that the expansion of the ATS trade and its high profits threaten security, health and 
the welfare of populations across the globe. 
While seizures of heroin, cocaine and cannabis remained largely stable between 2005 and 2009, ATS seizures, 
excluding ecstasy, showed a clear increase over the same period. In South-East Asia, for example, the number of 
methamphetamine pills seized grew significantly: from 32 million in 2008, to 93 million in 2009 and 133 million in 
2010. 
Injecting ATS use is also growing and increasing the risk of blood borne diseases such as HIV/AIDS. In Thailand, 
injecting is the second most common delivery system for ATS, while in New Zealand it is the most commonly injected 
drug. Injecting use is also now commonplace in some countries in Europe. 
In addition to amphetamines and ecstasy, established ATS markets have seen the emergence of so-called analogue 
substances falling outside of international control. Substances such as mephedrone or methylenedioxypyrovalerone 
(MDPV) are sold as ‘bath salts’ or ‘plant food’ and act as substitutes for illicit stimulant drugs such as cocaine or 
ecstasy. 
ATS are attractive to millions of drug users in all regions of the world because they are affordable, convenient to 
the user and often associated with a modern and dynamic lifestyle. Their risks are often underestimated in public 
perception. 
In terms of the overall number of ATS users in the last twelve months, this appears to have stabilised, but there were 
increases in some parts of the world where there were few problems with ATS. 
Such developments make ATS tidal by nature; rising and falling as demand increases and decreases around the 
globe. This also explains why the Assessment shows regions suffering high-tides or low-tides in ATS terms with the 
transition often occurring in extremely short periods of time. Most importantly, the flow of ATS trafficking exploits 
vulnerable states, often weakened by instability and insecurity. 
ATS manufacture has also expanded into new regions and there has been a diversification of the drug’s precursor 
chemicals and manufacturing methods. Additional countries in South-East Asia now report ATS manufacture, as 
well as the growth of interregional trafficking in countries with no previous history of the drug. 
Methamphetamine may also be expanding into Europe with several countries reporting an increase in its use and 
production. Illicit laboratories have been seized in many European countries. There are also signs that the drug may 
be replacing amphetamine in some parts of Europe. 
Once thought to be largely unaffected by the illicit manufacture and trafficking of ATS, West Africa has now been 
drawn into the trade’s orbit. Methamphetamine manufacture has been reported from Nigeria. Since 2008, seizures 
in several East Asian countries —notably Japan and the Republic of Korea—appear to have their origin in West 
Africa. ATS manufacture is also increasingly reported from Central America and South America. 
preface
42011 GLoBaL ATS ASSESSMENT
Data	is	fundamental	to	understanding	the	ebbs	and	flows	of	ATS.	Using	its	Global	Synthetics	Monitoring:	Analyses	
Reporting	and	Trends	(SMART)	programme,	UNODC	has	a	system	for	watching	the	drug’s	tidal	movements	in	some	
regions	of	the	world.	Thanks	to	the	programme,	there	is	more	knowledge	and	therefore	a	better	understanding	of	
the	problem;	in	turn,	this	will	assist	Governments	in	the	formulation	of	effective	responses.	However,	gaps	remain.	
To	deal	with	this	challenge,	UNODC	is	ensuring	that	the	twin-related	threats	of	drug	trafficking	and	Transnational	
Organised	Crime	are	mainstreamed	throughout	the	United	Nations	system,	mobilizing	joint	action	and	creating	a	
vision	for	the	effective	delivery	of	solutions.	These	activities	at	the	international	level	should	also	help	stem	the	ATS	
tide.	
Finally,	I	would	like	to	thank	the	donors	who	supported	this	initiative	and	who	made	this	Assessment	possible.	Fur-
ther	 investment	 is	necessary,	 if	we	are	to	build	on	this	Assessment	and	gain	a	clearer	appreciation	of	this	global	
problem.	
Yury	Fedotov
Executive	Director
United	Nations	Office	on	Drugs	and	Crime
5This	report	has	not	been	formally	edited.	
The	designations	employed	and	the	presentation	of	the	material	 in	this	publication	do	not	imply	the	expression	of	any	
opinion	whatsoever	on	the	part	of	the	Secretariat	of	the	United	Nations	concerning	the	legal	status	of	any	country,	terri-
tory,	city	or	area	or	of	its	authorities,	or	concerning	the	delimitation	of	its	frontiers	or	boundaries.	Countries	and	areas	are	
referred	to	by	the	names	that	were	in	official	use	at	the	time	the	relevant	data	were	collected.
The	 following	notes	describe	 certain	 terms,	 regional	 designations,	 data	 sources	 and	 timeframes	used	 throughout	 this	
document.
ats	–	Amphetamine-type	stimulants	(ATS)	are	a	group	of	substances	comprised	of	synthetic	stimulants	including	amphet-
amine,	methamphetamine,	methcathinone,	and	ecstasy-group	substances	(e.g.,	MDMA	and	its	analogues).
In	various	sections	of	this	report,	amphetamine	and	methamphetamine	are	also	referred	to	as	amphetamines-group	sub-
stances.	 In	cases	where	countries	 report	 to	UNODC	without	 indicating	the	specific	ATS	they	are	referring	to,	 the	term	
non-specified	amphetamines	is	used.	Tablets	which	are	marketed	to	contain	an	ecstasy-group	substance,	but	may	actually	
contain	a	variety	of	other	substances,	are	referred	to	as	ecstasy.
terms:	Since	there	is	some	scientific	and	legal	ambiguity	about	the	distinctions	between	drug	'use',	'misuse'	and	'abuse',	
this	report	uses	the	neutral	terms,	drug	'use'	or	'consumption'.	
maps: The	boundaries	and	names	shown	and	the	designations	used	on	maps	do	not	imply	official	endorsement	or	accept-
ance	by	the	United	Nations.	A	dotted	line	represents	approximately	the	line	of	control	in	Jammu	and	Kashmir	agreed	upon	
by	 India	and	Pakistan.	The	final	status	of	 Jammu	and	Kashmir	has	not	yet	been	agreed	upon	by	the	parties.	Disputed	
boundaries	(China/India)	are	represented	by	cross	hatch	due	to	the	difficulty	of	showing	sufficient	detail.	
Population data: Population	data	used	in	this	report	comes	from:	United	Nations,	Department	of	Economic	and	Social	
Affairs,	Population	Division.	World	Population	Prospects:	The	2008	Revision,	2009.	
regions:	In	various	sections,	this	report	uses	a	number	of	regional	designations.	These	are	not	official	designations.	They	
are	defined	as	follows:	
AFRICA
•• East	Africa:	Burundi,	Comoros,	Djibouti,	Eritrea,	Ethiopia,	Kenya,	Madagascar,	Mauritius,	Rwanda,	Seychelles,	
Somalia,	Tanzania	(United	Republic	of)	and	Uganda
•• North	Africa:	Algeria,	Egypt,	Libyan	Arab	Jamahiriya,	Morocco,	Sudan	and	Tunisia
•• Southern	Africa:	Angola,	Botswana,	Lesotho,	Malawi,	Mozambique,	Namibia,	South	Africa,	Swaziland,	Zambia	
and	Zimbabwe
•• West	and	Central	Africa:	Benin,	Burkina	Faso,	Cameroon,	Cape	Verde,	Central	African	Republic,	Chad,	Congo	
(Democratic	Republic	of),	Congo	(Republic	of),	Côte	d’Ivoire,	Equatorial	Guinea,	Gabon,	Gambia,	Ghana,	Guinea,	
Guinea-Bissau,	Liberia,	Mali,	Mauritania,	Niger,	Nigeria,	Sao	Tome	and	Principe,	Senegal,	Sierra	Leone,	Togo
AMERICAS
•• Caribbean:	Antigua	and	Barbuda,	Bahamas,	Barbados,	Bermuda,	Cuba,	Dominica,	Dominican	Republic,	Grenada,	
Haiti,	Jamaica,	Saint	Kitts	and	Nevis,	Saint	Lucia,	Saint	Vincent	and	the	Grenadines,	Trinidad	and	Tobago
•• Central	America:	Belize,	Costa	Rica,	El	Salvador,	Guatemala,	Honduras,	Nicaragua,	Panama
•• North	America:	Canada,	Mexico,	United	States	of	America	(USA)	
•• South	America:	Argentina,	Bolivia	(Plurinational	State	of),	Brazil,	Chile,	Colombia,	Ecuador,	Guyana,	Paraguay,	
Peru,	Suriname,	Uruguay,	Venezuela	(Bolivarian	Republic	of)
expLanatory notes
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ASIA
•• Central	Asia	and	Transcaucasia:	Armenia,	Azerbaijan,	Georgia,	Kazakhstan,	Kyrgyzstan,	Tajikistan,	Turkmenistan,	
Uzbekistan
•• Near	and	Middle	East/South-West	Asia:	Afghanistan,	Bahrain,	Islamic	Republic	of	Iran,	Iraq,	Israel,	Jordan,	Kuwait,	
Lebanon,	Oman,	Pakistan,	Qatar,	Saudi	Arabia,	Syrian	Arab	Republic,	United	Arab	Emirates	(UAE),	Yemen
•• East	and	South-East	Asia:	Brunei	Darussalam,	Cambodia,	China	(including	Hong	Kong,	Macao	and	Taiwan	Prov-
ince	of	China),	Indonesia,	Japan,	Republic	of	Korea,	Lao	PDR,	Malaysia,	Mongolia,	Myanmar,	Philippines,	Singa-
pore,	Thailand,	and	Viet	Nam
–	Greater	Mekong	Subregion	(GMS):	Cambodia,	Lao	PDR,	Myanmar,	Thailand,	Viet	Nam,	and	bordering	prov-
inces	of	China
–	North-East	Asia:	Japan,	Philippines,	Republic	of	Korea	
–	Southern	Archipelago:	Brunei	Darussalam,	Indonesia,	Malaysia	and	Singapore	
•• South	Asia:	Bangladesh,	Bhutan,	India,	Maldives,	Nepal	and	Sri	Lanka
EUROPE
•• East	Europe:	Belarus,	Republic	of	Moldova,	Russian	Federation	and	Ukraine
•• South-East	Europe:	Albania,	Bosnia	and	Herzegovina,	Bulgaria,	Croatia,	Montenegro,	Romania,	Serbia,	the	former	
Yugoslav	Republic	of	Macedonia	and	Turkey	
•• West	and	Central	Europe:	Andorra,	Austria,	Belgium,	Cyprus,	Czech	Republic,	Denmark,	Estonia,	Finland,	France,	
Germany,	Greece,	Hungary,	Iceland,	Ireland,	Italy,	Latvia,	Liechtenstein,	Lithuania,	Luxembourg,	Malta,	Monaco,	
Netherlands,	Norway,	Poland,	Portugal,	San	Marino,	Slovakia,	Slovenia,	Spain,	Sweden,	Switzerland	and	United	
Kingdom	
OCEANIA
•• Oceania:	Australia,	Fiji,	Kiribati,	Marshall	 Islands,	Micronesia,	Nauru,	New	Zealand,	Palau,	Papua	New	Guinea,	
Samoa,	Solomon	Islands,	Tonga,	Tuvalu,	Vanuatu,	and	other	Pacific	island	states	and	territories	
data sources and timeframes	–	Unless	indicated	specifically,	data	contained	in	this	report	draw	upon	official	sources	
as	reported	in	the	UNODC	Annual	Reports	Questionnaire	(ARQ)	by	Member	States,	annual	and	technical	reports	of	the	
International	Narcotics	Control	 Board	 (INCB),	 official	 government	 and	 inter-governmental	 entities	 (e.g.,	 Interpol/ICPO,	
Europol,	World	Customs	Organization,	Inter-American	Drug	Abuse	Control	Commission	of	(CICAD),	UNODC	Field	Office	
and	HONLEA	reports,	data	systems	(e.g.,	DAINAP,	CEN)	and	the	scientific	literature.	
Data	related	to	seizures	of	ATS,	their	precursors	and	clandestine	laboratories	are	subject	to	change	for	a	variety	of	reasons,	
such	as	new	or	late	data	being	added	or	revisions	in	data	already	provided	by	Member	States.	Thus,	some	figures	may	
differ	from	previously	published	figures.	All	data	reported	herein	reflect	the	most	up-to-date	and	accurate	 information	
available	at	the	time	of	writing.
7aBBreviations
the following abbreviations have been used in this report:
ACC Australian	Crime	Commission
ACCORD ASEAN	and	China	Cooperative	Operations	in	Response	to	Dangerous	Drugs
ADK National	Anti-Drugs	Agency,	Malaysia
ADLOMICO Anti-Drug	Liaison	Officials’	Meeting	for	International	Cooperation
AFP Australian	Federal	Police
AIDS	 Acquired	Immune-Deficiency	Syndrome
AIHW Australian	Institute	of	Health	and	Welfare
AIPAC Asia	Pacific	Amphetamine-Type	Stimulants	Information	Centre
ARQ	 UNODC	Annual	Reports	Questionnaire
ASEAN Association	of	Southeast	Asian	Nations
ATS	 Amphetamine-type	stimulants
BMK	 Benzyl	methyl	ketone	(P-2-P)
BNN National	Narcotics	Board,	Indonesia
BZP	 Benzylpiperazine
CCDAC Central	Committee	for	Drug	Abuse	Control,	Myanmar
CEN World	Customs	Organization’s	Customs	Enforcement	Network
CICAD	 Inter-American	Drug	Abuse	Control	Commission
CIS	 Commonwealth	of	Independent	States
DAINAP Drug	Abuse	Information	Network	for	Asia	and	the	Pacific
DCHQ National	Drug	Control	Headquaters	(Islamic	Republic	of	Iran)
DEA	 Drug	Enforcement	Administration	(USA)
DELTA	 UNODC	Database	on	Estimates	and	Long	Term	Trend	Analysis
EMCDDA	 European	Monitoring	Centre	for	Drugs	and	Drug	Addiction
ESPAD	 European	School	Survey	Project	on	Alcohol	and	other	Drugs
Europol European	Police	Office
Govt.	 Government
HIV	 Human	Immunodeficiency	Virus
HKNB Hong	Kong	Special	Administrative	Region	of	the	People's	Republic		
of	China	Narcotics	Bureau
HKSB Hong	Kong	Special	Administrative	Region	of	the	People's	Republic		
of	China	Security	Bureau
HONLEA Heads	of	National	Drug	Law	Enforcement	Agencies
ICMP	 UNODC	Global	Illicit	Crop	Monitoring	Programme
IDU Injecting	drug	use
INCB	 International	Narcotics	Control	Board
INCSR	 International	Narcotics	Control	Strategy	Report	(USA)
Interpol/ICPO	 International	Criminal	Police	Organization
JCITAC	 Japan	Customs	Intelligence	&	Targeting	Center
JMHCW	 Ministry	of	Health,	Labour	and	Welfare	(Japan)
JNPA	 National	Police	Agency	of	Japan
L-PAC l-phenylacetylcarbinol
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LCDC Lao	National	Commission	for	Drug	Control	and	Supervision
LSD Lysergic	acid	diethlyamide
MBDB	 N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine
MDA	 3,4-Methylenedioxyamphetamine	(tenamfetamine)
mCPP	 m-chlorophenylpiperazine
MDE 3,4-Methylenedioxyethylamphetamine
MDMA	 3,4-Methylenedioxymethamphetamine
MOHNZ	 Ministry	of	Health	(New	Zealand)
NACD National	Authority	for	Combating	Drugs,	Cambodia
NDARC	 National	Drug	and	Alcohol	Research	Centre	(Australia)
NDIC	 National	Drug	Intelligence	Center	(USA)
NDLEA	 National	Drug	Law	Enforcement	Agency	(Nigeria)
NGO	 Non-Governmental	Organization
NIDA	 National	Institute	of	Drug	Abuse	(USA)
NNCC	 National	Narcotics	Control	Commission	(China)
OAS/CICAD/MEM	 Organization	of	American	States/Inter-American	Drug	Abuse	Control	Commission/	
Multilateral	Evaluation	Mechanism
OECD Organization	for	Economic	Co-operation	and	Development	
ONCB	 Office	of	the	Narcotics	Control	Board	(Thailand)
P-2-P	 1-Phenyl-2-propanone	(BMK)
PEN International	Narcotics	Control	Board’s	Pre-Export	Notification	online	system	
PDEA	 Philippines	Drug	Enforcement	Agency
PMK 3,4-Methylenedioxyphenyl-2-propanone	(3,4-MDP-2-P)
RCMP	 Royal	Canadian	Mounted	Police
SACENDU South	African	Community	Epidemiology	Network	on	Drug	Use
SAMHSA	 Substance	Abuse	and	Mental	Health	Services	Administration	(USA)
SAPS	 South	African	Police	Service
SHORE Centre	for	Social	and	Health	Outcomes	Reserach	and	Evaluation	(New	Zealand)
SOCA Serious	Organised	Crime	Agency	(United	Kingdom)
SODC Standing	Office	on	Drugs	and	Crime	(formerly	Standing	Office	on	Drugs	Control),	Viet	Nam
SPO Supreme	Prosecutor’s	Office,	Republic	of	Korea
TFMPP 3-trifluoromethylphenyl-piperazine
UAE United	Arab	Emirates
UNAIDS	 Joint	and	Co-sponsored	United	Nations	Programme	on	Human	Immunodeficiency	Virus/
Acquired	Immunodeficiency	Syndrome
UNDCP	 United	Nations	International	Drug	Control	Programme
UNODC	 United	Nations	Office	on	Drugs	and	Crime
WCO	 World	Customs	Organization
WDR UNODC	World	Drug	Report
WHO	 World	Health	Organization
1988	Convention	 United	Nations	Convention	Against	Illicit	Traffic	in	Narcotic	Drugs	and		
Psychotropic	Substances,	1988
2C-B	 4-Bromo-2,5-dimethoxyphenethylamine	(Nexus)
2C-T-2	 4-Ethylthio-2,5-dimethoxyphenethylamine
3,4-MDP-2-P	 3,4-Methylenedioxyphenyl-2-propanone	(PMK)
4-MTA	 4-Methylthioamphetamine
Weights  and measurements 
u.	 unit
lt.	 litre
g/mg gram/milligram
kg	 kilogram
mt	 metric	ton
executive summary
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Amphetamine-type	stimulants	(ATS)	are	firmly	established	on	global	illicit	drug	markets	and	their	use	continues	to	exceed	
that	of	opiates	or	cocaine.	While	the	number	of	people	who	have	used	ATS	at	least	once	in	the	last	12	months	has	sta-
bilized	at	the	global	level,	increases	have	occurred	in	parts	of	the	world	that	previously	had	only	very	small	ATS-related	
problems.	
The	widespread	use	of	ATS	is	a	result	of	their	attractiveness	to	users:	they	seem	to	appeal	to	the	needs	of	today’s	societies	
and	have	become	part	of	what	 is	perceived	 to	be	a	modern	and	dynamic	 lifestyle;	 in	 some	segments	of	 society,	 they	
continue	to	be	used	frequently	for	occupational	purposes.	It	is	also	a	result	of	a	market	potential	with	continuously	high	
profits	and	low	risks	that	maintain	their	attractiveness	to	criminal	groups	around	the	world.	
Since	the	last	global	ATS	assessment	was	published	in	2008,1	there	have	been	several	new	developments.		
The	report	provides	evidence	for	these	developments	since	2008,	with	a	special	focus	on	subregional	patterns	and	trends,	
and	highlights	the	challenges	ahead.
expansion of ats manufacture to neW reGions
ATS	are	attractive	to	clandestine	operators	because	there	are	no	geographical	limitations	to	where	they	can	be	manufac-
tured,	there	is	a	large	variety	of	starting	materials	and	manufacturing	methods,	and	they	offer	considerable	profits.	
Amphetamines-group	substances,	(i.e.	amphetamine	and	methamphetamine)	account	for	most	ATS	manufactured	world-
wide,	while	the	manufacture	of	ecstasy-group	substances	(i.e.	MDMA,	MDA,	MDE)	is	significantly	less	widespread.	On	a	
global	scale,	after	strong	increases	peaking	in	2004,	the	number	of	illicit	laboratories2	declined	until	2007	and	increased	
in	2008	and	2009.	
Over	the	past	five	years,	ATS	manufacture	has	spread	to	new	regions	which	previously	reported	little	or	no	manufacture.	
In	South-East	Asia,	for	example,	Indonesia,	Malaysia	and,	to	a	lesser	extent,	Cambodia	used	to	be	primarily	transit	coun-
tries	for	ATS	but	now	report	significant	illicit	ATS	manufacture,	primarily	of	methamphetamine	and	ecstasy.	Indonesia	has	
reported	a	considerable	number	of	seizures	of	 large	sophisticated	illicit	 laboratories	manufacturing	crystalline	metham-
phetamine	and	ecstasy.	In	2009,	drug	law	enforcement	authorities	in	Indonesia	dismantled	a	total	of	37	ATS	manufactur-
ing	 operations.	 The	 continuing	 high	 levels	 of	 ecstasy	manufacture	 in	 Indonesia	 raise	 concern	 that	 the	 country	 could	
replace	Europe	as	the	source	of	MDMA	in	the	region.	Similar	developments	have	occurred	in	Malaysia,	which	used	to	be	
a	transit	country	for	small	amounts	of	crystalline	methamphetamine,	ecstasy	and	ketamine	destined	for	Australia,	China,	
Indonesia,	Japan,	Singapore	and	Thailand.	In	the	meantime,	Malaysia	has	become	a	significant	methamphetamine	manu-
facturing	location	and	this	demonstrates	the	speed	with	which	shifts	in	patterns	of	clandestine	manufacture,	trafficking	
and	use	can	occur.	Since	2008,	Malaysian	authorities	have	reported	the	dismantling	of	more	than	30	large	and	small-scale	
ATS	manufacturing	laboratories.	In	Cambodia,	official	reports	of	illicit	ATS	manufacture	first	emerged	in	2007	when	police	
dismantled	a	large-scale	laboratory	that	was	reported	to	have	manufactured	at	least	1	mt	of	chloropseudoephedrine,	an	
intermediate	in	the	manufacture	of	methamphetamine.	Illicit	ATS	manufacture	in	the	country	has	since	increased	consid-
erably.	ATS	manufacture	or	attempts	to	manufacture	have	also	been	reported	from	China	(including	Hong	Kong	SAR),	
Japan,	Republic	of	Korea	and	Thailand.
Reports	 of	ATS	manufacture	 have	 also	 emerged	 from	 countries	 in	Central	America	 and	 South	America.	 Six	 illicit	 ATS	
laboratories	were	 reported	seized	 in	2009.	However,	as	ATS	data	 from	the	 region	 is	 in	short	 supply,	partly	due	 to	 the	
traditional	focus	of	drug	control	authorities	on	traditional	drugs	such	as	cocaine	and	cannabis,	 it	 is	 likely	that	the	true	
situation	is	underreported.	ATS	manufacture	has	been	reported	from	Argentina,	Belize,	Brazil,	Guatemala,	Nicaragua	and	
Suriname.
1	 Accessible	at:	http://www.unodc.org/documents/scientific/ATS/Global-ATS-Assessment-2008-Web.pdf
2	 Includes	laboratories	of	any	size	and	state	of	operation,	as	well	as	waste	dumpsites	and	chemical	and	glassware	seizures	(‘warehouses’).
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For	a	long	time,	West	Africa	was	one	of	the	world’s	subregions	which	appeared	to	have	been	largely	unaffected	by	the	
illicit	manufacture,	trafficking	and	use	of	ATS.	However,	since	2008,	an	increase	in	methamphetamine	seizures	in	countries	
in	East	Asia	(primarily	Japan	and	Republic	of	Korea),	has	pointed	to	possible	manufacture.	In	2009,	evidence	of	possible	
ATS	manufacture	was	discovered	 in	Guinea	and	 in	2010,	 the	United	States	Government	 indicted	members	of	a	 large	
international	cocaine	trafficking	organization,	for,	inter alia,	the	intent	to	establish	an	illicit	laboratory	in	Liberia	for	large-
scale	manufacturing	of	methamphetamine.	In	June	2011,	a	methamphetamine	laboratory	was	discovered	in	Nigeria,	on	
the	outskirts	of	Lagos.	The	laboratory	had	an	estimated	capacity	of	160-200	kg	of	crystalline	methamphetamine	per	week.
In	the	Near	and	Middle	East/South-West	Asia	subregion,	the	Islamic	Republic	of	Iran	first	reported	illicit	manufacture	of	
methamphetamine	in	2008.	The	substance	is	used	locally	but	also	subsequently	trafficked	mostly	to	markets	in	East	and	
South-East	Asia.	 Strong	 increases	 in	amphetamine	 seizures,	mostly	 in	 the	 form	of	Captagon,3	 in	 some	countries,	 e.g.	
Jordan,	the	Syrian	Arab	Republic	and	the	United	Arab	Emirates	might	also	point	to	possible	manufacturing	activity	in	the	
region.	 Some	 law	 enforcement	 intelligence	 suggests	 that	manufacture	 of	 amphetamine	 (Captagon)	 has	 shifted	 from	
South-East	Europe	to	countries	in	the	Near	and	Middle	East.	The	decline	in	amphetamine	seizures	in	Bulgaria	and	Turkey	
would	support	this	development.	Several	countries	in	the	region	also	have	unusually	high	requirements	for	ATS	precursors	
such	as	ephedrine,	pseudoephedrine	or	P-2-P.	However,	aside	from	the	Islamic	Republic	of	Iran,	no	reports	of	illicit	manu-
facture	have	been	received	from	the	region	to	date.	
Due	to	stricter	controls	over	precursor	chemicals	necessary	to	manufacture	ATS	(particularly	ephedrine	and	pseudoephe-
drine	in	bulk	form),	traffickers	have	been	seeking	to	obtain	precursor	chemicals	in	different	physical	forms	to	avoid	detec-
3	 Captagon	was	originally	the	trade	name	for	fenetylline,	a	synthetic	stimulant.	Analysis	of	seized	Captagon	pills	show	that	most	contain	amphetamine	and	
other	ingredients	such	as	caffeine	and	theophylline.
intrinsic characteristics of ats contributing to their attractiveness vis-à-vis 
the traditional plant-based drugs heroin and cocaine:
on the demand side
•• ATS are attractive because they are perceived as enhancing performance and communication and have come to 
embody a modern and fashionable lifestyle (the extent to which ATS are used for occupational or recreational 
purposes depends on the specific substance);
•• ATS can be taken orally. In addition to being ‘convenient’ for the user, the use of pills also avoids injection or 
smoking and the dangers of social stigma associated with these administration routes;
•• ATS are affordable (available on retail markets in single pill units);
•• The recreational use of ATS is generally perceived as not being very harmful, and controllable; public health risks 
of ATS are frequently underestimated in public perception, as well as in the judicial and enforcement areas;
on the supply side
•• ATS are attractive because of high profits: with little initial investment, hugely profitable quantities of drugs can 
be manufactured;
•• ATS can be made readily from a variety of starting materials (precursors) using a variety of synthesis methods. 
When a traditional precursor becomes unavailable, the desired precursor may itself be synthesized from a pre-
precursor chemical;
•• ATS manufacture is not limited to certain geographic locations. It can take place anywhere, be easily camou-
flaged, and be relocated as enforcement pressure increases (e.g. makeshift laboratories set up to supply a single 
order and then dismantled to prevent detection);
•• Because there are no geographical limitations, ATS laboratories can be located close to the areas of consump-
tion, thus minimizing the risk of detection when trafficking end-products across international borders;
•• Awareness of ATS end-products and/or their precursors is still limited in some parts of the world where other 
drugs prevail, thus minimizing the risk for illicit operators and trafficking groups;
•• For operators of small-scale ‘kitchen’ laboratories (typically methamphetamine laboratories), ATS are attractive 
because manufacture does not usually require advanced knowledge of chemistry and can be accomplished by 
anyone from readily available chemicals. 
(Information drawn partly from previous UNODC publications: Understanding clandestine synthetic drugs (2001) and Ecstasy and amphetamines 
- Global survey 2003)
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tion.	Ephedrine	or	pseudoephedrine	are	obtained	in	the	form	of	pharmaceutical	preparations	(nasal	decongestants)	by	
diversion	from	local	pharmacies	and	subsequently	trafficked	around	the	world.	Traffickers	have	also	resorted	to	alternative	
manufacturing	methods,	which	typically	involve	either	synthesizing	necessary	chemicals	from	others	more	easily	available	
or	bypassing	their	use	entirely.
Ephedrine	and	pseudoephedrine	used	to	be	the	preferred	starting	materials	for	the	illicit	manufacture	of	methampheta-
mine.	However,	with	access	 to	these	substances	curtailed	by	more	effective	controls,	 traffickers	have	resorted	to	using	
P-2-P	as	the	starting	material.	In	Australia,	for	example,	an	increase	in	the	number	of	laboratories	using	P-2-P	as	a	precur-
sor	in	the	synthesis	of	amphetamines	was	reported	in	2009.	Phenylacetic	acid,	an	immediate	precursor	of	P-2-P,	has	also	
been	widely	used	but	controls	over	the	substance	were	strengthened	in	2010.4	In	response,	traffickers	have	been	using	
the	esters	of	phenylacetic	acid	which	may	be	readily	converted	to	phenylacetic	acid.	Methyl	phenylacetate	and	ethyl	phe-
nylacetate	 have	 been	 seized	 in	 illicit	 ATS	 laboratories	 in	Mexico.	Another	 substitute	 substance,	 l-phenylacetylcarbinol	
(l-PAC),	a	precursor	of	ephedrine),	was	reported	as	having	been	found	in	illicit	ATS	manufacturing	operations	in	Canada.	
neW ats trafficKinG routes in asia
Over	the	last	few	years,	the	ATS	market	has	moved	from	being	a	cottage-type	industry	(with	many	small-scale	manufac-
turing	operations)	to	more	of	a	cocaine	-	or	heroin	-type	market,	characterized	by	a	higher	level	of	integration	and	involve-
ment	 of	 organized	 crime	 groups	 that	 control	 the	 entire	 chain	 from	 the	 provision	 of	 precursors,	 to	manufacture	 and	
trafficking	of	the	end-product.	Recent	years	have	seen	a	greater	diversification	of	ATS	trafficking	routes,	particularly	 in	
South-East	Asia,	as	well	as	the	growth	of	 inter-regional	trafficking	through	countries	previously	not	 identified	as	being	
involved	in	ATS	trafficking.
South-East	Asia	has	experienced	significant	increases	in	the	seizures	of	methamphetamine	pills	originating	from	Myanmar.	
The	number	of	methamphetamine	pills	seized	increased	exponentially	in	2009.	More	than	94	million	pills	were	seized	in	
the	region	in	2009,	compared	to	32	million	pills	 in	2008.	Seizures	increased	sharply	again	in	2010,	reaching	a	total	of	
over	133	million	pills.	Methamphetamine	pills,	which	are	manufactured	in	the	Shan	state	of	Myanmar,	are	trafficked	along	
new	routes	to	Thailand,	China	and	Lao	People’s	Democratic	Republic.	The	Mekong	River	is	now	a	key	route,	likely	due	to	
Thailand’s	stricter	controls	aimed	at	suppressing	drug	trafficking	and	preventing	drug	use.	There	are	indications	of	new	
routes	 to	 the	western	part	of	Myanmar	and	also	 for	onward	 trafficking	 to	South	Asia.	Reports	 from	 India,	Nepal	and	
Bangladesh	in	2010	and	2011	indicate	that	South	Asia	is	also	increasingly	affected	by	the	trafficking	of	methamphetamine	
pills.	
Although	most	ATS	are	still	manufactured	within	the	regions	in	which	they	are	used,	there	are	indications	of	increasing	
inter-regional	trafficking.	North	America	(primarily	Canada)	and	East	and	South-East	Asia	have	emerged	as	sources	of	ATS	
for	international	markets.	Since	2008,	there	has	been	an	increase	in	methamphetamine	trafficking	cases	to	East	Asia	from	
West	Africa.	The	number	of	seizures	and	quantities	seized	in	East	Asia	found	to	have	originated	in	West	African	countries	
such	as	Benin,	Côte	d’Ivoire,	Cameroon,	Ghana,	Guinea,	Senegal	and	Nigeria	more	 than	 tripled	 in	2009.	ATS,	mostly	
methamphetamine,	is	trafficked	by	air	from	West	Africa	via	couriers.	Methamphetamine	trafficked	from	the	Islamic	Repub-
lic	of	Iran	to	countries	in	Asia	and	Oceania	(e.g.	Azerbaijan,	Japan,	Malaysia,	New	Zealand,	Thailand,	Sri	Lanka,	Uzbekistan)	
is	another	development	that	has	emerged	since	the	publication	of	the	2008	Global	ATS	Assessment.	Turkey	reports	that	
methamphetamine	is	smuggled	from	the	Islamic	Republic	of	Iran	into	Turkey,	then	trafficked	by	air	to	East	and	South-East	
Asia.	
emerGence of metHampHetamine in europe
There	are	 indications	that	methamphetamine	markets	may	be	expanding	in	Europe,	as	several	countries	have	reported	
increased	availability	of	the	drug	as	well	as	an	increase	in	use	and	more	widespread	reports	of	manufacture.	Illicit	meth-
amphetamine	laboratories	have	been	seized	for	the	first	time	in	several	European	countries,	 including	Austria,	Belarus,	
Lithuania,	Netherlands,	Poland	and	Portugal.	In	Germany,	more	methamphetamine	laboratories	have	been	reported	than	
amphetamine	since	2008.	Bulgaria	reported	the	seizure	of	two	mobile	methamphetamine	laboratories	in	2010;	the	first	
such	instance	since	2001.	In	Europe,	methamphetamine	is	primarily	sold	in	the	powder	form.	
There	 are	 signs	 that	methamphetamine	might	 be	 replacing	 amphetamine	 on	 the	 illicit	market	 of	 some	 countries,	 for	
example,	Sweden,	Norway,	Lithuania,	Latvia	and	Estonia.	Seizures	of	methamphetamine	in	Europe	increased	from	133	kg	
in	2005	to	697	kg	in	2009,	the	latest	year	for	which	data	are	available.	
4	 In	8	March	2010,	phenylacetic	acid	was	transferred	from	Table	II	to	Table	I	of	the	United	Nations	Convention	against	Illicit	Traffic	in	Narcotic	Drugs	and	Psy-
chotropic	Substances	of	1988	–	effective	as	of	17	January	2011	–	in	an	attempt	to	prevent	diversions	of	the	substance	into	illicit	ATS	manufacture	by	increas-
ing	international	controls	and	reporting.	In	April	2010,	the	Government	of	Mexico	strengthened	control	of	phenylacetic	acid	by	transferring	the	substance	
and	its	salts	and	derivatives	from	Table	II	to	Table	I	of	the	federal	law	on	precursor	control.	Mexico	also	brought	methylamine,	hydriodic	acid	and	red	phos-
phorus	under	its	national	control.	Those	three	substances	are	not	under	international	control	but	are	used	in	the	illicit	manufacture	of	ATS	(INCB,	2011b).	
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inJectinG ats use in some reGions
In	absolute	numbers,	most	ATS	users	continue	to	live	in	East	and	South-East	Asia,	the	most	populous	subregion	in	the	
world.	The	injecting	use	of	methamphetamine	and	its	associated	negative	health	consequences	has	been	reported	as	a	
growing	problem	in	East	and	South-East	Asia.	Lao	People’s	Democratic	Republic	and	Malaysia,	for	example,	reported	the	
injecting	use	of	crystalline	methamphetamine	for	the	first	time	in	2008	and	2009,	respectively.	In	Thailand,	injecting	is	the	
second	most	common	mode	of	administration	for	crystalline	methamphetamine	and	the	third	most	common	mode	of	
administration	for	methamphetamine	pills.	In	New	Zealand,	methamphetamine	is	the	most	commonly	injected	drug	and	
in	Japan,	injecting	is	the	primary	mode	of	administration	for	crystalline	methamphetamine.	High	rates	of	amphetamines	
injection	 are	 also	 reported	 in	 the	Czech	 Republic	 as	well	 as	 Sweden,	 Estonia,	 Finland,	 Latvia,	 Lithuania,	Georgia	 and	
Ukraine.
DecLine anD possiBLe resurGence of ecstasy anD emerGence of ana-
LoGue suBstances in estaBLisHeD ats marKets 
In	2008	and	2009,	many	European	countries	reported	a	declining	availability	of	ecstasy,	reflected	by	significant	declines	
in	ecstasy	seizures	as	well	as	decreasing	MDMA	content	detected	through	forensic	analysis.	 In	many	cases,	declines	 in	
supply	and	purity	were	accompanied	by	the	emergence	of	analogue	substances	not	under	international	control.	These	
substances	 are	marketed	as	 so-called	 ‘legal	highs’	 and	mimic	 the	effects	of	 taking	 illicit	 stimulant	 substances	 such	as	
ecstasy	 or	 amphetamines.	Widely	 used	 substances	 include	 BZP,	mephedrone	 (4-methylmethcathinone	 (4-MMC))	 and	
MDPV.	The	new	unregulated	synthetic	compounds	appeared	first	in	established	ATS	markets,	particularly	in	Europe,	the	
United	States,	Canada,	Australia	and	New	Zealand	but	have	meanwhile	spread	to	other	markets,	e.g.	Philippines.	
Most	 recent	 reports	point	 to	 the	 increasing	purity	of	ecstasy	and	a	possible	 resurgence	of	 the	drug	on	 the	 illicit	drug	
market.	The	Netherlands	reported	increasing	purity	of	ecstasy	in	2010,	which	was	at	82%,	compared	to	70%	in	2008	
and	2009.	
The	resurgence	of	ecstasy	could	also	have	impacted	on	the	availability	of	analogue	substances	such	as	mephedrone,	which	
seemed	to	have	disappeared	from	the	illicit	ecstasy	market	in	the	Netherlands	during	the	first	half	of	2010.	Ecstasy	seizures	
Greater mekong subregion: primary methamphetamine trafficking routes
Source: CCDAC, 2009 
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United 
Nations.
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are	at	a	five-year	high	in	the	USA,	with	a	total	of	3,411	kg	
reported	seized	in	2009,	a	15%	increase	over	2008.	Europol	
reports	that	it	is	likely	that	ecstasy	manufacture	and	traffick-
ing	will	begin	to	increase	again	in	the	coming	years,	which	
could	 affect	 the	 availability	 of	 unregulated	 substances	on	
the	ATS	market.	
Data constraints
Analysing	ATS	markets	 and	 developing	 an	 evidence	 base	
upon	which	 actions	 to	 counter	 the	ATS	 problem	 can	 be	
built	 relies	 on	 accurate,	 comparable	 and	 timely	 data.	
UNODC	analyses	 are	based	on	data	 reported	by	Member	
States.	However,	there	is	irregular	and/or	incomplete	report-
ing	from	several	key	regions,	including	South	Asia,	the	Near	
and	Middle	 East,	 parts	 of	 the	Americas,	 Africa	 and	most	
Pacific	 Island	 states	 and	 territories.	 As	 this	 report	 shows,	
these	are	often	the	very	regions	for	which	there	are	already	
indications	of	a	future	spread	of	the	ATS	problem.	
Irregular	 or	 incomplete	 reporting	 from	Member	 States	 is	
compounded	by	the	varying	quality	of	data	provided.	Spe-
cifically,	and	similar	to	other	drugs,	 information	about	the	
extent	 of	ATS	 use	 is	 the	weakest	 indicator,	 as	 household	
and	other	surveys	are	lacking	or	are	outdated	in	some	coun-
tries	in	several	of	the	most	affected	regions.	Unfortunately,	
this	happens	to	be	the	case	 in	several	populous	countries	
(for	 example,	 China	 and	 India).	 The	 lack	 of	 systematic	
forensic	information	on	the	specific	ATS	substances,	the	actual	precursors	used	and	the	size	and	capacity	of	clandestine	
laboratory	operations	 is	 another	 limitation.	Without	 these	data,	which	provide	 critical	 evidence	 for	both	demand	and	
supply	side	trends,	specific	regional	shifts	and	emerging	trends	in	ATS	markets	fail	to	be	detected	in	a	timely	manner.	Lack	
of	these	data,	together	with	lack	of	price	data,	also	affects	estimates	of	wholesale	and	retail	market	values,	mark-ups,	
and	the	profitability	of	the	ATS	market.
concLusions
After	cannabis,	ATS	are	the	second	most	widely	used	drugs.	The	number	of	ATS	users	has	stabilized	at	high	levels:	UNODC	
estimates	that	the	annual	prevalence	for	amphetamines-group	substances	ranged	between	0.3%	and	1.3%	in	2009,	or	
some	14	to	57	million	people	aged	15-64.	For	the	ecstasy	group,	global	annual	prevalence	is	estimated	at	between	0.2%	
and	0.6%	of	the	population	aged	15-64,	or	some	11	to	28	million	past-year	users.	The	scale	of	the	problem	is	underre-
ported,	as	some	large	countries	such	as	China	or	India	have	never	conducted	a	nationally	representative	survey	to	collect	
data	on	ATS	use.	
The	report	has	shown	that	the	ATS	problem	keeps	spreading	to	new	regions	and	countries	not	previously	affected	by	the	
phenomenon.	 It	 is	a	dynamic	problem	characterized	by	 rapid	changes	 in	 regional	 trends	 in	 the	 levels	of	manufacture,	
trafficking	and	use.	And	it	is	a	complex	problem,	with	a	great	variety	of	substances	sold	in	a	number	of	different	forms-	
as	powders,	pills	or	high	purity	crystals.
Due	to	the	complexity	and	dynamic	nature	of	the	ATS	phenomenon,	the	capacity	to	monitor	the	illicit	manufacture,	traf-
ficking	and	use	of	ATS	is	a	sizeable	and	often	enormous	challenge	for	many	Governments.	Attention	to	the	ATS	problem	
remains	uneven	across	the	world	and	there	is	a	need	to	establish	and	further	develop	ways	to	assess	the	ATS	situation	in	
key	regions.	In	the	Near	and	Middle	East,	the	region	with	the	highest	seizures	of	amphetamines,	there	is	a	strong	need	
to	broaden	the	information	and	knowledge	base.	Data	on	ATS	use	are	almost	non-existent	and	little	is	known	about	the	
origin	of	the	pills	which	are	seized	in	large	quantities	in	most	countries	in	the	region.	Africa,	increasingly	associated	with	
trafficking	of	precursors	and	expanding	ATS	manufacturing	capacity	is	another	region	which	would	benefit	from	invest-
ment	into	drug-related	problems.	Most	Pacific	Island	States	and	territories	lack	infrastructure	to	collect	and	provide	infor-
mation	on	ATS	yet	are	increasingly	associated	with	trafficking	of	precursors	and	the	transit	of	ATS.	
The	 international	community	has	recognized,	most	notably	 in	the	1998	UNGASS	Action	Plan on ATS	as	well	as	 in	the	
2008	Political	Declaration	and	Plan	of	Action	on	International	Cooperation	towards	an	Integrated	and	Balanced	Strategy	
europe: seizures of methamphetamine 2005-2009
Source: UNODC ARQ/DELTA
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to	Counter	the	World	Drug	Problem,	that	ATS	continue	to	pose	a	serious	and	constantly	evolving	challenge	to	interna-
tional	 drug	 control	 efforts;	 a	 challenge	which	 threatens	 the	 security,	 health	 and	welfare	 of	 the	population,	 especially	
youth,	and	has	called	on	Member	States	to	produce	comprehensive	national,	regional	and	global	responses.	
To	properly	respond	to	the	ATS	problem,	further	investments	in	ATS	information	systems	that	provide	accurate,	timely	and	
actionable	information	with	detail	at	the	subregional	or	national	level,	remain	among	the	highest	priorities	for	action.
Emerging	ATS	markets	need	to	be	monitored	and	addressed	proactively	before	they	are	established	and	become	a	sig-
nificant	added	burden	to	national	health	and	justice	systems.	UNODC	will	continue	to	identify	and	communicate	informa-
tion	on	emerging	trends	to	assist	relevant	Government	authorities	in	their	understanding	of	the	ATS	market.
Illicit	ATS	manufacture	needs	to	be	targeted	at	the	origin	by	further	increasing	the	effectiveness	of	precursor	control.	Such	
efforts	should	also	include	preventing	the	diversion	of	preparations	containing	ATS	precursors	and	of	derivatives	specially	
designed	to	circumvent	existing	controls.	
Finally,	it	is	evident	from	this	report	that	a	worsening	ATS	problem	is	correlated	with	a	lack	of	infrastructure	and	resources,	
and	priority	must	therefore	be	given	to	those	vulnerable	countries	and	subregions	where	ATS	are	spreading	most	rapidly	
and	where	data	are	known	to	be	lacking	or	insufficient.5	
5	 Vulnerability,	in	this	regard,	is	a	result	of	both	limited	awareness	and	lack	of	preparedness	to	address	the	ATS	phenomenon	adequately,	and	real	limitations	
in	human,	 financial	 and	 technological	 resources,	 i.e.	 the	overburdening	of	national	 infrastructures	and	 law	enforcement,	 judicial,	prison	and	health	 care	
resources.
ats marKets: 
reGionaL trenDs
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regional overview
East	and	South-East	Asia,	home	to	about	a	third	of	the	global	population,	has	one	of	the	most	established	ATS	markets	
in	the	world,	primarily	for	methamphetamine.	It	is	estimated	that	between	3.5	million	to	20.9	million	persons	in	the	region	
have	used	ATS	in	the	past	year.	All	11	countries	covered	in	this	chapter	have	reported	ATS	use,	and	in	several	of	those,	
ATS	have	emerged	as	 the	primary	drug	 threat	 in	 recent	 years,	displacing	 traditionally	used	plant-based	drugs	 such	as	
heroin,	opium	and	cannabis.	The	injecting	use	of	methamphetamine	and	its	associated	negative	health	consequences	is	
reported	as	a	growing	problem	in	the	region.	
Since	2006,	the	illicit	manufacture	of	ATS	has	continued	at	high	levels	in	the	region.	China,	Myanmar	and	the	Philippines	
remain	the	major	manufacturing	countries	in	East	and	South-East	Asia.	During	the	past	five	years	significant	numbers	of	
illicit	ATS	manufacturing	laboratories	have	also	been	reported	from	Indonesia,	Malaysia	and,	to	a	lesser	extent,	Cambodia.	
Previously,	these	latter	three	countries	had	been	primarily	transit	countries	for	ATS	but	have	more	recently	also	become	
key	manufacturing	centres.	In	addition,	a	small	number	of	ATS-related	laboratories	and	precursor	chemical	manufacturing	
sites	have	been	reported	from	China,	Hong	Kong,	China,	Japan,	Republic	of	Korea	and	Thailand.	Overall,	the	number	of	
illicit	ATS	laboratories	dismantled	between	2004	and	2009	increased	significantly,	from	13	to	458.	The	largest	number	of	
methamphetamine	laboratories	was	reported	in	China,	followed	by	Indonesia,	Malaysia,	Myanmar	and	the	Philippines.	
Limited	ecstasy	manufacture	takes	place	in	the	region,	including	in	China,	Indonesia	and	Malaysia.	
Trafficking	patterns	 in	East	and	South-East	Asia	have	also	shifted	during	the	past	few	years,	particularly	 in	the	Greater	
Mekong	subregion,	which	includes	Cambodia,	the	Lao	People’s	Democratic	Republic,	Myanmar,	Thailand,	Viet	Nam	and	
the	bordering	southern	provinces	of	China.	The	93.3	million	methamphetamine	pills	seized	in	2009	in	China,	Lao	People’s	
Democratic	Republic,	Myanmar	and	Thailand	represent	a	three-fold	increase	in	comparison	with	2008	figures.	In	2010,	
total	seizures	surpassed	133	million	pills.	
This	increased	trafficking	of	methamphetamine	pills	from	Myanmar	to	markets	in	the	region	was	reflected	by	the	single	
seizure	of	nearly	22	million	methamphetamine	pills	 in	February	2010	 in	Lao	People’s	Democratic	Republic,	one	of	 the	
largest	seizures	ever	in	the	region.	In	addition,	increasing	amounts	of	chemicals	and	pharmaceutical	preparations	used	for	
measure DruG Group 2005 2006 2007* 2008 2009
Laboratory (#) Methamphetamine
Other synthetic/combined stimulants
Ecstasy-group substances
49
-
-
66
1
7
98
-
27
11
244
33
16
391
51
total 49 77 125 288 458
Seizures 
(kg)
Methamphetamine 
Amphetamine
Non-specified amphetamines
Ecstasy-group substances
12,171.9
5,262.2
1,388.9
1,137.8
12,118.4
76.5
2,339.1
449.1
10,867.3
128.6
687.4
1,725.0
11,578.6
72.2
1.7
814.3
15,810.4
 -
175.0
496.5
total 19,960.8 14,983.2 13,408.3 12,466.8 16,481.9
Annual Prevalence 
(15-64)
Amphetamines-group substances
Ecstasy-group substances
0.9%
0.1%
0.9%
0.1%
0.8%
0.3%
0.8%
0.3%
0.8%
0.3%
* From 2007 onwards, reported prevalence percentage is based on midpoint of range. 
- Not reported. 
Source: UNODC ARQ/DELTA
east and south-east asia: ats laboratories, seizures, and annual prevalence rates (2004-2009)
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crystalline methamphetamine seizures in east and 
south-east asia, 2004-2010
 
Source: DAINAP
Ketamine seizures in east and south-east asia, 
2006-2010
Source: DAINAP
Greater mekong subregion: primary methamphetamine trafficking routes
Source: CCDAC, 2009 
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United 
Nations.
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the	manufacture	of	methamphetamine	are	being	diverted	and	trafficked	through	the	Greater	Mekong	Subregion.	Large	
volumes	of	pharmaceutical	preparations	containing	ephedrine	and	pseudoephedrine	have	been	reported	in	a	number	of	
countries	in	the	region,	most	notably	in	Cambodia	and	Myanmar.
Since	2008,	transnational	organized	criminal	groups	from	the	Islamic	Republic	of	Iran	and	West	Africa	have	been	playing	
a	greater	role	in	ATS	trafficking	in	East	and	South-East	Asia.	In	2009,	28	Iranians	were	arrested	for	attempting	to	smuggle	
methamphetamine	in	crystalline	and	liquid	forms	into	Indonesia.	Malaysia,	the	Philippines	and	Thailand	have	also	reported	
increasing	inflows	of	methamphetamine	and	other	ATS	into	the	country	by	Iranian	drug	trafficking	organizations.	Japan	
reported	the	arrest	of	more	than	130	Iranians	for	methamphetamine-related	offences	over	the	past	few	years,	including	
one	case	of	suspected	methamphetamine	manufacture	in	June	2010.	There	are	new	indications	that	West	African	groups,	
which	have	hitherto	trafficked	primarily	 in	cocaine	and	heroin,	may	be	diversifying	 into	the	region’s	 lucrative	metham-
phetamine	trade.	
ATS	use	in	East	and	South-East	Asia	continues	to	rise	and	by	2009	ATS	ranked	in	the	top	three	drugs	of	use	in	all	countries	
in	the	region.	Methamphetamine	in	pill	form	ranks	as	the	top	drug	of	use	in	the	Lao	People’s	Democratic	Republic	and	
Thailand,	while	methamphetamine	 in	 crystalline	 form	 ranks	 as	 the	most	 commonly	 used	 drug	 in	 Brunei	Darussalam,	
Cambodia,	Japan,	the	Republic	of	Korea	and	the	Philippines.	The	expansion	of	crystalline	methamphetamine	trafficking	
into	the	region	has	been	accompanied	by	an	upsurge	in	the	use	of	the	drug.	Ecstasy	use	is	reported	in	most	countries,	
albeit	at	relatively	low	and	declining	levels.
This	chapter	focuses	on	the	evolving	ATS	situation	in	East	and	South-East	Asia	since	2008.	The	coverage	is	divided	into	
subregions,	beginning	with	the	Greater	Mekong	Subregion,	followed	by	North-East	Asia	including	Japan,	the	Republic	of	
Korea	and	the	Philippines,	and	the	Southern	Archipelago	nations	of	Indonesia	and	Malaysia.
Greater meKonG suBreGion
The	Greater	Mekong	Subregion,	which	 includes	Cambodia,	the	Lao	People’s	Democratic	Republic,	Myanmar,	Thailand,	
Viet	Nam	and	bordering	provinces	of	southern	China,	continues	to	be	heavily	affected	by	the	manufacture,	trafficking	
and	use	of	ATS,	primarily	methamphetamine,	on	a	large	scale.	Whereas	previously	Myanmar,	the	bordering	provinces	of	
southern	China	and	Thailand	have	been	most	impacted	by	ATS,	the	problem	has	also	shifted	over	the	past	few	years	to	
Cambodia,	the	Lao	People’s	Democratic	Republic	and	Viet	Nam.	Emerging	ATS	trends	include	shifting	patterns	of	drug	
trafficking	routes	throughout	the	region	as	well	as	increasing	use	of	crystalline	methamphetamine.	While	not	yet	wide-
spread,	 the	 increasing	 injecting	use	of	methamphetamine	has	been	officially	 reported	by	Cambodia,	 the	 Lao	People’s	
Democratic	Republic	and	Thailand.	Meanwhile,	legal	and	drug	treatment	systems	continue	to	be	dominated	by	metham-
phetamine	cases.
myanmar
Myanmar	remains	the	major	source	of	methamphetamine	pills	 in	the	Greater	Mekong	Subregion.	Most	 illicit	metham-
phetamine	manufacture	takes	place	in	the	eastern	part	of	Shan	State.	Forensic	profiling	of	ATS	in	Thailand	suggests	there	
are	at	least	12	methamphetamine	manufacturing	sites	in	Myanmar.	In	addition,	there	are	indications	that	at	least	50	dif-
ferent	organized	criminal	groups	are	involved	in	activities	related	to	the	trafficking	of	drugs	from	Myanmar.1	The	presence	
of	different	types	of	‘WY’	methamphetamine	pills	 in	Kayah	State	and	Kayin	State,	which	are	30-50%	cheaper	 in	price	
compared	to	pills	produced	in	Shan	State,	suggests	possible	local	methamphetamine	manufacture	in	those	states.2
Methamphetamine	pills	manufactured	in	Shan	State	are	trafficked	along	new	trafficking	routes	that	have	emerged	since	
2003,	directly	to	Thailand,	China	and	the	Lao	People’s	Democratic	Republic,3	with	the	Mekong	River	now	a	key	route.4	
There	is	also	evidence	of	new	trafficking	routes	to	the	western	part	of	Myanmar	and	onward	trafficking	to	South	Asia.5
Between	1998	and	2010,	only	39	manufacturing	facilities	were	seized	in	Myanmar,	mostly	consisting	of	smaller	tableting	
operations,	with	 only	 two	 large-scale	 operations.	 This	 information	 is	 inconsistent	with	 the	 vast	 number	 of	 pills	 seized	
1	 ONCB,	2009.
2	 UNODC,	2010c.
3	 ONCB,	2009.
4	 This	may	be	due	to	increased	counter-narcotics	efforts	by	the	Government	of	Thailand,	aimed	at	the	suppression	of	drug	trafficking	and	the	prevention	of	
drug	use,	which	forced	drug	producers	and	traffickers	to	find	new	trafficking	routes.
5	 In	2009,	a	new	trafficking	route	emerged,	to	Rakhine	State	from	Yangon.	Pills	seized	in	Rakhine	State	in	2009	were	likely	for	export	rather	than	for	local	
consumption	(UNODC,	2010c).
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myanmar: domestic trafficking routes of  
methamphetamine pills
Source: CCDAC, 2009 
Note: The boundaries and names shown and the designations used 
on this map do not imply official endorsement or acceptance by the 
United Nations.
combined methamphetamine pill seizures in china, Lao people’s Democratic republic, myanmar and thailand 
 
Source: DAINAP
myanmar: seizures of ephedrine and  
pseudoephedrine, 1997-2010
*Cold tablets containing pseudoephedrine.  
Source: CCDAC, 2009
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throughout	the	region.6	No	reported	crystalline	metham-
phetamine	manufacturing	facilities	have	been	seized	in	the	
country,	but	most	crystalline	methamphetamine	seized	in	
northern	 Thailand	 during	 the	 past	 three	 to	 four	 years	
originated	 from	 the	Myanmar	 part	 of	 the	Golden	 Trian-
gle.7
Only	 two	million	methamphetamine	 pills	were	 seized	 in	
2010,	 compared	 to	 seizures	 of	 nearly	 24	million	 pills	 in	
2009.	Seizures	in	2008	and	2007	amounted	to	1.1	million	
pills	 and	 1.6	million	 pills,	 respectively.8	 The	 significant	
increase	 in	2009	was	 likely	due	to	Government	pressure	
on	ceasefire	groups,	many	of	which	manufacture	ATS,	to	
come	 under	Government	 control.	 Although	 seizures	 of	
methamphetamine	pills	dropped	sharply	in	2010,	seizures	
of	crystalline	methamphetamine	during	the	year	amounted	
to	226	kg,	showing	an	upward	trend	for	two	successive	
years.	The	amount	of	crystalline	methamphetamine	seized	
in	2009	amounted	to	124	kg	compared	with	a	total	of	only	20	kg	seized	between	2006	and	2008.9
Ephedrine	and	pseudoephedrine,	the	main	methamphetamine	precursors,	are	trafficked	into	the	country	from	China,	India	
and	Thailand.10	From	2003	to	2008,	less	than	1	mt	of	ephedrine	was	seized	each	year	except	for	2006	when	1.3	mt	were	
seized.	 In	2009,	ephedrine	seizures	 jumped	to	1.5	mt	and	then	dropped	again	 in	2010	to	34	kg.11	At	the	same	time,	
however,	Myanmar	has	reported	significant	seizures	of	cold	tablets	containing	pseudoephedrine,	with	9.4	million	such	
pills	seized	in	2009	and	4.5	million	pills	seized	in	2010.12	Increasing	seizures	of	pharmaceutical	preparations	that	contain	
ephedrine	and	pseudoephedrine	may	account	for	the	low	amount	of	bulk	ephedrine	seizures	in	recent	years,	as	precursor	
traffickers	have	started	to	use	different	forms	of	precursor	chemicals	in	order	to	avoid	law	enforcement	detection	and	to	
circumvent	strict	international	controls	on	precursor	chemicals.	
Most	 of	 the	methamphetamine	manufactured	 in	Myanmar	 is	 trafficked	 to	 other	 countries,	 primarily	 in	 the	Greater	
Mekong	Subregion.	However,	domestic	methamphetamine	use	is	reportedly	on	the	rise.	Use	of	methamphetamine	pills	
has	increased	every	year	since	2003.13	Use	has	spread	from	the	border	areas	near	manufacturing	centres	to	urban	areas.	
There	has	been	no	reported	domestic	use	of	crystalline	methamphetamine	to	date.14
thailand
Thailand	has	one	of	the	largest	markets	for	methamphetamine	in	the	region.	While	methamphetamine	pill	use	remains	
the	most	common	form	of	drug	use	 in	 the	country,	 the	use	of	crystalline	methamphetamine	has	become	 increasingly	
widespread.	
Domestic	manufacture	of	methamphetamine	in	Thailand	is	limited	to	small-scale	manufacture.	Over	the	past	three	years,	
law	enforcement	authorities	have	seized	methamphetamine	pill	tableting	operations	located	in	the	outskirts	of	Bangkok	
and	in	surrounding	provinces	as	well	as	in	the	northern	province	of	Chiang	Rai,	indicating	that	pill	pressing	operations	are	
taking	place	in	the	area	bordering	Myanmar.15	In	July	2010,	a	Swedish	national	arrested	in	the	eastern	province	of	Rayong	
was	charged	with	manufacturing	crystalline	methamphetamine	in	his	home.16	
Large	quantities	of	cold	tablets	containing	pseudoephedrine,	sourced	primarily	from	Thailand,	Malaysia	and	the	Republic	
of	Korea,	were	seized	in	Thailand’s	border	areas	and	at	Suvarnnabhumi	International	Airport	in	2009	and	2010.17	Most	
6	 UNODC,	2010c.
7	 This	has	been	suggested	by	authorities	from	Myanmar	and	Thailand	(ONCB,	2009).	
8	 UNODC,	2010c.
9	 UNODC,	2010c.
10	 ONCB,	2009	and	CCDAC,	2010.
11	 UNODC,	2010d.	The	increase	in	2006	was	due	to	greater	law	enforcement	efforts	(UNODC,	2008).
12	 DAINAP;	UNODC,	2010c.
13	 UNODC,	2010d.	
14	 UNODC,	2010d.
15	 ONCB,	2010a.
16	 ONCB,	2011.
17	 ONCB,	2010b.
myanmar: bottles of ephedrine-containing nasal drops 
seized in special region 1 (Kokang)
Source: CCDAC, 2009
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of	 the	 tablets	were	 believed	 to	 be	 destined	 for	 illicit	 ATS	
manufacturing	facilities	 in	Myanmar.	Since	2008,	approxi-
mately	 35	million	preparations	 and	192	 kg	of	 bulk	 pseu-
doephedrine	 have	 been	 seized	 in	 the	 country.18	 The	
increasing	quantity	of	the	seizures	 indicates	traffickers	are	
smuggling	larger	quantities	of	pharmaceutical	preparations	
to	production	centres.	
Although	 there	 is	 growing	 domestic	methamphetamine	
manufacture	in	Thailand,	the	majority	of	the	methamphet-
amine	pills	found	in	the	country	is	sourced	from	Myanmar.	
Due	to	increased	illicit	manufacture	in	Myanmar,	seizures	of	
methamphetamine	in	both	pill	and	crystalline	forms	in	Thai-
land	 have	 increased	 each	 year	 since	 2007.	 During	 that	
period,	methamphetamine	pill	seizures	rose	from	14	million	
pills	 in	2007	to	22	million	pills	 in	2008,	27	million	pills	 in	
2009	and	nearly	50	million	pills	in	2010.	At	the	same	time,	
seizures	 of	 crystalline	methamphetamine	 also	 increased	
dramatically,	with	47	kg	seized	in	2007,	53	kg	in	2008,	209	
kg	in	2009	and	773	kg	in	2010.19	
Most	of	the	methamphetamine	that	enters	Thailand	is	for	
domestic	use	but	limited	quantities	are	also	transshipped	to	
other	markets,	including	Europe,	North	America20	and	the	
Middle	East.	Crystalline	methamphetamine	is	trafficked	into	
the	country	from	Myanmar	and	Cambodia	both	for	domes-
tic	use	and	 for	onward	 trafficking	 to	Malaysia,	 the	Philip-
pines,	Hong	Kong,	China	and	Japan.21	As	in	several	other	
countries	 in	East	and	South-East	Asia,	 increasing	amounts	
of	crystalline	methamphetamine	are	trafficked	into	Thailand	
by	couriers	from	the	Islamic	Republic	of	Iran.	In	2009,	eight	Iranian	drug	traffickers	were	arrested	with	27	kg	of	crystalline	
methamphetamine.	From	January	to	September	2010,	79	Iranian	drug	traffickers	were	arrested	in	Thailand	with	nearly	
109	kg	of	the	drug.	Iranian	couriers	typically	attempt	to	traffic	methamphetamine	in	crystalline,	liquid	and	powder	form	
into	the	country	via	Suvarnnabhumi	International	Airport.22	
Most	ecstasy	in	Thailand	is	reportedly	trafficked	by	air	from	the	Netherlands.23	In	addition,	criminal	syndicates	based	in	
Malaysia	and	Singapore	traffic	ecstasy	into	Thailand	by	land	and	air.24	Most	ketamine	is	trafficked	into	Thailand	across	its	
borders	with	Cambodia	 and	Malaysia.	 In	 2010,	 police	 arrested	 seven	 Indian	 couriers	 and	 seized	 150	 kg	 of	 ketamine	
powder	at	Suvarnnabhumi	International	Airport.25	Reported	use	of	ecstasy	and	ketamine	in	Thailand,	however,	is	declin-
ing.	
The	use	of	methamphetamine	pills	and	crystalline	methamphetamine	has	shown	an	upward	trend	since	2008.	In	2010,	
more	than	80%	of	all	persons	who	received	drug	treatment	in	specialized	treatment	facilities	and	correctional	institutions	
reported	methamphetamine	pills	as	the	primary	drug	of	use.	Thailand	is	one	of	the	few	countries	in	the	region	that	pro-
vides	specialized	treatment	for	ATS	users.	
18	 ONCB,	2010b.
19	 DAINAP;	2010,	ONCB	2010b.
20	 INCB,	2010a.
21	 ONCB,	2010b.	
22	 ONCB,	2010b.
23	 ONCB,	2010a.
24	 ONCB,	2010b.
25	 ONCB,	2010b.
thailand: seizures of crystalline methamphetamine, 
2004-2010
Source: DAINAP
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DruG type
neW aDmissions aLL aDmissions
maLe femaLe totaL maLe femaLe totaL
Methamphetamine pills 73,530 6,940 80,470 89,822 8,225 98,047
Crystalline methamphetamine 939 691 1,630 1,214 805 2,019
Ecstasy-type (MDMA) 83 69 152 102 82 184
Cannabis 5,559 66 5,625 6,664 77 6,741
Cocaine 7 5 12 11 7 18
heroin 500 18 518 1,276 62 1,338
Inhalants 3,064 88 3,152 4,037 115 4,152
Ketamine 3 5 8 6 5 11
Kratom 1,904 52 1,956 2,136 53 2,189
Opium 713 205 918 1,451 436 1,887
total 86,302 8,139 94,441 106,719 9,867 116,586
Source: DAINAP
thailand: drug treatment admissions, 2010
DruG type
neW aDmissions aLL aDmissions
maLe femaLe totaL maLe femaLe totaL
Methamphetamine pills 64,690 6,945 71,635 78,620 8,196 86,816
Crystalline methamphetamine 350 351 701 435 408 843
Ecstasy-type (MDMA) 155 96 251 181 103 284
Cannabis 6,610 89 6,699 7,794 104 7,898
Cocaine 10 2 12 15 4 19
heroin 513 25 538 1,232 62 1,294
Inhalants 4,466 160 4,626 5,517 197 5,714
Ketamine 10 1 11 11 1 12
Kratom 1,385 35 1,420 1,527 34 1,561
Opium 795 261 1,056 1,482 485 1,967
total 78,984 7,965 86,949 96,814 9,594 106,408
Source: DAINAP
thailand: drug treatment admissions, 2009
DruG type  
(measurement)
2006 2007 2008 2009 2010
no. of 
seizures Quantity
no. of 
seizures Quantity
no. of 
seizures Quantity
no. of 
seizures Quantity
no. of 
seizures Quantity
Methamphetamine 
pills (pills)
36,252 13,820,000 73,014 14,340,000 113,877 22,115,911 105,916 26,640,206 125,195 48,587,522
Crystalline metham-
phetamine (kg)
734 92.2 1,258 47.4 1,960 52.9 2,507 209 6,602 733.02
Ecstasy-type (MDMA) 
(pills)
300 26,656 295 315,444 460 486,533* 296 58,024 147 16,081
Ketamine (kg) 95 22.7 63 2.8 140 18.1 130 18.9 154 172.03
* 2008 pill seizures converted into kg equivalents at 1 pill = 300 mg.
Source: DAINAP
thailand: ats and ketamine seizures, 2006-2010
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Lao people's Democratic republic
Drug	control	authorities	in	the	Lao	People’s	Democratic	Republic	have	identified	the	rapid	spread	of	ATS	and	other	syn-
thetic	drugs	as	the	country’s	primary	drug	threat.	Lao	People’s	Democratic	Republic	has	not	reported	any	illicit	metham-
phetamine	manufacture	since	1998.	Recent	seizure	data	indicate	that	methamphetamine	increasingly	transits	the	country	
from	Myanmar	 to	Cambodia,	 Thailand	 and	Viet	Nam,	 particularly	 along	 the	Mekong	 River	 and	 the	 country’s	 rapidly	
improving	road	network.26	In	2008,	157	seizures	of	methamphetamine	(about	81%	of	all	methamphetamine	seizures)	
were	made	en	route	from	the	Lao	People’s	Democratic	Republic	to	Thailand.27	
Prior	to	2008,	annual	seizures	of	methamphetamine	pills	in	the	Lao	People’s	Democratic	Republic	amounted	to	between	
0.5	million	and	2	million	pills,	except	in	2005	when	almost	4.7	million	pills	were	seized.	In	line	with	the	spike	in	metham-
phetamine	 pill	 seizures	 in	 other	 countries	 in	 the	Greater	Mekong	 Subregion,	 the	 Lao	 People’s	 Democratic	 Republic	
reported	a	more	than	four-fold	rise	in	pill	seizures	from	84	cases	in	2007	to	194	cases	in	2008	and	357	cases	in	2009.	In	
2010,	methamphetamine	 pill	 seizures	 increased	 significantly,	 due	 to	 a	 single	 seizure	 in	 February	 of	 21.8	million	 pills	
believed	to	have	originated	from	Myanmar,	evidently	en	route	to	Thailand.28	It	was	one	of	the	largest	methamphetamine	
pill	seizures	ever	in	the	Greater	Mekong	Subregion.	The	total	was	nearly	ten	times	higher	than	the	2.3	million	metham-
phetamine	pills	seized	in	2009.
In	addition,	there	are	indications	that	transnational	organized	drug	trafficking	groups	are	increasingly	smuggling	precursor	
chemicals	used	in	the	manufacture	of	ATS	through	the	Lao	People’s	Democratic	Republic.29	In	August	2009,	law	enforce-
ment	authorities	seized	large	quantities	of	cold	remedies	being	trafficked	to	Myanmar	from	Viet	Nam	through	Lao	People’s	
Democratic	Republic,	which	were	intended	to	provide	pseudoephedrine	for	methamphetamine	manufacture.
The	spillover	of	methamphetamine	from	Myanmar	has	impacted	drug	use	patterns	in	the	Lao	People’s	Democratic	Repub-
lic	which	were	 previously	 dominated	 by	 opium	use.	 In	 2005,	 government	 authorities	 in	 the	 Lao	 People’s	Democratic	
Republic	 reported	 the	escalation	of	methamphetamine	use	along	trafficking	 routes	adjacent	 to	 the	Mekong	River	and	
identified	methamphetamine	pills	as	the	primary	drug	of	use	in	the	country.	In	the	same	year,	the	Lao	People’s	Democratic	
Republic	recorded	its	first	crystalline	methamphetamine	seizure,	indicating	that	the	supply	of	methamphetamine	entering	
the	country	was	diversifying.	Injecting	use	of	methamphetamine	was	reported	for	the	first	time	in	2008.
ATS	use	is	highest	in	urban	areas	and	is	increasing	among	young	drug	users.	UNODC	estimates	that	in	2008,	an	estimated	
1.4%	of	the	population	aged	15-64	had	used	methamphetamine	at	least	once	in	the	previous	year.30	There	is	also	increas-
ing	ATS	use	in	some	rural	areas	that	formerly	cultivated	opium	poppy.31	Over	the	past	five	years,	more	than	80%	of	all	
drug-related	arrests	and	the	majority	of	drug	treatment	admissions	have	involved	methamphetamine	in	pill	form,32	rep-
resenting	a	considerable	burden	on	the	 limited	 law	enforcement,	 judicial,	prison	and	health	care	 resources	of	 the	Lao	
People’s	Democratic	Republic.	
Lao people’s Democratic republic: seizures of methamphetamine pills, 2006-2010
DruG type measurement 2006 2007 2008 2009 2010
Methamphetamine pills No. of pills 1,755,989 1,272,815 1,227,205 2,335,330 24,530,177
Source: DAINAP
number of patients at somsanga treatment and rehabilitation center, 2003-2009 
DruG type 2003 2004 2005 2006 2007 2008 2009
Total no. of patients 1,714 2,658 1,376 1,177 1,894 1,682 1,964
Females 0 0 25 28 137 105 118
Source: LCDC, 2010b
26	 LCDC,	2010a.
27	 WCO,	2009.
28	 LCDC,	2011.
29	 INCB,	2011a.
30	 UNODC,	2011a.
31	 LCDC,	2010a.
32	 DAINAP.
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cambodia
Cambodia	has	a	significant	and	increasing	problem	with	the	illicit	manufacture,	trafficking	and	use	of	ATS.	In	addition,	
the	country	is	being	targeted	by	transnational	drug	trafficking	organizations	as	a	transit	route	for	ATS	and	other	drugs	to	
other	countries	both	in	and	outside	the	region.	
Official	reports	of	illicit	ATS	manufacture	in	Cambodia	first	emerged	in	2007	when	police	dismantled	a	large-scale	labora-
tory	 in	Kompong	Speu	province	 that	was	 reported	 to	have	manufactured	at	 least	1	mt	of	chloropseudoephedrine,	an	
intermediate	in	the	manufacture	of	methamphetamine.	Illicit	ATS	manufacture	in	the	country	has	since	increased	consid-
erably.	In	2009,	Cambodia	reported	the	seizure	of	five	laboratories	and	precursor	manufacturing	sites.33	
Seizures	of	substantial	quantities	of	precursor	chemicals	used	for	illicit	ATS	manufacture	have	also	been	reported	in	Cam-
bodia	in	recent	years.	In	2009,	Cambodian	authorities	seized	886	kg	of	preparations	containing	pseudoephedrine,	2,814	
kg	of	ephedra	grass,	13	kg	of	ephedra	seeds	as	well	as	1,373	kg	of	unknown	 liquids.34	 In	 the	same	year,	Cambodia	
reported	its	first	seizure	of	an	extraction	site	for	ephedrine,	in	the	Kompong	Cham	province,	which	was	utilizing	ephedra	
grass	suspected	to	have	been	trafficked	from	northern	China.35	
In	August	2010,	drug	 law	enforcement	authorities	 in	Cambodia	recorded	the	 largest	single	seizure	of	smuggled	pseu-
doephedrine	to	date	in	the	country.	About	12.9	million	tablets	were	seized	in	Banteay	Meanchey	province	near	the	Thai-
Cambodia	border.	The	seizure	was	carried	out	in	cooperation	with	law	enforcement	officers	from	the	Republic	of	Korea	
and	Thailand.36	Significant	seizures	of	pseudoephedrine	tablets	were	also	reported	in	December	2010	in	Phnom	Penh.	
Safrole-rich	oils	(SRO),37	have	various	licit	commercial	uses	in	the	perfume	and	pesticide	industry,	but	can	be	diverted	for	
the	illicit	manufacture	of	ecstasy.	SRO	continue	to	be	illicitly	harvested	and	sold,	although	at	far	lower	levels	than	in	pre-
vious	years.	
While	there	is	some	indication	that	the	domestic	manufacture	of	ATS	is	increasing,	most	ATS	found	in	Cambodia	is	traf-
ficked	from	neighbouring	countries.	Previously,	ATS	entered	Cambodia	primarily	through	its	border	with	Thailand,	whereas	
over	the	past	few	years	most	ATS	seized	in	Cambodia	have	been	smuggled	across	its	border	with	the	Lao	People’s	Dem-
ocratic	Republic,	in	particular	through	the	remote	northern	provinces	along	the	Mekong	River.	A	large	amount	of	the	ATS	
and	other	drugs	trafficked	into	Cambodia	is	destined	for	illicit	markets	in	other	countries.38	Some	of	the	methampheta-
mine	trafficked	into	the	country	is	re-tableted	and	sold	on	the	streets	as	low	purity	methamphetamine	pills.39	
Since	2007,	methamphetamine	pill	seizures	in	the	country	have	declined,	which	may	be	an	indication	of	increased	domes-
tic	illicit	ATS	manufacture	and	a	reduced	need	for	the	trafficking	of	the	drugs	into	the	country.	In	2010,	methamphetamine	
pill	seizures	in	Cambodia	totaled	82,746,	nearly	40%	lower	than	the	2009	total	and	nearly	30%	lower	than	the	2008	
total.	At	the	same	time,	however,	the	10kg	of	crystalline	methamphetamine	seized	in	the	country	in	2010	is	more	than	
twice	the	amount	seized	in	2009	(4.6kg)	and	represents	the	highest	amount	seized	in	the	country	since	2007.	
Although	 the	domestic	 use	of	methamphetamine	 in	Cambodia	 remains	high,	government	 experts	 have	 reported	 two	
successive	years	of	declining	use.	In	2009,	users	of	methamphetamine	in	both	pill	and	crystalline	form	accounted	for	about	
70%	of	all	 illicit	drug	users.	Cambodian	authorities	report	that	use	of	crystalline	methamphetamine	has	overtaken	the	
use	of	methamphetamine	pills.40	Preliminary	data	reported	by	Cambodia	in	2011,	however,	indicates	a	possible	spike	in	
methamphetamine	pill	seizures.
33	 NACD,	2009.
34	 NACD,	2010a.
35	 NACD,	2009.
36	 NACD,	2010b;	UNODC,	2010b.
37	 Safrole	is	a	substance	listed	in	Table	1	of	the	United	Nations	Convention	Against	Illicit	Trafficking	in	Narcotic	Drugs	and	Psychotropic	Substances	of	1988,	as	
well	as	 in	Cambodia’s	Drug	Law.	The	 International	Narcotics	Control	Board	defines	safrole-rich	oils	as	being	 ‘any	mixtures	or	natural	products	containing	
safrole	present	in	such	a	way	that	it	can	be	used	or	recovered	by	readily	applicable	means’	(INCB,	2009b).
38	 NACD,	2011.
39	 NACD,	2010c.
40	 DAINAP.
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viet nam
Viet	Nam	is	becoming	the	next	big	market	 for	methamphetamine	manufactured	 in	 the	region,	partly	due	to	 its	 large,	
increasingly	affluent	and	urban	population.	The	use	of	heroin	and	opium	continue	to	dominate	in	the	country.	The	use	
of	methamphetamine	pills	and	ecstasy	has	increased	every	year	since	2003.41	Crystalline	methamphetamine	use,	which	
was	first	reported	in	Viet	Nam	in	2008,42	has	since	risen	significantly,	especially	among	young	persons	in	urban	areas.43	
Methamphetamine	manufacture	in	Viet	Nam	appears	minimal,	with	the	first	manufacturing	laboratory	reported	disman-
tled	in	June	2005.44	However,	the	full	extent	of	ATS	manufacture	and	the	trading	of	precursor	chemicals	in	Viet	Nam	is	
difficult	 to	 assess	 due	 to	 the	 limited	 information	 available.	 The	 large	 number	 of	 chemical	wholesalers,	 suppliers	 and	
manufacturers	 in	Viet	Nam	provides	 an	 increasing	opportunity	 for	 the	diversion	of	precursor	 chemicals	 into	 illicit	ATS	
manufacture.	Some	of	the	pseudoephedrine	seized	in	Australia	in	2008-2009	was	reportedly	shipped	from	Viet	Nam.45	
Seizures	of	ATS	are	not	uniformly	reported	in	Viet	Nam,	but	the	limited	data	show	that	in	the	first	six	months	of	2010,	a	
total	of	22	kg	and	more	than	83,000	pills	of	methamphetamine	pills	were	seized.46	Most	of	the	methamphetamine	found	
in	Viet	Nam	and	smaller	amounts	of	heroin	are	sourced	from	Myanmar	and	are	trafficked	into	the	country	by	land	from	
Cambodia.47
During	the	past	few	years,	an	increasing	amount	of	synthetic	drugs	as	well	as	hallucinogens	which	are	not	controlled	by	
the	Government	of	Viet	Nam	have	been	seized	by	police	in	major	provinces	and	cities.	The	use	of	TFMPP	(Trifluorometh-
ylpennylpiperazine),	BZP	and	‘Sea	Water’	 (Gamma	Hydroxybutyric	Acid,	or	GHB),	widespread	 in	entertainment	venues,	
has	been	identified	by	Vietnamese	authorities	as	a	new	trend	and	several	reports	state	that	these	drugs	are	available	for	
sale	on	the	Internet.48
china
ATS	use	 in	China	had	become	 increasingly	widespread	by	 the	end	of	 the	1990s	and	by	 the	early	2000s	ATS	use	had	
overtaken	opium	as	the	second	most	commonly	used	drug	 in	the	country.	Ketamine	use	has	also	become	increasingly	
prevalent	since	it	was	first	reported	in	2004,	as	the	country	is	a	major	producer	of	the	substance.	The	lack	of	nationally	
representative	drug	use	prevalence	estimates,	however,	 remains	a	major	challenge	to	the	adequate	monitoring	of	ATS	
trends	in	the	country.	
Most	of	the	methamphetamine	used	in	China	is	manufactured	domestically.	However,	compared	to	other	countries	in	the	
Greater	Mekong	Subregion,	China	experienced	a	surge	in	methamphetamine	pills	trafficked	into	the	country	from	Myan-
mar	in	2009	and	2010,49	a	trend	reflecting	the	substantial	and	increasing	seizures	of	methamphetamine	pills	in	Yunnan	
province	bordering	Myanmar.50	 In	2009,	more	 than	40	million	methamphetamine	pills51	were	 seized	 in	China,	which	
41	 DAINAP.
42	 DAINAP.
43	 SODC,	2010a.
44	 SODC,	2008.
45	 INCB,	2011a.
46	 DAINAP.
47	 SODC,	2009.	
48	 SODC,	2010b.
49	 NNCC,	2010a.
50	 Methamphetamine	seizures	in	the	province	rose	from	2.2	mt	in	2008	to	3.2	mt	in	2009	and	4.6	mt	in	2010	(NNCC,	2010b;	NNCC,	2011a).
51	 Figures	for	‘China’	do	not	 include	additional	significant	seizures	made	in	the	Special	Administrative	Regions	(SAR)	of	Hong	Kong	and	Macao,	and	Taiwan	
Province.
DruG type measurement 2005 2006 2007 2008 2009 2010
Methamphetamine pills No. of pills 351,651 428,553 420,287 116,772 137,249 82,746
Crystalline methamphetamine kg 2 16.2 6.75 1.9* 4.6 9.9
Ecstasy-type (MDMA) No. of pills – – 300 33 3,352 1,056
Ketamine kg – – – 495** 1.14 0.001
* Plus 15 'small packs' undefined weight. ** Small bottles, undefined weight.
Source: DAINAP
cambodia: seizures of selected drugs, 2005-2010
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accounted	 for	 roughly	 40%	of	 all	 the	methamphetamine	
pills	 seized	 in	 the	East	 and	South-East	Asia	 region	during	
the	year,	as	compared	to	only	approximately	6	million	pills	
seized	in	China	in	2008.	In	2010,	the	total	number	of	meth-
amphetamine	pills	seized	amounted	to	over	58.4	million.
Despite	 the	 impact	of	 the	 spillover	of	Myanmar-manufac-
tured	methamphetamine	pills	 in	2009,	aggregate	seizures	
of	methamphetamine	 (in	 both	 pill	 and	 crystalline	 forms)	
during	the	year	(6.6	mt)	remained	within	the	range	of	the	
6.1	mt	and	6.8	mt	seized	each	year	during	the	2005-2009	
period.	 In	 2010,	 aggregate	 seizures	 of	methamphtamine	
increased	to	9.9	mt,	with	large	amounts	seized	in	Yunnan	
province;	a	reflection	of	the	diversification	of	ATS	trafficking	
routes	in	the	Greater	Mekong	Subregion.52	
Seizures	of	illicit	ATS	manufacturing	facilities	in	China	have	
increased	 significantly	 since	 2005	 and	 a	 considerable	
number	 of	 ketamine	manufacturing	 facilities	 have	 also	
been	 dismantled.	 China	 reports	 the	 highest	 seizures	 of	
ketamine	in	the	world,	having	reported	annual	seizures	of	
about	5.4	mt	for	the	past	four	years.	The	5.3	mt	of	keta-
mine	 seized	 in	China	 in	 2008	 accounted	 for	 nearly	 two-
thirds	of	the	8.2	mt	seized	globally	during	the	year.53
ATS	manufacture	 in	China	 is	becoming	more	sophisticated	and	increasingly	diversified	with	the	synthesis	of	precursors	
and	the	different	stages	of	manufacturing	being	divided	across	provinces,	including	Taiwan	Province	of	China.54	In	2010,	
a	total	of	378	illicit	ATS	manufacturing	laboratories	were	detected55	compared	to	391	facilities	in	200956	and	244	facili-
ties	in	2008.57	Prior	to	2006,	most	illicit	ATS	manufacturing	activity	in	China	occurred	in	the	south-eastern	provinces	of	
Guangdong	and	Fujian.	However,	increased	law	enforcement	efforts	appear	to	have	shifted	some	manufacture	to	central	
China.	In	2009,	most	of	the	clandestine	manufacturing	laboratories	seized	were	in	Guangdong,	Sichuan,	Henan,	Hunan	
and	Hubei	provinces	and	were	manufacturing	crystalline	methamphetamine	and	ketamine.58	
Significant	seizures	of	precursor	chemicals	continued	to	be	reported	in	China.	 In	2010,	234	such	cases	were	reported,	
including	the	seizure	of	869	mt	of	controlled	precursor	chemicals	and	49	mt	of	uncontrolled	chemicals.	In	2009,	China	
reported	1,366	violations	of	precursor	chemical	control	and	the	seizure	of	approximately	3.2	mt	of	precursors,	including	
the	seizure	of	nearly	9	mt	of	hydroxylamine	hydrochloride,	a	precursor	used	in	the	manufacture	of	ketamine.59			
Hong Kong (special administrative region of china)
Most	clandestine	ATS	manufacture	in	Hong	Kong,	China	has	consisted	of	ecstasy-type	tableting	and	repackaging	opera-
tions.60	However,	Hong	Kong	police	 reported	 the	 seizure	of	 two	small-scale	 clandestine	crystalline	methamphetamine	
manufacturing	 facilities	 in	 2009	 and	 the	 dismantling	 of	 a	 larger	 crystalline	methamphetamine	manufacturing	 facility	
located	in	an	industrial	estate	in	2010.61
Ecstasy	use	has	declined	in	recent	years,	possibly	due	to	the	growing	popularity	of	the	significantly	less	expensive	keta-
mine.	Much	of	the	ecstasy	seized	in	Hong	Kong,	China	contains	substances	other	than	MDMA,	such	as	ketamine	and	
methamphetamine	and,	more	recently,	trifluoromethylphenylpiperazine	(TFMPP),	which	is	currently	not	controlled	in	Hong	
Kong,	China.62
52	 NNCC,	2011b.	
53	 UNODC,	2010e.
54		 NNCC,	2009.
55	 NNCC,	2011b.
56	 It	has	not	been	established	whether	all	391	illicit	laboratories	were	related	to	ATS	(NNCC,	2010b).
57	 UNODC,	2010e.
58	 NNCC,	2011a.
59	 NNCC,	2010c.
60	 HKNB,	2010.
61	 HKNB,	2011.
62	 HKNB,	2011.
china: ats seizures, 2001-2010
Source: DAINAP
0
2,000
4,000
6,000
8,000
10,000
12,000
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
Se
iz
u
re
s 
(m
et
ri
c 
to
n
s)
28
2011 GLoBaL ATS ASSESSMENT
	
Ketamine	users	account	 for	nearly	38%	of	all	drug	users	 in	Hong	Kong,	China.	Among	drug	users	below	 the	age	of	
21	an	estimated	84%	have	used	ketamine.63	Previously,	most	of	 the	ketamine	 trafficked	 into	Hong	Kong,	China	was	
trafficked	in	small	quantities	across	the	land	boundary	with	mainland	China,	by	a	large	number	of	traffickers.	By	2005,	
large,	multi-kilo	quantities	of	ketamine	originating	in	India	and	transported	into	Hong	Kong,	China	via	South-East	Asia	
were	 also	 detected.	 There	 are	 indications	 that	 criminal	 syndicates	 are	 increasingly	 procuring	 the	 precursor	 chemical	
hydroxylamine	 hydrochloride	 to	manufacture	 ketamine	 in	 illicit	 laboratories	 rather	 than	 diverting	 the	 drug	 from	 the	
legitimate	market.64	
The	use	of	methamphetamine,	primarily	in	crystalline	form,	emerged	in	Hong	Kong,	China	in	the	early	1990s,	and	has	
stabilized	in	recent	years	at	about	10%	of	the	drug	user	population	and	approximately	16-21%	of	reported	drug	users	
under	the	age	of	21.65	Seizures	of	crystalline	methamphetamine	have	remained	stable	since	2007	at	about	43	kg	per	
year.	Most	of	the	crystalline	methamphetamine	trafficked	into	Hong	Kong,	China	is	trafficked	from	mainland	China;	some	
of	it	destined	for	overseas	markets	such	as	Australia.66
taiwan province of china
Taiwan	Province	of	China	is	a	source	of	methamphetamine	manufacture	and	remains	a	source	for	pharmaceutical	prepa-
rations	containing	pseudoephedrine	that	are	destined	for	countries	in	Central	America	and	Oceania.	
In	2010,	Taiwan	Province	of	China	reported	its	largest	ever	ketamine	seizure	of	850	kg	which	originated	from	mainland	
China,	as	well	as	an	additional	480	kg	of	ketamine	which	was	detected	on	board	a	fishing	vessel.	 In	November	2010,	
authorities	seized	60	kg	of	amphetamine	originating	from	mainland	China	with	a	street	value	of	USD1.6	million	at	Taipei	
Port.	During	the	year,	authorities	also	reported	the	seizure	of	about	20	kg	of	pseudoephedrine	pills	and	a	manufacturing	
laboratory	in	Kaohsiung	with	a	manufacturing	capacity	of	approximately	1.5	mt	of	methamphetamine.67	
Taiwan	Province	of	China	also	seizes	significant	and	increasing	quantities	of	ketamine	and	methamphetamine	that	origi-
nate	from	mainland	China.	India	also	remains	a	source	of	diverted	ketamine	trafficked	into	Taiwan	Province	of	China.
nortH-east asia
The	major	drug	control	problem	in	North-East	Asia	continues	to	be	the	use	of	ATS,	primarily	crystalline	methamphetamine.	
ATS	manufacture	remains	limited	in	Japan	and	the	Republic	of	Korea,	although	significant	quantities	of	crystalline	meth-
amphetamine	are	manufactured	in	the	Philippines.	
Japan
In	Japan,	crystalline	methamphetamine	continues	to	be	the	main	drug	of	use.	The	country	first	experienced	widespread	
methamphetamine	use	in	the	1950s,	and	again	in	the	mid-1980s	and	late	1990s.68	Manufacture	of	methamphetamine	
in	Japan	is	extremely	rare,	but	in	June	2010,	two	Iranian	nationals	were	arrested	on	suspicion	of	manufacturing	metham-
phetamine	 in	 their	home.	 In	 addition,	 Japan	has	 reported	 several	 incidents	 involving	 the	diversion	of	pharmaceuticals	
containing	ATS	precursor	chemicals	since	2003,	with	66	such	cases	being	reported	in	2008.	In	2010,	authorities	reported	
several	incidents	of	domestic	methamphetamine	manufacture	and	seizures	of	liquid	methamphetamine	at	various	inter-
national	airports	in	Japan,69	pointing	to	the	possible	risk	of	expanding	domestic	illicit	manufacture,	especially	as	meth-
amphetamine	prices	in	the	country	are	increasing.70
Traditionally,	 China	 has	 been	 the	 primary	 source	 of	methamphetamine	 seized	 in	 Japan,	 but	 in	 recent	 years	metham-
phetamine	from	other	countries	around	the	world	has	been	trafficked	into	the	country.71	Much	of	the	methamphetamine	
found	in	Japan	is	smuggled	from	overseas	by	international	and	Japanese	drug	trafficking	organizations.	More	than	half	
of	the	arrests	related	to	methamphetamine	during	the	past	five	years	have	involved	local	‘Boryokudan’	(‘Yakuza’)	organ-
63	 HKSB,	2011.
64	 HKNB,	2010.
65	 HKNB,	2010.
66	 HKNB,	2010.
67	 INCSR,	2011.
68	 JNPA,	2011.	
69	 INCSR,	2011.
70	 JMHLW,	2009.
71	 JNPA,	2010a;	JNPA,	2010b.
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ized	crime	members.	As	with	many	countries	in	Asia,	many	
nationals	 from	 the	 Islamic	 Republic	 of	 Iran	 have	 been	
arrested	in	Japan	in	methamphetamine-related	cases	in	the	
past	 few	 years,	 including	 85	 in	 2009	 and	 50	 in	 2010.72	
Much	of	the	methamphetamine	trafficked	into	Japan	con-
sists	 of	 small	 packages	 carried	 by	 couriers	who	 enter	 the	
country	by	air	 and	 sea.	However,	 sophisticated	 trafficking	
networks	 are	playing	an	 increasing	 role	 in	methampheta-
mine	trafficking	in	Japan,	which	is	reflected	by	the	number	
of	large	seizures	recorded	in	the	country.	Since	2008,	Japan	
has	 reported	an	average	of	352	kg	of	methamphetamine	
seized	 each	 year,	 slightly	 less	 than	 the	 amounts	 seized	 in	
the	early	part	of	the	decade.73
Crystalline	methamphetamine	 use	 in	 Japan	 has	 remained	
generally	stable	during	most	of	the	past	decade.	Injecting	is	
the	primary	mode	of	administration	for	crystalline	metham-
phetamine	 in	 the	country.	Methamphetamine	pill	use	has	
not	 been	 reported	 in	 Japan.	 Use	 of	 ecstasy	 pills	 is	more	
common	 but	 declining	 numbers	 of	 arrests	 and	 declining	
seizures	of	the	drug	over	the	past	several	years	suggest	that	
use	has	gone	down.74	During	the	past	decade	about	80%	
of	 all	 drug-related	 arrests	 in	 the	 country	 have	 involved	
methamphetamine.	 In	 addition,	more	 than	 50%	 of	 all	
drug-related	treatment	demand	from	clients	 in	psychiatric	
treatment	 facilities	 was	 for	 ATS	 use	 (last	 reported	 in	
2005).75	
republic of Korea
Crystalline	methamphetamine,	commonly	known	locally	as	‘philopon’	or	‘hiroppon’	in	the	Republic	of	Korea,	remains	the	
most	commonly	used	drug	and	has	accounted	for	about	60-70%	of	all	drug-related	arrests	in	the	country	since	2008.	
However,	reported	use	and	availability	of	the	drug	have	since	declined,	which	is	also	reflected	by	the	continually	declining	
seizures,	from	approximately	26	kg	in	2008	to	11	kg	in	2010,	and	steadily	rising	prices	for	the	drug.76	ATS	users	have	
accounted	for	more	than	95%	of	all	persons	admitted	to	drug	treatment	in	the	country	since	2008.
72	 JNPA,	2011.	
73	 JNPA,	2011.
74	 JNPA,	2010b.
75	 JMHLW,	2007.
76	 SPO,	2011.
DruG type 2006 2007 2008 2009 2010
Methamphetamine 11,606 12,009 11,025 11,655 11,999
Ecstasy-type (MDMA) 370 296 281 107 62
Source: JNPA, 2011
Japan: ats-related arrests, 2006-2010
DruG type measurement 2006 2007 2008 2009 2010
Crystalline methamphetamine Kg 126.8 339.3 397.5 356.3* 302.3
Ecstasy-type (MDMA) and 
other synthetic drugs
Pills 186,226 1,233,883 217,172 85,688 17,326
* UNODC, 2010d.
Source: JNPA, 2011
Japan: ats seizures, 2006-2010
sources of methamphetamine trafficking to Japan, 
2010
Source: JNPA, 2011
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Most	of	the	crystalline	methamphetamine	found	in	the	Republic	of	Korea	has	come	from	mainland	China	but	increasing	
amounts	of	the	drug	are	entering	the	country	from	Cambodia,	Malaysia,	South	Africa	and	the	Taiwan	Province	of	China.77	
In	recent	years,	several	nationals	of	China	and	Thailand	have	been	arrested	in	the	Republic	of	Korea	for	trafficking	meth-
amphetamine.78	
Limited	illicit	methamphetamine	manufacture	has	been	reported	in	the	Republic	of	Korea	since	the	late	1990s.	However,	
in	2010	authorities	reported	the	seizure	of	four	small-scale	‘kitchen-type’	clandestine	methamphetamine	manufacturing	
operations.79	In	2008	and	2009	there	were	no	reported	seizures	of	precursor	chemicals	in	the	Republic	of	Korea,	although	
it	has	been	indicated	as	one	of	the	source	countries	for	ephedrine	trafficked	to	Australia.80	In	August	2010,	approximately	
12.8	million	 pharmaceutical	 preparations	 containing	 pseudoephedrine,	 originating	 from	 the	 Republic	 of	 Korea,	were	
seized	in	Cambodia	after	having	been	trafficked	across	the	land	border	with	Thailand.	However,	it	is	unclear	whether	these	
products	were	intended	for	direct	use	or	for	use	in	illicit	methamphetamine	manufacture.81
republic of Korea: ats-related arrests, 2006-2010
DruG type 2006 2007 2008 2009 2010
ATS 6,006 8,521 7,457 7,965 6,771
total 7,709 10,649 9,898 11,875 9,732
Source: SPO, 2011
republic of Korea: ats seizures, 2006-2010
DruG type measurement 2006 2007 2008 2009 2010
Crystalline methamphetamine kg 21.5 23.7 25.5 15.2 11.8
Methamphetamine pills No. of pills 0 196 151 1 5
Ecstasy -type (MDMA) No. of pills 356 18,323 714 894 486
Source: SPO, 2011
retail prices of crystalline methamphetamine in the republic of Korea, 2006-2010
DruG type measurement 2006 2007 2008 2009 2010
Crystalline methamphetamine Per gram 860 770 536 664 693
Source: SPO, 2011
philippines
Crystalline	methamphetamine	(‘shabu’)	has	been	the	most	commonly	used	drug	in	the	Philippines	for	the	past	two	dec-
ades	and	significant	illicit	methamphetamine	manufacture	and	trafficking	continue	to	occur.	In	2009,	crystalline	metham-
phetamine	users	accounted	for	62%	of	all	drug	users	 in	the	country	and,	since	2004,	they	have	accounted	for	almost	
63%	 of	 persons	 receiving	 drug	 treatment.	 Since	 2008,	
about	 two-thirds	of	all	drug-related	arrests	 in	 the	country	
have	been	related	to	crystalline	methamphetamine.	There	is	
no	 reported	 use	 of	methamphetamine	 pills	 in	 the	 Philip-
pines.	
In	major	cities	the	use	of	ecstasy	 is	becoming	 increasingly	
popular	 among	 young	 nightclub	 goers.	 Ecstasy	 use,	
however,	 remains	 limited	 due	 to	 the	 high	 price	 and	 low	
availability.	 The	 use	 of	 synthetic	 substances,	 such	 as	
Benzylpiperazine	 (BZP),	 or	 ‘mimic	 ecstasy’,	 has	 also	 been	
noted.82
77	 SPO,	2010.
78	 SPO,	2009.
79	 SPO,	2011.
80	 INCB,	2010a.
81	 UNODC,	2010b.
82	 PDEA,	2010.
profile of drug users in the  
philippines, 2010
•• poly-drug	users	
•• more	than	six	years	duration	of	taking	drugs			
•• 57.23%	single	
•• 33.92%	unemployed	
•• majority	of	the	patients	were	only	able	to	finish		
high	school	
•• male	to	female	ratio	9:1	
•• 20	to	29	years	age	bracket	
	
Source: PDEA, 2011
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Illicit	crystalline	methamphetamine	manufacture	in	the	Phil-
ippines	was	 first	 reported	 in	1996,	 and	 in	1997,	 the	 first	
industrial-scale	clandestine	manufacturing	 facility	was	dis-
mantled.	 From	 2002	 to	 2010,	 a	 total	 of	 72	 clandestine	
crystalline	methamphetamine	laboratories	were	dismantled	
by	drug	law	enforcement	authorities.83	Over	the	past	few	
years,	methamphetamine	manufacture	 has	 shifted	 from	
large	and	medium-sized	 facilities	 to	 smaller	 ‘kitchen	 type’	
laboratories	in	metropolitan	areas	and	has	been	character-
ized	by	the	manufacture	of	increasingly	higher	purity	meth-
amphetamine.	 Overall	methamphetamine	 seizures	 have	
declined	sharply	in	the	Philippines	since	2008,	from	845	kg	
to	149	kg	in	2009	and	64	kg	in	2010.84
Domestically	manufactured	methamphetamine	is	also	traf-
ficked	to	countries	 in	the	region	such	as	Cambodia,	 Indo-
nesia	 and	 Thailand	 as	 well	 as	 to	 countries	 outside	 the	
region.	 The	 Philippines	Drug	Enforcement	Agency	 reports	
that	nine	transnational	criminal	groups	and	85	local	groups	
are	 involved	 in	drug	manufacturing	and	 trafficking	 in	 the	
country.	 85	Methamphetamine	 is	 also	 trafficked	 into	 the	
country	from	China,	primarily	by	maritime	vessels.86	
83	 PDEA,	2011.
84	 DAINAP.
85	 PDEA,	2010.
86	 PDEA,	2009.	
primary ats trafficking routes for the philippines
Source: PDEA, 2010 
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United 
Nations. Lines represent origin and intended destination, not necessarily the exact route used, and may include completed or stopped trafficking 
attempts.
philippines: rehabilitation centre admissions, 
2006-2010
Source: PDEA, 2011
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soutHern arcHipeLaGo
As	key	transit	countries	for	methamphetamine	trafficking,	both	Indonesia	and	Malaysia	have	recently	experienced	increas-
ing	problems	with	the	manufacture	and	use	of	ATS	drugs,	particularly	methamphetamine	in	crystalline	form.
malaysia
Previously,	Malaysia	was	a	key	transit	country	for	small	amounts	of	crystalline	methamphetamine,	ecstasy	and	ketamine	
en	route	to	consumers	in	Australia,	China,	Indonesia,	Japan,	Singapore	and	Thailand,	due	to	the	high	prices	of	these	drugs	
in	the	aforementioned	countries.87	Over	the	past	five	years,	Malaysia	has	also	become	a	significant	methamphetamine	
manufacturing	 location,	demonstrating	the	speed	with	which	shifts	 in	patterns	of	clandestine	manufacture,	trafficking	
and	use	can	occur.
Since	2008,	authorities	have	reported	the	dismantling	of	more	than	30	large	and	small-scale	ATS	manufacturing	labora-
tories.	In	2009,	authorities	seized	11	such	facilities,	primarily	located	in	Kuala	Lumpur	and	southern	Malaysia,	as	well	as	
a	large	quantity	of	precursor	chemicals,	including	80	kg	of	ephedrine	and	80	kg	of	pseudoephedrine.	In	2010,	Malaysia	
reported	the	seizure	of	six	large	methamphetamine	manufacturing	laboratories,	one	large	ecstasy	manufacturing	facility	
and	one	large	ketamine	producing	operation.88
The	country	is	also	being	targeted	by	Iranian	drug	trafficking	organizations.	 In	2009	and	2010,	more	than	150	Iranian	
nationals	were	arrested	for	attempting	to	smuggle	crystalline	methamphetamine	into	Malaysia.89	Myanmar	is	the	primary	
source	 of	methamphetamine	pills	 trafficked	 into	Malaysia	 and	 is	 also	 a	 source	 of	 some	 crystalline	methamphetamine	
found	 in	the	country.	Ecstasy	 is	generally	smuggled	 into	the	country	from	the	Netherlands,90	although	seizures	of	 the	
drug	have	declined	sharply	since	2008.
Ketamine	is	smuggled	into	Malaysia	(mainly	by	Indian	nationals)	from	Chennai,	India,	via	air	and	sea	routes.91	Ketamine	
seizures	doubled	each	year	between	2007	and	2009,	when	nearly	1.1	mt	of	the	substance	were	seized.	In	2010,	ketamine	
seizures	dropped	to	334	kg.
In	 2008,	 crystalline	methamphetamine	 seizures	 in	Malaysia	 increased	 ten-fold	 from	 the	previous	 year	 to	 679	 kg,	 and	
increased	by	another	70%	in	2009	to	1,160	kg,	due	to	a	single	seizure	of	972	kg	of	crystalline	methamphetamine	in	May	
2009.	Crystalline	methamphetamine	seizures	dropped	to	887	kg	in	2010,	but	still	represented	the	second	highest	seizure	
total	ever	reported	in	the	country.
ATS	use	has	increased	considerably	in	Malaysia	in	the	past	few	years.	In	2010,	an	estimated	36%	of	all	drug	users	in	the	
country	used	ATS,	compared	with	18%	in	2009	and	8%	in	2008.92	Injecting	use	of	crystalline	methamphetamine	was	
reported	for	the	first	time	in	Malaysia	in	2009.	
indonesia
Similar	to	Malaysia,	Indonesia	was	formerly	a	transit	country	for	ATS	which	has	gone	on	to	develop	significant	problems	
with	ATS	manufacture	and	use.	By	2010,	crystalline	methamphetamine	surpassed	cannabis	as	the	primary	drug	of	use	in	
the	country.
For	the	past	six	years,	Indonesia	has	reported	a	considerable	number	of	seizures	of	large	sophisticated	illicit	laboratories	
manufacturing	crystalline	methamphetamine	and	ecstasy.	In	2009,	drug	law	enforcement	authorities	in	Indonesia	disman-
tled	a	 total	of	37	ATS	manufacturing	operations,	 the	highest	 figure	 reported	to	date.	The	seized	facilities	 included	12	
small-scale	‘kitchen	type’	laboratories	in	private	residences,	suggesting	that	some	ATS	manufacturers	are	reducing	the	size	
of	their	facilities	to	avoid	detection	by	the	law.93	Of	the	26	illicit	ATS	manufacturing	facilities	dismantled	in	2010,	nine	
were	small-scale	crystalline	methamphetamine	manufacturing	operations	and	12	were	ecstasy	methamphetamine	opera-
tions.	An	additional	three	ecstasy	tableting	facilities	were	also	seized	during	the	year.94	The	continuing	high	level	of	ecstasy	
manufacture	in	Indonesia	raises	concern	that	the	country	could	replace	Europe	as	the	principal	source	of	MDMA	in	the	
region.	
87	 RMP,	2010a.
88	 DAINAP.
89	 RMP,	2010b.
90	 RMP,	2010a.
91	 RMP,	2010a.
92	 RMP,	2010c.
93	 BNN,	2010.
94	 DAINAP.
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Although	the	illicit	manufacture	of	large	quantities	of	ATS	has	partially	eliminated	the	need	for	the	trafficking	of	ATS	into	
the	country,	a	significant	amount	of	crystalline	methamphetamine	seized	 in	 Indonesia	 in	2009	was	reported	as	having	
been	smuggled	into	the	country	from	the	Islamic	Republic	of	Iran	by	Iranian	couriers,	as	well	as	from	China.	During	the	
year,	more	than	25	Iranian	couriers	were	arrested	for	methamphetamine	smuggling	at	international	airports	in	Indonesia.	
Authorities	in	Indonesia	also	report	drug	trafficking	activity	by	West	African	criminal	syndicates.95	
ATS	seizures	in	Indonesia	have	fluctuated	in	recent	years	but	have	shown	an	overall	decreasing	trend.	Seizures	of	crystal-
line	methamphetamine	in	2008	totaled	710	kg	but	dropped	to	238	kg	in	2009	and	354	kg	in	2010.	Similarly,	ecstasy	
seizures	in	2009	and	2010	were	approximately	two-thirds	below	the	amounts	seized	in	2007	and	2008	when	over	one	
million	pills	were	seized	in	each	year.	
soutH asia 
South	Asia	 is	 located	at	the	crossroads	of	drug	supply	between	the	sources	 in	South-East	Asia	(formerly	known	as	the	
‘Golden	Triangle’)	and	West	Asia.	Traditionally,	the	subregion	has	been	affected	by	the	illicit	manufacture,	trafficking	and	
use	of	drugs,	mostly	opiates.	Over	the	past	few	years,	however,	South	Asia	has	become	an	area	for	illicit	ATS	manufacture	
and	ATS	 trafficking.	The	 fact	 that	 India	has	one	of	 the	 largest	chemical	 industries	 in	 the	world	and	Bangladesh	has	a	
growing	chemical	 industry	has	made	South	Asian	countries	increasingly	vulnerable	to	potential	exploitation	by	criminal	
organizations.	
South	Asia	has	witnessed	several	types	of	illicit	ATS	manufacture,	ranging	from	small-scale	‘kitchen-type’	laboratories	to	
larger	scale	manufacturing	facilities.	In	addition,	criminal	organizations	have	engaged	in	the	extraction	of	ephedrine	or	
pseudoephedrine	from	pharmaceutical	preparations	or	have	developed	new	techniques	for	the	illicit	chemical	synthesis	
of	 ephedrine.	 There	has	 also	been	 an	 increase	of	 ketamine	 trafficking	 to	neighbouring	 East	 and	 South-East	Asia	 and	
outside	Asia.
South	Asia	is	also	a	transit	region	for	the	ATS	trafficked	from	neighbouring	South-East	Asia.	Trafficking	of	methampheta-
mine	pills	from	Myanmar	into	India,	Nepal	and	Bangladesh	is	on	the	rise.
india
India	has	one	of	the	largest	chemical	industries	in	the	world	and	is	one	of	the	major	exporters	of	ephedrine	and	pseu-
doephedrine,	 the	chemicals	 frequently	used	 in	 the	 illicit	manufacture	of	methamphetamine.	The	first	known	 illicit	ATS	
laboratory	was	detected	and	dismantled	in	Kolkata	in	May	2003.	In	2004,	a	laboratory	was	seized	in	Hyderabad	(south-
eastern	 India),	 and	another	 laboratory	was	 seized	 in	Gurgaon	 (northern	 India)	 in	2006.	 Several	 additional	 facilities	or	
attempts	 to	 establish	 facilities	 for	 the	 illicit	manufacture	 of	 ATS,	mostly	methamphetamine,	were	 uncovered	 by	 law	
enforcement	agencies	between	2004	and	2010.
In	2007,	an	illicit	laboratory	for	the	manufacture	of	methamphetamine	and	the	extraction	of	precursors	from	pharmaceu-
tical	preparations	was	discovered	in	Mumbai.	This	discovery	highlights	the	fact	that	traffickers	have	resorted	to	diverting	
pharmaceutical	preparations	to	circumvent	stricter	controls	over	precursor	chemicals	in	bulk	form.	This	trend	has	contin-
ued	and	India	reported	seizures	of	1.2	mt	of	ephedrine	preparations	to	the	International	Narcotics	Control	Board	in	2009.	
In	addition,	criminal	organizations	have	also	started	to	manufacture	precursor	chemicals	illicitly	as	indicated	by	the	dis-
covery	of	a	clandestine	ephedrine	laboratory	in	the	northwest	of	India	in	2009.
In	 2010,	 two	 clandestine	methamphetamine	 laboratories	 and	 two	 ephedrine	 laboratories	were	 discovered,	 and	 large	
quantities	of	methamphetamine	and	its	precursors	ephedrine	and	pseudoephedrine	were	seized	on	the	premises.96
Traditionally,	ATS	precursors	were	trafficked	from	India	to	Myanmar,	but	recently,	precursors	from	India	in	bulk	or	in	the	
form	of	pharmaceutical	preparations	have	been	seized	in	various	regions,	particularly	in	Central	America,	North	America	
and	Africa.	Along	with	China,	India	is	the	most	frequently	mentioned	source	country	of	seized	illicit	shipments	of	ephe-
drine	and	pseudoephedrine.	
ATS	are	routinely	seized	in	India.	Seizures	of	methamphetamine	and	amphetamine	pills	are	predominantly	made	in	the	
northeast	of	the	country	bordering	Myanmar,	which	is	also	the	source	of	these	products.	Methamphetamine	powder,	on	
the	other	hand,	is	primarily	manufactured	in	India.	
India	 has	 also	 become	 a	 significant	 source	 for	 ketamine,	 a	 hallucinogenic	 substance	 not	 under	 international	 control.	
Ketamine	is	manufactured	legally	in	India.	In	recent	years,	ketamine	of	Indian	origin	has	been	smuggled	into	countries	in	
95	 BNN,	2009.
96	 India,	MOHA,	2011.
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East	and	South-East	Asia	where,	it	is	often	sold	as	ecstasy	or	mixed	with	methamphetamine	as	an	adulterant.	Seizures	of	
ketamine	increased	from	60	kg	in	2005	to	more	than	1	mt	in	2009.97	Most	seizures	of	ketamine	have	been	made	in	the	
south	of	India.	
The	prevalence	of	use	of	amphetamine-type	stimulants	in	a	country	home	to	a	significant	part	of	the	world’s	population	
is	not	known.	The	last	household	survey	on	drug	use	was	carried	out	 in	2000-2001	but	ATS-related	specific	questions	
were	not	included.	Anecdotal	reports,	however,	suggest	that	ATS	use	is	on	the	rise.	
Bangladesh
Bangladesh	borders	India,	which	is	a	significant	manufacturer	of	ATS	precursors	and	Myanmar,	a	major	source	of	meth-
amphetamine	pills.	In	addition,	Bangladesh	has	a	fairly	large	and	growing	chemical	and	pharmaceutical	industry	and	over	
the	past	few	years	has	emerged	as	a	source	for	ATS	precursors,	mainly	in	the	form	of	pharmaceutical	preparations,	which	
have	been	trafficked	to	destinations	 in	Central	America	and	the	Caribbean.	Several	 large	seizures	of	pseudoephedrine	
preparations	were	reported	in	2009	from	the	Dominican	Republic	(409,200	pills),	Guatemala	(700,000	pills)	and	Hondu-
ras	(over	two	million	pills).	
ATS	use	has	 reportedly	become	widespread	 in	urban	areas	of	Bangladesh,	particularly	 in	 the	 capital	Dhaka.	Metham-
phetamine	pills	are	the	most	commonly	used	synthetic	drug	and	there	are	signs	that	use	of	methamphetamine	pills	 is	
replacing	the	use	of	codeine-based	cough	syrups.	No	representative	household	drug	use	survey	has	been	undertaken	in	
Bangladesh.	
nepal
No	illicit	ATS	manufacture	has	been	reported	from	Nepal.	A	seizure	of	800	grams	of	methamphetamine	at	Kathmandu	
international	airport,	involving	an	Iranian	national	was	reported	in	2008.	This	could	suggest	that	Nepal	may	be	increasingly	
used	as	a	transit	point	for	ATS	trafficking	to	destinations	in	South	and	East	Asia.	There	was	also	one	arrest	in	2009	and	
one	in	2010	involving	Iranian-manufactured	crystalline	methamphetamine.	Nepal	does	not	produce	precursors,	but	the	
pharmaceutical	 industry	 is	developing	fast	and	the	absence	of	 legislative	controls	on	precursor	chemicals	 increases	the	
country's	vulnerability	to	traffickers.
centraL asia anD countries of tHe caucasus
The	amount	of	information	available	from	the	Central	Asian	countries	of	the	Caucasus	related	to	ATS	is	sparse,	but	Gov-
ernment	reports	suggest	that	ATS	expansion	may	be	occurring,	albeit	from	very	low	levels.	The	subregion	has	experienced	
some	 small-scale	 illicit	manufacture	 of	methcathinone,	which	was	made	 from	 the	 naturally	 occurring	 ephedra	 plant.	
Georgia	reported	its	first	methamphetamine	seizure	in	2006	(2.42	kg),	while	Kazakhstan	reported	a	seizure	of	3.6	kg	of	
ecstasy	 in	2005	and,	most	 recently,	 a	 small	 seizure	 (0.03	kg)	of	 amphetamine	 in	2009.	Armenia	 and	Kyrgyzstan	also	
reported	small	seizures	(less	than	one	kg)	of	methamphetamine	in	2009.
A	2009	survey	of	adolescents	carried	out	 in	Tbilisi,	Georgia,	reported	a	2%	lifetime	prevalence	of	ATS	and	noted	that	
ecstasy	was	the	second	most	available	drug	to	young	people,	after	cannabis.	Illicit	manufacture	of	methamphetamine	and	
methcathinone	 from	over-the-counter	 preparations	 containing	 ephedrine,	 pseudoephedrine	 and	phenylpropanolamine	
has	been	observed.	Methamphetamine	is	injected.	In	2008,	an	increase	was	noted	in	the	number	of	patients	attending	
addiction	clinics	whose	principal	drug	was	methamphetamine	or	methcathinone.98
97	 Directorate	of	Revenue	Intelligence	and	Narcotics	Control	Board,	India.
98	 Source:	Javakhishvili,	et	al.,	2011.
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Oceania	could	be	characterized	as	a	region	of	a	large	maritime	area,	with	enormous	differences	in	the	size,	population	and	
capacity	of	countries.	Around	three	quarters	of	people	in	the	region	live	either	in	Australia	or	New	Zealand.	This	means	
that	whatever	occurs	in	these	ATS	markets	accounts	for	the	overall	regional	trend.	The	interpretation	of	the	ATS	situation	
in	the	Pacific	island	states	and	territories	remains	difficult	due	to	the	lack	of	ATS	data.
The	region's	proximity	to	Asia	and	its	chemical	industry	has	been	widely	abused	by	criminal	groups	to	obtain	the	necessary	
precursors	for	the	manufacture	of	ATS.	For	the	last	few	years,	the	primary	embarkation	points	for	seized	precursors	have	
been	China	and	Thailand.	
Methamphetamine	in	this	region	is	largely	manufactured	for	domestic	consumption.	Trafficking	of	methamphetamine	as	
a	final	product	has	decreased	over	the	years.	On	the	other	hand,	ecstasy	is	trafficked	into	the	region	from	other	countries	
such	as	Canada.	Some	ecstasy	is	still	manufactured	locally	but	the	purity	has	dropped	over	the	past	few	years	due	to	the	
shortage	of	the	necessary	precursors.	Other	synthetic	substances	like	mephedrone,	BZP	or	4-MEC	are	often	used.
After	a	strong	increase	in	the	number	of	dismantled	laboratories	in	2005	and	seizures	in	2007,	figures	remained	stable.	
However,	2009	data	show	a	significant	 increase	 in	 the	number	of	dismantled	 laboratories.	The	 increase	of	dismantled	
laboratories	does	not	correspond	with	the	level	of	ATS	seizures	which	has	remained	at	relatively	low	levels	since	2007.
Australia	and	New	Zealand	have	been	characterized	by	fairly	high	levels	of	ATS	use.	The	following	is	a	summary	of	the	
main	trends	over	the	2005-2009/10	period	in	Australia	and	New	Zealand,	supplemented	with	available	information	about	
the	ATS	situation	in	Pacific	Island	states	and	territories.
australia
The	illicit	ATS	market	in	Australia	consists	of	almost	exclusively	domestically	manufactured	methamphetamine	and	ecstasy,	
most	of	which	is	trafficked	into	Australia	from	overseas.	Some	amphetamine	is	also	being	manufactured.
In	2009-2010,	a	total	of	602	laboratories	were	seized	in	Australia,	the	highest	number	of	seizures	since	2004-2005,	when	
380	laboratories	were	reported	dismantled.	Most	seized	laboratories	(251	out	of	602)	were	reported	from	Queensland.	
Increases	were	also	recorded	in	Victoria.	While	there	were	no	detections	in	2008-2009,	in	2009-2010,	101	laboratories	
were	seized.
measure DruG Group 2005 2006 2007* 2008 2009
Laboratory 
(#)
Methamphetamine
Amphetamine
Other synthetic/combined stimulants
Ecstasy-group substances
204
-
370
10
211
-
355
7
190
-
328
19
393
-
-
11
134
-
297
20
total 584 573 537 404 451
Seizure  
(kg)
Methamphetamine
Amphetamine
Non-specified amphetamines
Ecstasy-group substances
131.7
167.1
39
1,446.7
216.4
30.1
1,506.3
540.5
173.7
23.17
0.9
4,665.6
47.5
1
263.7
58.4
170.8
57
25.4
63.5
total 1,784.5 2,293.3 4,863.3 370.6 316.7
Annual  
Prevalence  
(15-64)
Amphetamines-group substances
Ecstasy-group substances
2.9%
2.9%
2.1%
3.2%
2.4%
3.8%
2.4%
3.8%
2.4%
3.8%
* From 2007 onwards, reported prevalence percentage is based on midpoint of range. 
- Not reported. 
Source: UNODC ARQ/DELTA
oceania: ats laboratories, seizures, and annual prevalence rates (2005-2009)
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The number of extraction laboratories for ephedrine and pseudoephedrine increased from 38 in 2008-2009 to 44 in 
2009-2010. 
The most common method of manufacture detected in ATS clandestine laboratories in Australia is the hypophosphorous 
method, followed by the Birch method, the red phosphorous method and the P-2-P method. With the exception of the 
P-2-P method, all other methods experienced a substantial increase. The number of seized laboratories using the red 
phosphorus method more than doubled, from 16 in 2008–09 to 51 in 2009–10.
The number of ecstasy laboratories decreased from 19 in 2008–09 to 17 in 2009–10. By far, the most laboratories are 
reported from New South Wales (12), followed by Queensland (3) and South Australia (2). 
Australian law enforcement authorities also seized manufacturing equipment, notably pill presses. On 1 March 2010, a 
new regulation on the prohibition of importation of pill presses came into force and a total of 57 pill presses were seized 
in 2009–10, compared to 26 in 2008–09. Most pill presses were seized in New South Wales (30). 
The number of ATS arrests decreased by 15% nationally, from 16,000 in 2008-09 to 14,000 in 2009–10 but still remain 
historically high. Compared to 2005–06, arrests are 40% higher. User offences accounted for 71% of the total ATS arrests 
in 2009–10. The percentage of detainees testing positive for amphetamines has been decreasing since 2006. In 2008, it 
was lower than at any point in time since 2000.
The number of ATS (excluding ecstasy) seizures increased by 71% in 2009–10, from 391 in 2008–09 to 672. The highest 
number of seizures reported in the last five years was 743 in 2006–07.  
At 67kg, seizures of amphetamines declined significantly in 2009-2010, compared to 2008-2009 when 346 kg were 
seized. Of the 67 kg of total amphetamines seized, slightly more than half (35.8 kg) was in the form of crystalline meth-
amphetamine. In 2009-2010, most of the seized amphetamines shipments came from Spain. South Africa was another 
important point of embarkation, accounting for 28% of seizures totalling more than 500 grams. China, including Hong 
Kong, was another embarkation point. 
Ecstasy seizures have hit a five-year low in Australia, in terms of both seizures and weight. About 6 kg of ecstasy were 
detected at the Australian border in 2009-2010, half the amount seized in 2008-2009 (12 kg). It should be noted that all 
Australia: number of dismantled ATS laboratories
Source: ACC, 2011 
Note: Data are based on financial year (1 July-30 June).
Australia: adult detainees who tested positive for  
amphetamines (%), 2003-2008
Source: UNODC ARQ/DELTA 
Note: Data are based on financial year (1 July-30 June).
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individual	seizures	of	ecstasy	made	at	the	Australian	border	
in	2009-2010	were	below	1	kg.	In	terms	of	weight,	parcel	
post	accounted	for	about	half	of	ecstasy	seizures.	Canada	
was	a	prominent	embarkation	country	for	ecstasy	in	terms	
of	both	weight	and	number.
Seizures	 of	 precursors	 (ephedrine,	 ephedra,	 P-2-P,	 pheny-
lacetic	Acid,	phenylpropanolamine/norephedrine	and	pseu-
doephedrine)	used	in	illicit	ATS	manufacture	have	shown	a	
marked	 decline.	 In	 2009-2010,	 only	 562	 kg	were	 seized,	
compared	to	2,097	kg	in	2008-2009.	During	the	last	decade,	
2008-2009	saw	the	highest	amounts	of	precursors	seized,	
with	more	than	50%	of	seizures	being	GHB	precursors.
According	to	the	National	Drug	Strategy	Household	Survey	
2007,	 20	 to	 29	 year	 olds	 have	 consistently	 reported	 the	
highest	 proportion	 of	 amphetamine-group	 users	 in	 the	
population	 since	 1998.	 Lifetime	 prevalence	 in	 this	 age	
group	was	 16%	 (470,000),	 last	 12	months	 7.3%,	 and	
3.5%	 in	 the	 last	month	 (2007	data).1	Methamphetamine	
powder	use	in	the	age	group	of	14	years	and	older	in	the	
last	12	months	decreased	by	0.9%	to	2.3%	in	2007	com-
pared	to	3.2%	in	2004.	The	use	of	ecstasy	in	the	same	age	
group	 in	 the	 last	 12	months	 increased	by	0.1%	 to	3.5%	
(608,400)	and	reached	an	all	time	high.
In	a	2010	national	study	of	regular	drug	users,	the	propor-
tion	of	80%,	78%	and	82%	respondents	described	meth-
1	 There	is	no	updated	information	on	the	annual	prevalence	of	amphetamines		
use	among	the	general	population	since	2007.
australia: ats seizures (excluding ecstasy) by the aus-
tralian customs Border and protection service, 2005-
2010
Source: Australian Customs Border and Protection Service, 2010; 
Australian Customs Border and Protection Service, 2008 
Note: Data are based on financial year (1 July-30 June).
australia: total weight and number of seizures  
of crystalline methamphetamine detected by the  
australian customs Border and protection service, 
2005-2010
Source: Australian Customs Border and Protection Service, 2010; 
Australian Customs Border and Protection Service, 2008 
Note: Data are based on financial year (1 July-30 June).
australia: total weight and number of seizures of 
ecstasy detected by the australian customs Border 
and protection service, 2005-2010
Source: Australian Customs Border and Protection Service, 2010; 
Australian Customs Border and Protection Service, 2008 
Note: Data are based on financial year (1 July-30 June).
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amphetamine powder (speed), base and ice as easy or very 
easy to obtain. Participants purchased all forms of metham-
phetamine from a variety of sources, most commonly 
through friends and known dealers. 
The price2 for a gram of all forms of methamphetamine in 
2010 remained relatively stable compared to 2009. The 
average national price for speed and base increased from 
$250 to $300 and from $200 to $250 respectively. The 
price for crystalline methamphetamine remained stable 
compared to 2009 ($400).
During 2009–10, the median purity ranged from 4.4% in 
Tasmania to 17% in Western Australia. Western Australia 
has continuously recorded high purities in comparison to 
other jurisdictions over the past decade. The median purity 
of methamphetamine within Australia has been declining 
since 2006-07.
Ecstasy is considered as ‘easy’ or ‘very easy’ to obtain by 
74% of regular ecstasy users. Significantly more partici-
pants in 2010 reported ecstasy to be difficult to very diffi-
cult to obtain compared to 2009 results (26% in 2010, 
12% in 2009). Most jurisdictions reported the availability 
had remained stable.
The median price for a pill of ecstasy ranged from $23 in 
2 A degree of caution should be exercised when considering these figures, 
as fewer than 10 participants in each jurisdiction reported recent purchase 
of different forms of methamphetamine.
New Zealand: dismantled ATS laboratories,  
2000-2010
*2011 figures are for January to end March only. 
Source: New Zealand, 2011
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South Australia to $35 in Western Australia. That is a slight increase compared to the price of $20 reported from most 
jurisdictions in 2009.
In 2009-10, the median purity of ecstasy-group substances ranged from 6.8% in South Australia to 23% in Western 
Australia. This is the greatest range recorded since 2000–01. All jurisdictions reported decreases in the median purity, 
apart from Western Australia which has remained relatively stable.
New Zealand
ATS manufacture in New Zealand is primarily related to methamphetamine (locally known as ‘P’) for domestic consump-
tion. Methamphetamine is illegally manufactured mainly from imported pharmaceutical preparations containing ephe-
drine and pseudoephedrine (usually Contac NT from China). Domestic outlaw motorcycle gangs are heavily involved in 
the manufacture and distribution. There are also indicators of possible Vietnamese involvement in the manufacture of 
methamphetamine.
The number of dismantled clandestine ATS laboratories remains relatively stable. In 2010, 130 ATS laboratories were 
discovered. Most of these laboratories were manufacturing methamphetamine or were pseudoephedrine extraction labo-
ratories. One ‘combined ATS’ laboratory was involved in the manufacture of methamphetamine and possibly ecstasy. This 
laboratory was allegedly established to meet local demand for ecstasy. The laboratory was using a pill press to produce 
ecstasy pills. There are currently no legislative or regulatory controls on the importation, possession, and use of pill presses 
in New Zealand.
All laboratories were using ephedrine or pseudoephedrine as the main precursor. The reported yield for both was 50%.
The majority of laboratories continue to be located on private premises on the Upper North Island. The shortage of ephe-
drine and pseudoephedrine has forced some manufacturers to extract ephedrine from the ephedra plant. A laboratory 
extracting ephedrine/pseudoephedrine from the ephedra plant was seized in July 2010.
For 2010, New Zealand reported seizures of 30.4 kg of methamphetamine, a 50% increase compared to 2009. More 
than half of this amount (19.5 kg) was seized at the border, mainly in the form of internal concealments and mail inter-
cepts. Seizures of amphetamine remain relatively small. In 2010, only 0.5 kg of amphetamine were reported seized. 
Primary embarkation points for detections of methamphetamine were Hong Kong, China, China, Indonesia and Australia. 
For amphetamine, the primary embarkation points were Thailand, China and the USA.
The median price for a gram of methamphetamine remains at the same level for the third year in a row (NZ$ 700). The 
mean price for a gram, however, has reportedly increased from NZ$ 738 to NZ$ 780 for a gram.3 
The reported price for amphetamine powder was NZ$ 30 per point (0.1g) and for methamphetamine in powder/crystal 
form NZ$ 780 per gram. 
The purity of methamphetamine in powder/crystal form remains stable at 74%. Methylsulfonylmethane (MSM)4 is the 
usual diluent for methamphetamine in New Zealand.
Thirty-four % of frequent drug users reported that methamphetamine was ‘very easy’ to obtain whereas 2 % reported 
that it was very difficult.
In 2010, New Zealand authorities seized 45,109 ecstasy pills. That is an almost three-fold increase compared to 2009 
when 15,477 pills were seized. The purity of the ecstasy pills remains low. The analyses in the majority of the cases iden-
tified the pills as containing either very little or no MDMA. Pills sold as ecstasy often contain substances like mephedrone, 
ketamine, 4-MEC, BZP, TFMPP, caffeine, Bk-MBDB (butylone), methenamine, methylone and cathinone. 
The price for one ecstasy pill ranges from NZ$ 40 to NZ$ 70 and remained stable compared to 2009. Frequent drug users 
reported the purity of ecstasy to be decreasing compared to 2006 and 2007. The availability of ecstasy was reported  as 
being ‘stable’/ ‘more difficult’ to obtain over the past six months in 2009.
The number of seizures of ephedrine and pseudoephedrine by New Zealand Customs has increased significantly since 
2004. Seizures peaked in 2009, when almost 5.4 million pills (1,203 kg) were seized. In 2010, the number of seized 
precursors dropped by 20% to 4.3 (967 kg). Preliminary data for 2011 shows that seized quantities continue to decline 
in 2011. Asian organized crime groups are predominant in trafficking of ephedrine, pseudoephedrine, and metham-
phetamine.
3 SHORE, 2010. 
4 MSM is often sold as a dietary supplement.
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Primary	embarkation	points	 for	detections	of	ephedrine	 in	2010	were	Thailand,	United	Arab	Emirates	and	China.	 For	
pseudoephedrine	the	primary	embarkation	points	were	China,	Hong	Kong,	China	and	the	United	Kingdom.
Seizures	of	methamphetamine	at	the	border	have	increased	considerably.	In	2010,	Customs	seized	19.5	kg	of	metham-
phetamine	which	represents	an	81%	increase	in	seizures	at	the	border	compared	with	the	previous	year.	Furthermore,	in	
the	first	two	months	of	2011	alone,	Customs	seized	another	6.1	kg	of	methamphetamine.	Organized	crime	groups	from	
the	Islamic	Republic	of	Iran	and	West	Africa	are	involved	in	trafficking	methamphetamine	to	New	Zealand.
The	lifetime	amphetamines	prevalence	rate	among	the	general	population	is	10.8%.	Annual	prevalence	among	the	gen-
eral	population	aged	16-64	years	is	2.1%,	one	of	the	highest	in	the	world.	Men	were	significantly	more	likely	to	use	all	
types	of	ATS	than	women.	For	both	men	and	women,	the	prevalence	of	having	ever	used	amphetamines	peaked	in	the	
18-24	years	age	group	and	decreased	with	increasing	age	thereafter.	
Methamphetamine-related	convictions	have	been	on	 the	 rise	 since	2004	when	1,167	people	were	convicted.	 In	2009,	
there	were	2,435	convictions	compared	to	2,058	in	2008.
pacific isLanD states  
anD territories
The	Pacific	Island	region	covers	millions	of	square	kilometers	of	ocean,	strategically	located	between	Asia,	Australia	and	
New	Zealand.	The	countries	and	territories	in	the	region	are	a	mixture	of	independent	states,	associated	states,	integral	
parts	of	non-Pacific	 island	countries	and	dependent	 states.	 Islands	vary	 in	 terms	of	 size	and	population,	 ranging	 from	
Papua	New	Guinea	which	has	a	population	of	about	six	million	to	Niue,	with	a	population	of	less	than	2,000.
The	Pacific	Islands	are	vulnerable	due	to	their	close	proximity	to	major	amphetamine-type	stimulants	(ATS)	markets.	There	
are	millions	of	potential	customers	and	the	potential	for	spill-over	effect	exists.	A	similar	spill-over	effect	has	been	observed	
in	States	and	territories	in	the	Caribbean	which	are	used	for	the	transshipment	of	cocaine	from	South	America	to	North	
America	or	Europe.	Good	air	and	sea	links	to	South-East	Asia,	 long	coastlines	which	are	difficult	to	patrol,	 limited	law	
enforcement	capacity	and	a	multitude	of	small	 islands	 increase	the	vulnerability.	 In	addition,	there	 is	a	growing	risk	of	
drug	crimes	from	returning	deportees	with	links	to	criminal	organizations.	
new Zealand: border seizures of ephedrine and  
pseudoephedrine 2004-2010
*2011 figures are for January to end March only. 
Source: New Zealand, 2011
new Zealand: annual prevalence rate of ampheta-
mines among population aged 16-64, by age group 
and gender, 2007
Source: MohNZ, 2010
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ATS	 awareness	 is	 low	 and	 very	 few	drug	monitoring	 sys-
tems	exist	in	the	region.	Information	related	to	ATS	manu-
facture,	trafficking	and	use	in	the	Pacific	Island	States	and	
territories	 is	 virtually	 non-existent.	 The	 very	 low	 rate	 of	
adherence	to	the	United	Nations	drug	control	Conventions	
is	an	obstacle	towards	gaining	an	insight	into	drug-related	
issues.	Only	Fiji,	Federated	States	of	Micronesia	and	Tonga	
are	parties	to	all	treaties,	making	the	Pacific	the	region	with	
the	lowest	rate	of	treaty	adherence.	Of	the	12	non-parties	
to	 the	 1988	Convention,	 seven	 are	 located	 in	Oceania.	
Most	 Pacific	 Island	 States	 and	 territories	 do	 not	 submit	
ARQs,	none	were	submitted	for	2009.
There	 have	 been	 reports	 of	 kitchen-scale	methampheta-
mine	laboratories	seized	in	Guam	and	there	are	indicators	
that	manufacture	may	be	 spreading	 to	other	 islands.	 The	
most	significant	manufacturing	case	so	far	was	reported	in	
Fiji	 in	 2004.	 It	 involved	 an	 industrial-scale	methampheta-
mine	 laboratory.	 The	 laboratory	was	 operated	 by	 Asian	
organized	 crime	 groups	 and	 purportedly	 contained	 700	
litres	of	liquid	methamphetamine,	5	kg	of	finished	crystal-
line	methamphetamine	 and	 enough	 precursors,	 including	
thionyl	 chloride,	 on	 site	 for	 the	manufacture	 of	 an	 addi-
tional	 1	mt	 of	methamphetamine.	 Production	 cycle	 esti-
mates	for	this	laboratory	were	between	500	and	1,000	kg	
of	 crystalline	methamphetamine	per	week,	making	 it	one	
of	 the	 largest	 laboratories	 ever	 seized.	 There	 have	 been	
reports	 of	 ATS	 precursor	 seizures.	 The	 biggest	 seizure	 of	
ATS	precursors	was	reported	in	2002.	Authorities	of	Papua	
New	Guinea	stopped	a	shipment	containing	ephedrine	from	India	and	pseudoephedrine	from	China	and	seized	a	total	of	
12	mt	of	precursor	chemicals.	There	have	been	also	reports	of	diversion	of	pharmaceutical	preparations	containing	pseu-
doephedrine	in	Tonga,	which	were	believed	to	be	destined	for	New	Zealand.
ATS,	particularly	methamphetamine,	are	seized	throughout	the	region.	In	Tonga,	17.7	kg	of	methamphetamine	believed	
to	be	destined	for	Australia	were	seized	in	2009.	Liquid	methamphetamine	was	reported	seized	in	French	Polynesia	(340	
grams),	five	seizures	of	smaller	quantities	of	methamphetamine	were	seized	in	the	mail	in	Guam.	In	February	2011,	4	kg	
of	a	methamphetamine-cocaine	mixture	were	found	in	a	vehicle	in	Tonga.	The	United	States	Postal	Inspection	Service	also	
reported	that	packages	containing	small	amounts	of	methamphetamine	had	been	sent	through	the	postal	system.	
A	recent	ATS	study	of	use	among	young	people	shows	that	the	use	rates	in	this	region	vary	considerably,	but	most	tend	
to	be	higher	than	those	for	Australia	or	New	Zealand,	with	the	highest	in	the	Marshall	Islands5	(lifetime	prevalence	ATS:	
15.4%	men,	10.5%	women)	and	Vanuatu6	 (lifetime	prevalence	ATS:	12.3%	men,	3.4%	women).7	However,	data	are	
insufficient	to	establish	any	trends.
As	countries	often	do	not	have	the	necessary	legislation,	infrastructure	and	enforcement	capabilities	in	place	to	prevent,	
detect,	seize	or	report	the	substances,	the	‘leakage’	of	substances	into	the	domestic	market	might	have	significant	con-
sequences.
5	 Youth	Risk	Behavior	Surveillance	System,	School	students	sample	2007,	(n=1522)	(Howard	at	al.,	2011).
6	 Second	Generation	BSS	15–24,	2008,	(n	=	301)	(Howard	at	al.,	2011).
7	 Howard	at	al.,	2011.
new Zealand: methamphetamine-related convictions, 
2004-2009
Source: New Zealand, 2011
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regional overview
ATS	trafficking	and	use	in	the	Near	and	Middle	East/South-West	Asia	continue	to	increase,	with	countries	such	as	Saudi	
Arabia,	the	Syrian	Arab	Republic	and	Jordan	witnessing	substantial	increases	in	ATS	seizures	since	2008.	Since	2007,	the	
only	reports	of	illicit	ATS	manufacture	have	come	from	the	Islamic	Republic	of	Iran;	the	origin	of	the	other	significantly	
large	 seizures	 in	 the	 region	 remaining	unidentified.	The	absence	of	manufacture	 reports	 is	 inconsistent	with	both	 the	
quantity	of	seizures	and	the	availability	of	key	ATS	precursors	in	the	region.
Historically,	 the	Near	and	Middle	East/South-West	Asia	has	served	as	a	corridor	 for	 trafficking	drugs	 from	eastern	and	
southern	Asia	to	illicit	drug	markets	in	Europe.	For	ATS,	however,	recent	trends	indicate	a	reversal	of	traditional	trafficking	
trends	in	some	areas.	For	example,	whereas,	up	to	2007-2008,	methamphetamine	was	trafficked	to	the	Islamic	Republic	
of	 Iran	from	China	and	Malaysia,	of	 late,	methamphetamine	has	been	smuggled	out	of	the	Islamic	Republic	of	 Iran	to	
markets	in	Asia	and	the	Pacific,	including	Indonesia,	Japan,	Malaysia,	New	Zealand	and	Thailand.
With	the	exception	of	Israel,	data	on	ATS	use	are	sparse	to	the	point	of	being	non-existent.
Official	reports	to	UNODC	of	illicit	ATS	laboratories	manufacturing	ATS	in	the	region	first	emerged	in	2007	when	Lebanon	
reported	 the	 detection	 of	 a	 laboratory	 reported	 to	 have	 been	manufacturing	 counterfeit	 Captagon	 pills	 containing	
amphetamine.	Since	then,	there	have	been	no	further	reports	of	illicit	amphetamine	laboratories,	a	fact	which	is	inconsist-
ent	with	the	high	seizures	of	amphetamine	 in	the	region.	Reports	of	 illicit	methamphetamine	manufacture	have	come	
exclusively	from	the	Islamic	Republic	of	Iran,	while	there	have	been	no	reports	at	all	of	illicit	manufacture	of	ecstasy-group	
substances.
Some	countries	in	Near	and	Middle	East/	South-West	Asia	have	unusually	high	requirements	of	ephedrine,	pseudoephe-
drine	and	P-2-P	which	could	lead	to	the	diversion	of	these	chemicals	from	licit	channels	to	illicit	ATS	manufacture.
Pseudoephedrine	is	among	the	most	frequently	used	starting	materials	in	the	illicit	manufacture	of	methamphetamine.	
Countries	reporting	very	high	estimates	include	the	Syrian	Arab	Republic,	Pakistan,	Jordan,	Iraq	and	Afghanistan.	
measure DruG Group 2005 2006 2007* 2008 2009
Laboratory  
(#)
Methamphetamine 
Amphetamine 
Other synthetic/combined stimulants 
Ecstasy-group substances
- 
- 
- 
-
- 
- 
- 
-
- 
1 
- 
-
4 
- 
- 
-
6 
- 
- 
-
total 0 0 1 4 6
Seizures  
(kg)
Methamphetamine
Amphetamine
Non-specified amphetamines
Ecstasy-group substances
3.4
10,309.9
832.0
64.5
239.6
15,613.8
2,070.5
2.0
41.0
19,167.9
21.3
272.1
1,472.9
19,638.7
89.5
28.8
719.8
24,771.6
69.0
9.2
total 11,209.8 17,925.9 19,502.3 21,229.9 25,569.6
Annual Prevalence 
(15-64)
Amphetamines-group substances
Ecstasy-group substances
 0.1%
 <0.1%
 0.2%
  <0.1%
**
**
**
**
 1.0%
 -
* From 2007 onwards, reported prevalence percentage is based on midpoint of range. ** No estimate could be calculated due to lack of data.  
- Not reported.
Source: UNODC ARQ/Delta
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near and middle east/south-West asia: annual legitimate requirements for pseudoephedrine, 2006-2010*
*Where years are missing, it indicates that no requirements were reported to INCB by countries that year. 
Source: INCB – Annual legitimate requirements reported by Governments for ephedrine, pseudoephedrine, 3,4 methylenedioxyphenyl-2- 
propanone, 1-phenyl-2-propanone and their preparations (Kilograms)
Near and Middle East/South-West Asia: annual legitimate requirements for pseudoephedrine 2006-
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For	ephedrine,	Pakistan	currently	reports	the	fourth	highest	
legitimate	 requirement	 for	 ephedrine	 in	 the	 world	
(22,000kg);	behind	China,	USA	and	the	Republic	of	Korea.	
Countries	with	 such	 high	 legitimate	 requirements	 can	 be	
attractive	targets	for	precursor	diversion.	
For	P-2-P,	 Jordan	has	 reported	 the	world’s	highest	annual	
legitimate	 requirement,	 accounting	 for	more	 than	half	 of	
the	global	total.	The	high	legitimate	need	is	based	on	the	
purported	formulation	of	P-2-P	into	‘cleaning	and	disinfec-
tion’	products.1	The	 International	Narcotics	Control	Board	
(INCB)	 has	 pointed	 out	 that	 the	 volume	 represents	 a	 sig-
nificant	risk	of	diversion	into	illicit	Captagon	manufacture,	
particularly	 as	 P-2-P	 is	 not	 an	 essential	 ingredient	 in	 the	
formulation	of	cleaning	and	disinfection	products	and	alter-
native	chemicals	exist.2	
Total	ATS	seizures	reported	to	UNODC	from	countries	in	the	
Near	 and	Middle	 East/South-West	 Asia	 have	more	 than	
doubled	since	2005,	 from	11.2	mt	 in	2005	to	25.6	mt	 in	
2009;	 representing	 over	 a	 third	 of	 global	ATS	 seizures	 in	
2009.	Most	 seizures	 concern	 counterfeit	 Captagon	 pills,	
believed	to	contain	amphetamine	as	the	principal	psycho-
tropic	ingredient.3	The	three	countries	reporting	the	highest	
seizures	 are	 Saudi	 Arabia,	 Jordan	 and	 the	 Syrian	 Arab	
Republic.	 At	 24.8	mt,	 total	 seizures	 of	 amphetamine	 in	
2009	from	the	region	constituted	75%	of	global	ampheta-
mine	seizures,	up	from	63%	in	2008.	
The	 origin	 of	 the	 amphetamine	 sold	 as	Captagon	 in	 the	
region	 is	unknown.	Traditionally,	 the	substance	was	believed	to	have	been	manufactured	 illicitly	 in	South-East	Europe,	
notably	Bulgaria,	and	trafficked	to	the	region,	often	transiting	Turkey	by	air	or	sea.	Some	countries	in	the	region,	e.g.	the	
Syrian	Arab	Republic	and	Jordan,	have	named	Turkey	as	a	source.	A	recent	report	by	the	Turkish	National	Police	concluded	
that	 criminal	 organizations	 have	 shifted	Captagon	manufacture	 to	 the	 Syrian	Arab	 Republic.4	 This	 shift	which	would	
appear	to	be	consistent	with	the	significant	decline	in	the	amount	of	seizures	in	Turkey,	which	have	fallen	from	almost	
20	million	pills	in	2006	to	2.8	million	pills	in	2009.5	
For	methamphetamine,	the	 Islamic	Republic	of	 Iran	reports	the	highest	seizures	 in	the	region.	The	five	other	countries	
reporting	smaller	seizures	of	methamphetamine	between	2005	and	2009	were	Bahrain,	Israel,	Kuwait,	Saudi	Arabia	and	
the	United	Arab	Emirates.
With	9	kg	recorded	in	2009,	ecstasy	seizures	in	the	region	remain	comparatively	low.	Other	countries	such	as	Lebanon,	
Pakistan	and	Saudi	Arabia	have	been	 reporting	 small	quantities,	between	2	kg	and	29	kg,	 since	2006.	The	 last	 large	
seizure	was	reported	from	Israel	in	2007	(252.8kg).	
The	estimate	of	annual	prevalence	of	ATS	in	the	Near	and	Middle	East/South-West	Asia	is	calculated	as	being	between	
0.2%	and	1.7%	(between	0.5	and	4.3	million	people)	and	the	wide	range	reflects	the	limited	prevalence	data	available	
for	the	region.	The	lack	of	adequate	resources	and	monitoring	systems	has	resulted	in	very	 limited	information	on	the	
extent	and	patterns	of	and	trends	in	drug	abuse	in	the	region	which	in	turn	hampers	the	ability	of	Governments	to	devise	
appropriate	responses	to	the	problem.
It	is	likely,	however,	that	the	plentiful	supply	of	amphetamine	in	the	region	will	have	an	effect	on	ATS	use.	Jordan,	Pakistan	
and	Qatar	reported	a	perceived	increase	in	the	use	of	amphetamine-type	stimulants	over	the	past	few	years.	Rising	meth-
1	 INCB,	2011a.	Concerns	about	the	 legitimacy	of	the	shipments	to	Jordan	and	their	final	destination,	 Iraq,	were	supported	by	the	results	of	the	 laboratory	
analysis	of	the	alleged	cleaning	product	communicated	to	the	Board,	which	showed	no	traces	of	P-2-P.	(INCB,	2011b).
2	 INCB,	2010b.
3	 Captagon	was	originally	the	trade	name	for	fenethylline,	a	synthetic	stimulant.	Analysis	of	seized	Captagon	pills	show	that	most	contain	amphetamine	and	
other	ingredients	such	as	caffeine	and	theophylline.
4	 Turkey,	2011.	
5	 Turkey,	2011.
Jordan: reported annual legitimate requirement for 
phenyl-2-propanone (p-2-p)
Source: INCB – Annual legitimate requirements reported by Govern-
ments for ephedrine, pseudoephedrine, 3,4 methylenedioxyphenyl-
2-propanone, 1-phenyl-2-propanone and their preparations 
(Kilograms)
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total ats seizures in the near and middle east, 
2005-2009
Source: UNODC ARQ/DELTA
Distribution of amphetamine seizures in the  
near and middle east/ south-West asia, 2009  
(by kg equivalents)
Source: UNODC ARQ/DELTA
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amphetamine	 use	 has	 been	 confirmed	 by	 the	 Islamic	
Republic	of	Iran.	Use	of	ecstasy	and	cathinone	(“hagigat”)	
has	reportedly	increased	in	Israel.6
saudi arabia 
Saudi	Arabia	continues	to	be	a	major	market	for	ATS	in	the	
Near	and	Middle	East,	and	in	2009,	was	identified	by	other	
countries	in	the	region	as	a	major	destination	for	ampheta-
mine,	 specifically	 Captagon,	 trafficked	 on	 their	 territory.	
Following	a	 significant	 increase	 in	 recorded	 seizures	 since	
2003,	seizures	have	shown	the	first	signs	of	stabilization	at	
an	average	of	13.2	mt	since	2006.	In	2009,	seizures	made	
in	 Saudi	 Arabia	 constituted	 about	 one	 third	 of	 global	
amphetamine	 seizures	 (33	mt)	 and	 almost	 one	 fifth	 of	
global	ATS	 seizures	 (71	mt).	 The	 largest	 single	 seizure	 of	
amphetamine	 in	 2009	 (2.5	mt)	was	made	 at	 the	 border	
with	Jordan.	Saudi	Arabia	also	reports	seizures	of	metham-
phetamine,	with	145	kg	being	seized	in	2009.
Information	 on	ATS	use	 is	 hard	 to	 come	by	 but	 scientific	
research	suggests	that	72.8	percent	of	patients	treated	for	
drug	 problems	 in	 Saudi	Arabia	 are	 addicted	 to	 ampheta-
mines.7	Captagon	and	other	amphetamines	are	reportedly	
used	mainly	 by	 students,	 drivers,	 and	 employees	 seeking	
prolonged	 energy.	 The	 extremely	 high	 level	 of	 seizures	 is	
also	 an	 indicator	 that	 illicit	manufacture	might	 be	 taking	
place	in	the	country	but	no	detection	of	illicit	 laboratories	
has	ever	been	reported	to	UNODC.	
syrian arab republic
ATS	 seizures	 in	 the	 Syrian	Arab	 Republic	 have	 increased	
more	 than	 six-fold	 since	2005.	 Seizures	 of	 amphetamine,	
mostly	 in	 the	 form	 of	 Captagon	 pills,	 almost	 doubled	
between	2008	and	2009	to	reach	3.7mt	(22	million	pills).	
Government	 reports	 to	UNODC	 associate	 the	 increase	 in	
trafficking	with	 large	 demand	 for	 the	 drug	 and	 attribute	
the	 increase	 in	seizures	 to	cooperation	with	neighbouring	
countries.	The	Government	has	never	reported	the	detec-
tion	of	any	ATS	laboratories	to	UNODC.
Jordan
ATS	seizures	in	Jordan	have	increased	significantly	in	recent	
years.	Between	2008	and	2009,	seizures	of	Captagon	dou-
bled,	from	2.4	mt	(approximately	14	million	pills)	to	4.9	mt	
(29	million	 pills).	 Preliminary	 reports	 for	 2010,	 however,	
indicate	 a	 substantial	 decrease	 in	 seizures.	 The	 increasing	
supply	 of	 Captagon	may	 be	 spilling	 over	 into	 the	 illicit	
domestic	drugs	market	and	the	Government	has	reported	
admissions	to	treatment	of	Captagon	users.	
6	 Bar-Hamburger	et	al.,	2009.
7	 Abu	Madini	et	al.,	2008.
saudi arabia: seizures of ats, 2005-2009
Source: World Customs Organization
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near and middle east/south-West asia: ats seizures, 2005 - 2009
Source: UNODC ARQ/ DELTA
islamic republic of iran
Illicit	methamphetamine	manufacture	 in	the	 Islamic	Republic	of	 Iran	was	first	 reported	to	UNODC	in	2008,	when	four	
laboratories	were	detected.	Six	laboratories	were	reported	seized	in	2009.	Methamphetamine	seizures	have	been	increas-
ing	since	2005.	However,	whereas	between	2005	and	2007,	reported	seizures	of	methamphetamine	ranged	between	2.3	
kg	and	38	kg,	in	2008	seized	quantities	increased	sharply.	In	the	first	nine	months	of	2010,	seizures	of	methamphetamine	
were	already	up	55%	(883	kg)	from	seizures	for	the	same	period	in	2009	(571	kg).8	
Since	2008,	reports	of	an	increasing	number	of	Iranian	nationals	caught	smuggling	methamphetamine	to	other	parts	of	
Asia	have	been	received.	Traffickers	from	the	 Islamic	Republic	of	 Iran	have	been	apprehended	 in	Azerbaijan,	Malaysia,	
Thailand,	Japan,	Sri	Lanka	and	Uzbekistan,	often	transiting	through	countries	such	as	Qatar,	Turkey	and	the	United	Arab	
Emirates.	Turkey	has	reported	that	methamphetamine	is	being	smuggled	overland	from	the	Islamic	Republic	of	Iran	into	
Turkey	and	then	trafficked	by	air	to	East	and	South-East	Asia.9	Indonesian	and	Philippine	authorities	also	mentioned	Iran	
as	a	country	of	origin	 for	methamphetamine	 in	2009.	Government	authorities	have	 reported	further	strengthening	of	
control	measures	over	precursors	and	other	chemicals	used	 in	 the	manufacture	of	methamphetamine	 to	prevent	 their	
diversion	from	licit	channels.10
Research	by	the	Iranian	Drug	Control	Headquarters	(DCHQ)	has	shown	that	abuse	of	stimulants,	including	amphetamine	
and	methamphetamine,	is	on	the	rise.11	In	2009,	the	Islamic	Republic	of	Iran	reported	an	increase	in	the	prevalence	of	
ATS	as	well	as	an	increase	in	those	receiving	treatment	for	amphetamines-group	substances.
other countries 
Other	countries	reporting	 large	amphetamine	seizures	 in	2009	include	Yemen	(854	kg)	Qatar	(758	kg)	and	the	United	
Arab	Emirates	(129	kg),	indicating	that	the	trafficking	of	amphetamine	is	becoming	more	widespread.	In	August	2010,	
8	 DCHQ,	2011.
9	 Turkey,	2011.
10	 DCHQ,	2011.
11	 DCHQ,	2011.
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Qatar’s	Drug	Combating	Department	(DCD)	arrested	members	of	an	international	criminal	network	engaged	in	drug	traf-
ficking,	 intercepting	 2.2	million	 pills	 sold	 as	Captagon	 during	 a	 controlled	 delivery.12	 The	United	Arab	 Emirates	 also	
reported	multi-million	pill	seizures	of	Captagon	in	2009	and	2010.
Small	quantities	of	methamphetamine	were	seized	 in	Afghanistan	 in	2010	and	2011.	From	January	to	June	2011,	the	
Forensic	Laboratory	of	the	Counter	Narcotics	Police	of	Afghanistan	analysed	a	total	of	6	samples	of	crystalline	metham-
phetamine,	compared	to	one	sample	in	2010.	It	is	believed	that	the	methamphetamine	was	trafficked	into	Afghanistan	
from	a	neighbouring	country.
Pakistan	may	become	the	next	target	for	the	manufacture	of	synthetic	drugs.	 In	March	2011,	245	kg	of	ephedrine,	a	
precursor	chemical	used	in	the	manufacture	of	methamphetamine,	were	seized	from	a	container	in	Pakistan	–	the	first	
registered	seizure	of	that	substance	in	the	country.	In	April	2011,	Pakistan	authorities	seized	4	kg	of	methamphetamine	
from	a	Malaysian	national	attempting	to	smuggle	the	drug	into	the	country	in	his	suitcase.
12	 UNODC,	2010b.
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regional overview
Trends	 in	 illicit	ATS	manufacture	and	use	 in	Europe	continue	to	be	 largely	stable	but	some	notable	new	developments	
have	emerged	in	recent	years.	While	in	most	countries	the	main	ATS	of	concern	continue	to	be	amphetamine	and	ecstasy-
group	substances,	there	is	evidence	that	methamphetamine	markets	may	be	expanding.	In	addition,	the	appearance	of	
new	“designer	drugs”	on	the	market	such	as	mephedrone	constitutes	a	worrying	new	trend.
At	406,	the	number	of	ATS	laboratories	dismantled	in	2009	declined	by	almost	40%	from	2008,	to	the	lowest	number	
of	 seized	 laboratories	 reported	 to	UNODC	 from	 the	 region	 since	 2003.	 The	 drop	 is	 largely	 due	 to	 the	 decline	 in	 the	
reported	number	of	methamphetamine	laboratories	dismantled	between	2008	and	2009.	
Europe,	 notably	West	 and	Central	 Europe,	 continues	 to	 be	 an	 important	market	 for	 amphetamine,	 in	 terms	 of	 both	
manufacture	 and	 use.	 Reported	 amphetamine	manufacture	 remains	 concentrated	 in	 Europe,	which	 accounted	 for	 all	
seized	illicit	amphetamine	laboratories	reported	to	UNODC	in	2009	and	for	over	80%	of	laboratories	reported	in	2008.	
In	2008,	there	was	a	significant	drop	in	the	number	of	seized	amphetamine	laboratories	reported	to	UNODC,	from	102	
in	2007,	to	41	in	2008	and	44	in	2009.1	Europol	reports	that,	from	2002	to	2010,	most	of	the	illicit	amphetamine	labo-
ratories	seized	in	Europe	were	in	Poland,	followed	by	the	Netherlands	and	Germany.	Manufacturing	sites	differ	by	coun-
try,	with	larger-scale	illicit	manufacture	taking	place	in	the	Netherlands	and	small	to	medium	scale	manufacture	in	Poland,	
Lithuania	and	Estonia.2
The	 countries	 of	 origin	 of	 amphetamine	most	 frequently	mentioned	 by	 national	 authorities	 are	 the	Netherlands	 and	
Poland,	while	the	most	frequently	mentioned	destinations	are	Germany,	the	United	Kingdom	and	the	Scandinavian	coun-
tries.	
The	decline	 in	 amphetamine	 laboratories	 reported	 since	2008	 is	 not	 consistent	with	 seizures	of	 the	drug	which	have	
remained	high,	averaging	8	mt	between	2005	and	2009	and	comprising	about	11%	of	the	global	total	seized	in	2009.	
Between	2008	and	2009,	Europe’s	share	in	the	global	seizure	of	amphetamine	fell	from	about	one	third	to	just	under	one	
1	 The	largest	number	of	amphetamine	laboratories	reported	in	2009	was	by	the	Russian	Federation	(20),	followed	by	Poland	(8)	and	Germany	(6).
2	 Europol,	2011b
measure DruG Group 2005 2006 2007* 2008 2009
Laboratory  
(#)
Methamphetamine
Amphetamine
Ecstasy-group substances
311
150
14
477
122
11
406
102
10
605
41
4
361
44
1
total 475 610 518 650 406
Seizures 
(kg)
Methamphetamine
Amphetamine
Non-specified amphetamines
Ecstasy-group substances
133.1
8,039.0
1,733.6
4,708.5
189.8
6,019.5
5,224.4
5,648.6
390.7
8,791.0
2,034.2
5,838.5
323.1
9,438.1
9.4
1,763.4
696.5
8,116.7
263.4
994.8
total 14,614.2 17,082.3 17,054.4 11,534.0 10,071.4
Annual  
Prevalence 
(15-64)
Amphetamines-group substances
Ecstasy-group substances
0.5%
0.6%
0.45%
0.54%
0.5%
0.7%
0.55%
0.7%
0.55%
0.7%
*From 2007 onwards, reported prevalence percentage is based on midpoint of range.
Source: UNODC ARQ/DELTA
europe: ats laboratories, seizures, and annual prevalence rates (2005-2009)
52
2011 GLoBaL ATS ASSESSMENT
illicit amphetamine laboratories: seizures by country 
of origin, (2002-2010)
Source: Europol, 2011b
quarter	–	largely	due	to	increases	in	seizures	in	the	Near	and	
Middle	East.	
In	2008	and	2009,	amphetamine	seizures	in	Europe	consti-
tuted	about	80%	of	total	ATS	seizures	 in	Europe	–	repre-
senting	 a	 significant	 departure	 from	previous	 years	when	
the	seizure	of	ecstasy-group	substances	made	up	a	substan-
tial	 proportion	 of	 seizures.3	 This	 was	 due	 to	 the	 sharp	
decline	in	the	seizures	of	ecstasy-group	substances	reported	
to	 UNODC	 since	 2007	which	 contributed	 to	 the	 overall	
reduction	 in	 total	ATS	 seizures	 in	 the	 region	 in	2008	and	
2009.	Ecstasy-group	 substances	 in	 the	EU	continue	 to	be	
sourced	 almost	 exclusively	 from	 the	 Netherlands	 and	
Belgium,4	with	the	Netherlands	being	the	most	frequently	
mentioned	country	of	origin	for	ecstasy	by	European	coun-
tries.	 Reports	 of	 both	 the	 seizures	 of	 ecstasy-group	 sub-
stances	and	 the	numbers	of	 laboratories	dismantled	have	
been	 largely	 in	 decline	 since	 2005,	with	 only	 one	 illicit	
ecstasy	 laboratory	being	reported	 in	2009	by	Belgium	–	a	
sign	that	manufacture	of	the	drug	formerly	concentrated	in	
Europe	has	 started	 to	 shift	 to	other	 regions	of	 the	world	
such	as	Australia	and	Indonesia.5	
In	 2011,	 Europol	 pointed	 to	 a	 significant	 reduction	 in	
ecstasy	manufacture	in	recent	years	which	it	attributed	to	a	
3	 Ecstasy	accounted	for	only	10%	of	ATS	seizures	in	Europe	in	2009,	compared	with	6%	for	methamphetamine	(UNODC,	2011a).
4	 Europol,	2011a.
5	 The	highest	number	of	dismantled	ecstasy	laboratories	in	2009	was	reported	from	Asia	and	Oceania,	namely	Indonesia	(18)	and	Australia	(19).
europe: seizures of illicit ats laboratories, 2001-2009
Source: UNODC ARQ/DELTA
europe: total ats seizures, 2003-2009
Source: UNODC ARQ/DELTA
Spain, 3
Bulgaria, 8
Denmark, 1
Estonia, 11
Germany, 32
Netherlands, 96
United 
Kingdom, 3
Poland, 104Belgium, 20
Lithuania, 4
106
195
396
311
477
406
605
361
131 144
198
150
122
102
41 4428 18 20 14 11 10 4 1
42
33
320
100
200
300
400
500
600
700
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
Se
iz
ed
 la
b
o
ra
to
ri
es
 (
#)
M ethamphetamine
Amphetamine
Ecstasy-group substances
0.1 0.1 0.1 0.2 0.4 0.3 0.7
5.4 5.6
8.0
6.0
8.8 9.4 8.1
1.4
4.9
1.7 5.2
2.06.1
7.4
4.7
5.6 5.8
1.8
1.0
0.3
0
2
4
6
8
10
12
14
16
18
20
20
03
20
04
20
05
20
06
20
07
20
08
20
09
Se
iz
u
re
s 
o
f 
A
TS
 (
m
t 
eq
u
iv
al
en
ts
)
Ecstasy-group substances
Non-specif ied amphetamines
Amphetamine
Methamphetamine
53
europe
shortage	of	the	precursor	chemical	PMK;	however,	Europol	predicts	that	ecstasy	manufacture	and	trafficking	will	begin	
to	increase	again	in	the	coming	years.6	
Reports	 of	 illicit	methamphetamine	manufacture	 in	 the	 form	of	mostly	 small-scale	 laboratories	 continued	 to	 emerge	
mainly	from	the	Czech	Republic	and,	to	a	lesser	extent,	Slovakia	and	Germany.	In	comparison	to	most	other	regions	of	
the	world,	illicit	manufacture	of	methamphetamine	is	fairly	low.	However,	Austria,	Belarus,	Lithuania,	Netherlands,	Poland	
and	Portugal	have	all	 recently	 reported	first	 time	seizures	of	methamphetamine	 laboratories	which	 indicates	 that	 illicit	
methamphetamine	activity	may	be	spreading	through	the	region.	
The	European	Monitoring	Centre	for	Drugs	and	Drug	Addiction	(EMCDDA)	and	Europol	point	to	a	possible	replacement	
of	amphetamine	by	methamphetamine	on	 the	 illicit	market	especially	 in	 some	Nordic	and	Baltic	 countries.7	EMCDDA	
reports	that	methamphetamine	manufacture	 in	Lithuania	and	Poland	mainly	serves	 illicit	drug	markets	 in	Scandinavian	
countries,	where	the	substance	is	possibly	being	sold	as	a	replacement	for	amphetamine.8	Like	amphetamine,	in	Europe,	
methamphetamine	is	usually	found	in	powder	form.9	Since	2004,	Scandinavian	countries	have	consistently	accounted	for	
over	half	of	total	annual	European	methamphetamine	seizures.	Together,	Norway,	Sweden,	Lithuania	and	Russian	Fed-
eration	account	for	most	methamphetamine	seized	in	Europe.10
Overall,	 surveys	show	a	 relatively	 low	annual	prevalence	of	amphetamines-group	substances	 in	much	of	 the	 region	of	
between	0.5%	and	0.6%,	with	prevalence	being	higher	in	West	and	Central	Europe	than	in	East	and	South-East	Europe.11	
Within	West	and	Central	Europe,	Czech	Republic,	Denmark,	United	Kingdom,	Norway	and	Estonia	remain	the	countries	
with	the	highest	annual	prevalence	rates.	In	South-East	Europe,	Bosnia	and	Herzegovina	and	Bulgaria	have	high	annual	
prevalence	rates	of	amphetamines	use.	On	average,	3.7	%	of	all	European	adults	have	used	amphetamines	at	least	once.	
Following	general	increases	in	the	1990s,	reports	of	stabilizing	or	even	decreasing	trends	in	amphetamine	and	ecstasy	use	
in	the	general	population	in	Europe	are	supported	by	the	most	recent	data.
Amphetamine	is	the	more	commonly	used	substance	in	most	parts	of	Europe.	At	less	than	5%,	the	proportion	of	problem	
amphetamine	users	 is	relatively	small	 in	the	majority	of	European	countries	and	trends	 in	amphetamine	users	entering	
treatment	between	2003	and	2008	have	 remained	broadly	 stable	 in	most	countries.12	 In	Sweden,	Finland	and	Latvia,	
treatment	for	use	of	amphetamine	as	the	primary	drug	is	proportionally	much	higher.13	Along	with	the	Czech	Republic,	
Estonia	and	Lithuania,	 these	countries	have	also	 reported	high	 rates	of	 injecting	use	of	amphetamine	among	primary	
amphetamine	users	in	recent	years	(ranging	from	52%	to	82%).14	
Until	 recently,	methamphetamine	use	was	 largely	 confined	 to	 the	Czech	Republic	 and	Slovakia	but	 some	countries	 in	
Northern	Europe	have	begun	to	report	the	increased	presence	of	methamphetamine	on	their	markets.15	Use	of	amphet-
amines	primarily	 takes	place	 in	 recreational	 settings,	and	 lifetime	prevalence	 rates	vary,	with	 rates	as	high	as	30-70%	
recorded	in	some	studies	in	Czech	Republic,	Hungary,	Slovakia	and	the	United	Kingdom.	There	are	indications,	however,	
that	amphetamines	have	become	less	widespread	among	party	goers	than	cocaine,	ecstasy	and	new	substances	such	as	
mephedrone.16	
The	annual	prevalence	of	ecstasy	use	in	Europe	is	estimated	at	0.7%	of	the	adult	population	and	is	higher	in	West	and	
Central	Europe	(0.8%)	than	in	East	and	South-East	Europe	(0.6%).	Most	European	countries	are	now	reporting	stabilizing	
trends	of	ecstasy	use.	The	Czech	Republic,	Latvia,	Slovakia	and	United	Kingdom	remain	countries	with	high	ecstasy	use	
prevalence	rates	in	the	general	population,	with	most	users	aged	15-34.	Targeted	surveys	in	nightlife	settings	in	European	
countries	suggest	that	the	prevalence	and	patterns	of	stimulants	and	ecstasy	use,	together	with	alcohol,	remains	high.	
6	 Europol,	2011a.	
7	 EMCDDA	and	Europol,	2009.
8	 EMCDDA,	2010a.	Unlike	many	regions	where	crystalline	methamphetamine	and	methamphetamine	smoking	are	increasingly	prevalent,	methamphetamine	
in	Europe	is	available	almost	exclusively	in	powder	form,	and	so	is	difficult	to	distinguish	from	amphetamine	(also	in	powder	form)	in	both	appearance	and	
effect.	(EMCDDA,	2010b).
9	 EMCDDA,	2010b.
10	 Norway	reports	the	highest	seizures	of	methamphetamine,	followed	by	Sweden,	Lithuania	and	the	Russian	Federation.
11	 In	most	West	and	Central	European	countries,	problem	amphetamines	use	represents	a	small	 fraction	of	overall	problem	drug	use,	except	 for	 the	Czech	
Republic	and	some	of	the	Nordic	countries.	Those	who	report	amphetamine	as	their	primary	substance	account	for	less	than	5%	of	drug	users	in	treatment,	
on	average,	in	Europe	(UNODC,	2011a).
12	 EMCDDA,	2010a.
13	 Sweden	(32%),	Finland	(20%)	and	Latvia	(15%).	Five	other	countries	(Belgium,	Denmark,	Germany,	Hungary,	Netherlands)	report	between	6%	and	10%	of	
treatment	entries	from	clients	citing	amphetamine	as	their	primary	drug.
14	 EMCDDA,	2010a.
15	 EMCDDA,	2010a.
16	 EMCDDA,	2010b.
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Germany: ats seizures, 2003-2009
Source: UNODC ARQ/DELTA
Germany: seized ats laboratories, 2003-2009
Source: UNODC ARQ/DELTA
Germany: number of drug users who came to the attention of the police for the first time 2000-2009
Source: National Reports (2001-2009) to the EMCDDA by the Reitox National Focal Point Germany
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Some	studies	even	suggest	that	drug	use	patterns	among	club-goers	are	becoming	increasingly	polarized,	that	is,	show-
ing	ever	higher	prevalence	rates,	in	sharp	contrast	to	the	situation	among	the	general	population.17
Europe	continues	to	provide	some	of	the	best	and	most	comprehensive	information	related	to	ATS	use,	trafficking	and	
manufacture.	 The	 following	 sections	 focus	on	 selected	 European	 countries	 and	 examine	 the	 latest	ATS	 trends	by	 sub	
region.
West anD centraL europe
Germany
Amphetamine	seizures	have	been	steadily	increasing	over	the	past	decade,	with	seizures	increasing	almost	three-fold	from	
484	kg	in	2003	to	almost	1.4	mt	in	2009.	In	2010,	however,	amphetamine	seizures	dropped	to	1.2	mt	(-13%).	Seizures	
of	methamphetamine	 (in	 the	 form	of	crystalline	methamphetamine)	averaged	about	10	kg	annually	until	2010,	while	
ecstasy	seizures	have	continued	to	decrease,	with	no	seizures	reported	in	2009.	
In	2008,	for	the	first	time,	more	illicit	methamphetamine	laboratories	were	dismantled	in	Germany	than	amphetamine	
laboratories	–	a	trend	which	continued	in	2009.	However,	the	laboratories	continue	to	be	small-scale	and	methampheta-
mine	appears	to	be	still	not	very	common	in	Germany	in	comparison	with	other	substances.	Nevertheless,	alongside	the	
established	trend	of	the	trafficking	of	small	quantities	of	methamphetamine	manufactured	in	the	Czech	Republic	to	Ger-
many,	 the	manufacture	 of	 crystalline	methamphetamine	 in	 illicit	 kitchen	 laboratories	was	 found	 to	 have	 increased	 in	
2008.	
Most	amphetamine	seized	in	Germany	was	trafficked	into	the	country	from	the	Netherlands	and,	to	a	lesser	extent,	Bel-
gium,	Poland	and	the	Czech	Republic	while	the	majority	of	seized	ecstasy	pills	originated	in	the	Netherlands.	Approxi-
mately	 64%	of	 amphetamines	 seized	 in	 2009	were	 confiscated	 in	 the	 provinces	 of	 Saxony	 and	Bavaria,	with	 smaller	
quantities	of	the	drug	also	being	seized	 in	Thuringia.	As	 in	previous	years,	 in	2009,	crystalline	methamphetamine	was	
seized	mainly	in	the	regions	close	to	the	Czech	Republic.18	In	2010,	a	total	of	almost	27	kg	of	crystalline	methampheta-
mine	were	seized,	the	largest	ever	total	amount.	While	more	than	half	of	the	total	quantity	was	seized	in	Saxony	and	one	
fifth	was	seized	in	Bavaria,	there	were	also	some	individual	cases	in	North	Rhine	Westphalia	and	Hesse,	areas	which	are	
not	traditionally	associated	with	the	drug.	In	2010,	small	amounts	of	amphetamines	were	seized	at	Frankfurt	airport,	with	
drugs	in	transit	to	Japan.19
There	was	an	increase	in	the	annual	prevalence	of	amphetamines	in	2009	(0.7%)	over	the	previous	national	estimate	in	
2006	 (0.5%),	while	 the	annual	prevalence	of	 ecstasy	 rate	has	 remained	at	0.4%	 (down	 from	0.8%	 in	2006).	Recent	
research	also	indicates	that	substance	use	in	Germany’s	clubbing	scene	is	on	the	decline.20	This	increase	in	the	prevalence	
of	amphetamines	and	decrease	in	ecstasy	use	is	reflected	by	data	from	the	German	Federal	Criminal	Police	Office	which	
shows	that	the	number	of	amphetamine	users	who	came	to	the	attention	of	police	for	the	first	time	grew	substantially	
between	2000	and	2009	(outpacing	all	other	drug	groups	combined),	while	there	was	a	significant	decline	in	the	number	
of	new	police	contacts	for	ecstasy.21	The	increase	was	even	more	pronounced	for	users	of	crystalline	methamphetamine	
who	came	to	the	notice	of	the	police	for	the	first	time.	In	2010,	there	were	642	first	time	users	of	crystalline	metham-
phetamine,	up	from	364	persons	in	2009.	
the netherlands
The	Netherlands	remains	a	manufacturing	country	of	both	amphetamine	and	ecstasy.	Following	a	decline	in	2004,	the	
number	of	laboratories	seized	remained	fairly	stable	between	2005	and	2008	(16-18)	with	a	peak	in	2007.	Although	no	
data	was	reported	to	UNODC	in	2009,	a	recent	national	report	records	the	dismantling	of	24	illicit	manufacturing	sites	
for	synthetic	drugs	in	2009.22	The	increase	in	the	seizure	of	illicit	laboratories	between	2008	and	2009	is	attributed	to	a	
threefold	increase	in	the	detection	of	amphetamine	laboratories	in	2009.	Illicit	manufacturing	facilities	of	other	synthetic	
drugs	such	as	mCPP,	methamphetamine	and	2C-B	were	also	dismantled.	Only	one	illicit	ecstasy	manufacturing	site	was	
reported	in	2009.23
17	 UNODC,	2011a	and	EMCDDA,	2010a.
18	 Germany,	2011.
19	 Germany,	2010b.
20	 EMCDDA,	2010a.
21	 UNODC,	2010a.
22	 Netherlands,	2011.
23	 Netherlands,	2011.
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netherlands: seizures of ats, 2003-2009*
*No data was reported for 2009 and therefore 2008 data was used.  
Source: UNODC/ARQ DELTA
Two	 illicit	 conversion	 laboratories	 of	 BMK	 from	a-phenyl-
acetonitrile	 (benzyl	 cyanide)	were	 reportedly	 seized	 in	 the	
Netherlands	at	the	end	of	2010	and	in	early	2011.24
Illicit	amphetamine	manufacture	appears	to	be	mainly	con-
centrated	 in	the	south	of	the	country,	and	seizures	of	the	
drug	 are	mainly	 in	 powder	 form.	 Seizures	 have	 strongly	
fluctuated	 since	 2003.	 Despite	 the	 decline	 in	 seizures	 in	
2008,	 police	 reports	 indicate	 that	 the	 ATS	 laboratories	
detected	that	year	(principally	in	the	west	and	south	of	the	
country)	were	bigger	and	more	large-scale	than	before.	
Changes	 in	 the	manufacturing	 process	 of	 ecstasy	were	
noted	in	2008:	the	process	is	increasingly	being	divided	into	
different	stages	in	diverse	locations	(including	mobile	loca-
tions)	in	a	possible	attempt	to	reduce	the	risk	of	detection	
due	to	increased	law	enforcement.25
The	 decline	 in	 ecstasy	 seizures	 between	 2007	 and	 2008	
may	be	a	direct	result	of	a	lower	perceived	availability	of	the	
drug	in	2008,	a	fact	which	is	supported	by	several	studies	
pointing	to	a	collapse	of	the	ecstasy	market	in	2008	and	the	
first	half	of	2009.	During	that	period,	the	proportion	of	pills	
sold	 as	 ecstasy	 containing	 only	MDMA-like	 substances	
decreased	(to	71%	in	2008),	while	the	proportion	of	ecstasy	
pills	 containing	 miscellaneous	 substances	 increased	 to	
24	 Europol,	2011b.
25	 Netherlands,	2010.
netherlands: seized ats laboratories, 2003-2009*
* No data was reported to UNODC for 2009. however, the Centre of 
Expertise on Synthetic Drugs and Precursors reports 24 seizures of 
manufacturing locations for synthetic drugs in 2009 (Netherlands, 
2011). 
Source: UNODC/ARQ Delta and Netherlands, 2011
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18%.26	 Similarly,	 the	 concentration	 of	 amphetamine	 in	 the	 amphetamine	 samples	 decreased	which	might	 indicate	 a	
reduced	availability	of	the	precursor	chemicals	needed	to	manufacture	ecstasy	and	amphetamine.	
Though	the	trend	appeared	to	continue	during	the	first	half	of	2009,27	there	are	signs	of	a	recovery	of	the	ecstasy	market	
in	the	second	half	of	2009	and	2010.	Europol	reports	a	resurgence	of	ecstasy	since	mid-2010.28	Purity	of	ecstasy	report-
edly	 increased	 in	2010.	The	resurgence	of	ecstasy	could	also	have	 impacted	on	the	availability	of	mephedrone,	which	
seemed	to	disappear	from	the	illicit	ecstasy	market	in	the	Netherlands	during	the	first	half	of	2010.29
united Kingdom
In	2009,	amphetamine	seizures	in	the	UK	dropped	sharply	from	the	high	level	of	2008	(3.5mt)	to	reach	a	level	comparable	
to	amounts	seized	in	2003-2007.	Despite	the	decline,	the	quantity	seized	was	the	largest	reported	by	any	European	coun-
try	that	year.	Ecstasy	seizures	have	continued	to	decline,	reaching	a	low	of	62.6	kg	in	2009	–	a	60%	decline	from	2008.	
Despite	continued	high	seizures	of	amphetamine	and	high	rates	of	ATS	use,	no	reports	of	illicit	manufacture	have	been	
submitted	 to	UNODC	 since	 2003,	 though	 some	 small-scale	manufacture	 of	 amphetamine	 is	 said	 to	 take	 place	 in	 the	
UK.30	
Annual	prevalence	rates	of	ATS	in	the	UK	remain	relatively	high,	roughly	double	the	European	average	in	2009.	However,	
when	 compared	with	 2003/04,	 the	 annual	 prevalence	 rate	 for	 ecstasy	 among	16-59	 year	 olds	 in	 England	 and	Wales	
(1.6%)	shows	a	20%	decline	while	the	rate	of	annual	amphetamines	use	(1.0%)	has	decreased	by	33%.	Scotland	regis-
ters	much	higher	annual	prevalence	rates	of	1.4%	for	amphetamines	(2009)	and	2.5%	for	ecstasy	(2009).31	
Methamphetamine	use	was	estimated	for	England	and	Wales	for	the	first	time	in	the	2008/09	British	Crime	Survey.	 In	
2009/10,	just	1%	of	16	to	59	year	olds	reported	lifetime	use.	Among	16	to	24	year	olds,	lifetime	use	was	0.9%,	while	
recent	use	(last	year)	and	current	use	(last	month)	were	both	0%.32
Concurrent	with	trends	in	other	European	countries	such	as	the	Netherlands,	the	purity	of	amphetamines	in	the	UK	also	
fell	in	2008,	following	several	years	of	stable	purity	levels.33	The	MDMA	content	of	ecstasy	pills	also	fell	sharply	in	2008,	
with	adulterants	such	as	caffeine	and	BZP	also	detected	in	the	pills.34	In	2008	there	were	reports	of	users	switching	to	
the	more	expensive	MDMA	powder,	which	is	a	higher	purity	product.35
It	is	noteworthy	that	the	proportion	of	pills	analyzed	by	the	Forensic	Science	Service	in	2008	that	contained	MDMA	only	
was	51%,	falling	from	73%	in	2007	and	99.5%	in	2005.	This	decline	was	mainly	due	to	the	presence	of	piperazines	in	
a	large	proportion	of	the	seizures.36	
26	 This	was	mainly	due	to	an	increase	in	pills	containing	mCPP	but	in	2009	other	substances	such	as	mephedrone	and	4-fluoramphetamine	were	also	found.	
(Netherlands,	2010).
27	 During	the	first	half	of	2009,	the	percentage	of	ecstasy	pills	containing	an	MDMA-like	substance	decreased	by	70%.
28	 Europol,	2011b.
29	 Netherlands,	2011.
30	 United	Kingdom,	2010.
31	 According	to	a	government	source,	annual	prevalence	rates	in	Scotland	in	2006	were	2.2%	for	amphetamines	and	3.2%	for	ecstasy,	meaning	prevalence	
rates	in	Scotland	have	also	declined	in	recent	years.
32	 Home	Office,	2010.
33	 The	Serious	Organised	Crime	Agency	(SOCA)	reports	that	most	street-level	amphetamine	seized	through	Project	Endorse	is	under	five	per	cent	purity,	some-
times	as	low	as	one	per	cent	(SOCA	2009).	
34	 The	majority	of	ecstasy	pills	analyzed	by	FSS	and	LGC	Forensics	in	2008	contained	MDMA	as	the	main	drug	with	adulterants	such	as	caffeine	and	BZP	also	
detected.	(United	Kingdom,	2010).
35	 ibid.	The	mean	purity	of	MDMA	powder	at	street	level	in	2008	was	62%	and	79%	at	wholesale	level.	
36	 United	Kingdom,	2010.
netherlands: content of pills sold as ecstasy based on laboratory analyses, 2006-2010    
2006 2007 2008 2009 2010*
Number of pills analysed 2,523 2,319 2,183 2,181 1,186
Only MDMA-like substances 83.2% 84.6% 70.5% 70.8% 82.3%
(Meth)amphetamine 1.8% 0.7% 1.1% 4.9% 3.0%
MDMA-like substances and (meth)amphetamine 2.2% 1.3% 1.4% 1.3% 1.3%
Others** 4.5% 3.8% 7.4% 1.4% 1.4%
Miscellaneous*** 8.3% 9.6% 17.7% 21.7% 11.9%
* Data for 2010 are from January-June.
** Category ‘Others’ may include samples with MDMA and for example, caffeine and other pharmacologically active non-scheduled substances.
*** In 2009, the category ‘Miscellaneous’ consisted mainly of mCPP (11.6%) and mephedrone (7.4%).  
Source: Netherlands, 2011
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united Kingdom: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
czech republic
Historically,	manufacture	of	methamphetamine	(in	the	form	
of	Pervitin)37	has	been	concentrated	in	the	Czech	Republic.	
Methamphetamine	 is	 also	 the	 primary	ATS	 of	 use	 in	 the	
country,	as	well	as	the	most	frequently	trafficked	ATS.	The	
Czech	Republic	accounts	for	most	methamphetamine	labo-
ratories	detected	in	Europe.	The	number	of	detected	illicit	
small-scale	laboratories	peaked	in	2008	at	434	and	declined	
in	2009	 to	342.	Further	decreases	are	 reported	 for	2010.	
Most	methamphetamine	is	manufactured	for	domestic	use,	
smaller	quantities	are	trafficked	to	neighbouring	countries	
such	 as	 Germany	 and	 Slovakia.38	 The	main	method	 of	
sourcing	precursors	 for	 illicit	methamphetamine	manufac-
ture	 currently	 appears	 to	 be	 extraction	 of	 ephedrine	 and	
pseudoephedrine	 from	over-the-counter	medical	 prepara-
tions.	 Europol	 pointed	 to	 the	 reported	manufacture	 of	
crystalline	methamphetamine	in	the	Czech	Republic	by	an	
organized	crime	group	from	the	Western	Balkans	–	while	it	
is	possible	that	this	was	an	isolated	instance,	there	is	a	need	
to	monitor	this	development	and	prevent	a	possible	spread	
of	 crystalline	methamphetamine	 trafficking	 and	 use	 in	
Europe.39
37	 Pervitin	 used	 to	 be	 the	 trade	 name	 for	 a	methamphetamine-containing	
pharmaceutical	drug.
38	 EMCDDA	and	Europol,	2009.
39	 Europol,	2011a.
england and Wales: annual prevalence of ats among 
the general population*, 2003/04-2009/10
*Aged 16 to 59 years. 
Source: home Office, 2010
england and Wales: mean percentage purity of  
certain drugs seized by police, 2003-2008*
*From 2008 data have been provided from Forensic Science Service 
(FSS) and LGC Forensics. Previous data were from FSS only. 
**mg of MDMA base per pill. 
Source: United Kingdom, 2010
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West anD centraL europe / CZECh REPUBLIC / SWEDEN / NORWAy
The	Czech	Republic	currently	has	the	highest	annual	preva-
lence	 rate	 for	 both	 amphetamines	 (1.7%)	 and	 ecstasy	
(3.6%)	 in	 Europe.	Methamphetamine	 is	 reported	 as	 the	
primary	drug	by	a	large	proportion	of	clients	entering	treat-
ment	in	the	Czech	Republic	(59%)	and	injecting	is	reported	
as	the	main	route	of	drug	administration	by	80	%	of	meth-
amphetamine	users	 in	the	country.40	The	European	Moni-
toring	Centre	 for	Drugs	 and	Drug	Addiction	 and	 Europol	
have	 suggested	 possible	 diffusion	 of	methamphetamine	
from	 the	 stable	 chronic	 population	 into	 the	 recreational	
drug	scene.	
sweden
While	seizures	of	amphetamine	in	Sweden	declined	slightly	
between	2007	and	2009	when	compared	with	2004-2006,	
seizures	of	methamphetamine	have	been	 increasing,	with	
the	country	confiscating	a	record	154	kg	of	methampheta-
mine	 in	 2009.	 This	 reflects	 the	 increasing	 availability	 of	
methamphetamine	on	 the	 illicit	 drugs	market	 in	 Sweden.	
Recent	 research	 in	 the	 country	 finds	 that	methampheta-
mine	use	is	increasing	and	is	prevalent	in	most	of	the	coun-
try.	 As	 there	 is	 no	 illicit	 ATS	manufacture	 in	 the	 country,	
amphetamines	 are	 thought	 to	 be	 smuggled	 into	 Sweden	
from	 either	 Estonia,	 Lithuania	 and	 Poland	 or	Netherlands	
and	Belgium.41	
Sweden	now	reports	an	annual	prevalence	rate	of	amphet-
amines	of	0.8%.	At	32%,	the	proportion	of	drug	users	that	
reported	entering	treatment	for	use	of	amphetamine	as	the	
primary	drug	 in	Sweden	is	also	over	six	times	higher	than	
the	European	average	(less	than	5%).	Sweden	also	reports	
a	 high	 injecting	 rate	 for	 amphetamines	 users	 attending	
outpatient	centres	(67%).42
norway 
In	Norway	(as	in	Sweden),	both	amphetamine	and	metham-
phetamine	are	sold	as	white	powder,	making	it	difficult	to	
distinguish	 between	 them.43	Most	 amphetamines	 on	 the	
Norwegian	market	originate	from	illicit	 laboratories	 in	the	
Netherlands,	Russian	Federation,	Poland	and	Lithuania.	The	
largest	 quantities	 seized	 come	 from	 the	Netherlands	 and	
Poland,	through	Germany	and	Denmark	and	via	Sweden.44	
No	illicit	manufacture	has	been	reported	from	Norway	since	
2004	(when	one	amphetamine	and	one	ecstasy	laboratory	
were	 dismantled)	 and	 authorities	 estimate	 that	manufac-
ture,	if	any	exists,	is	small-scale.
From	2006	to	2009,	Norway	recorded	the	largest	seizures	
of	methamphetamine	 in	 Europe,	 and	 apart	 from	a	dip	 in	
2008,	 seizures	 have	 been	 steadily	 increasing	 since	 the	
beginning	of	the	decade	reflecting	the	increasing	frequency	
40	 EMCDDA,	2010a.
41	 EMCDDA,	2010a.
42	 EMCDDA,	2010b.
43	 Norway,	2010.
44	 Norway,	2010.
czech republic: seized methamphetamine  
laboratories, 2003-2009
Source: UNODC/ARQ DELTA 
sweden: seizures of ats, 2003-2009
Source: UNODC/ARQ DELTA 
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with	which	the	drug	is	being	trafficked	to	the	country.	Sei-
zures	 of	methamphetamine	 surpassed	 those	 of	 ampheta-
mine	 for	 the	 first	 time	 in	2009,	accounting	 for	 a	 total	of	
51%	of	ATS	seized	that	year.	For	the	first	time,	two	seizures	
of	 crystalline	methamphetamine	 chloride	were	made	 in	
2009.	Both	 seizures	 (6	 and	7.7	grams	 respectively)	 had	a	
purity	of	almost	100	per	cent.45
Toxicological	 data	 from	 the	 National	 Institute	 of	 Public	
Health	also	provide	evidence	of	the	increasing	presence	of	
methamphetamine	in	Norway.	In	2009,	methamphetamine	
was	 the	 second	most	 commonly	 found	 substance	 after	
alcohol	in	blood	samples	from	drivers	suspected	of	driving	
under	 the	 influence,	 found	 in	32%	of	 the	blood	 samples	
that	were	analyzed	for	alcohol,	intoxicating	medicinal	drugs	
and	narcotic	substances	–	a	fourfold	increase	since	2001.	
The	use	of	methamphetamine	in	Norway	has	increased	over	
the	past	years	and	is	now	thought	to	be	more	widely	used	
in	the	country	than	amphetamine.	The	reason	for	this	shift	
from	amphetamine	to	methamphetamine	is	thought	to	be	
the	increasing	availability	of	the	drug.	
In	2009,	the	average	purity	for	amphetamine	and	metham-
phetamine	was	 about	 29%	and	 44%	 respectively,	 repre-
senting	a	decline	 in	purity	 levels	for	amphetamine	and	an	
increase	for	methamphetamine.46	The	proportion	of	MDMA	
in	ecstasy	pills	declined	sharply	 from	2007-2009;	while	 in	
2006,	nearly	100%	of	 seized	pills	 contained	MDMA,	 this	
proportion	had	reduced	to	around	20%	in	2009.47
 
poland
Poland	is	one	of	the	major	European	illicit	amphetamine	manufacturers	and	was	one	of	the	most	frequently	mentioned	
countries	of	origin	 for	amphetamine	 in	2009.	Poland	dismantled	eight	amphetamine	 laboratories	 in	2009	 (the	 lowest	
number	of	laboratories	reported	in	ten	years),	and	identified	Germany,	Scandinavia	and	the	United	Kingdom	as	the	main	
destinations	for	amphetamine	manufactured	in	Poland.	
Seizures	 of	 amphetamine	 in	 Poland	 are	 relatively	 high,	 averaging	 about	 400	 kg	 per	 year	 (2005-2009).	 Traditionally,	
amphetamine	in	Poland	was	available	in	the	form	of	white,	beige	or	dark	brown	powder,	but	is	increasingly	distributed	
in	pill	form.48	Poland	seized	almost	60	kg	of	ecstasy	in	2009	(6%	of	the	European	total)	and	reported	that	some	of	the	
ecstasy	on	its	territory	originated	in	Poland	as	well	as	in	the	Netherlands.49	
Despite	 the	 relatively	 stable	 number	 of	 illicit	 ATS	 laboratories	 dismantled	 each	 year	 (about	 15),	 in	 2009,	 authorities	
reported	a	worrying	rise	in	the	scale	of	these	manufacturing	facilities,	usually	detached	houses	located	in	small	towns.50	
A	further	development	of	concern	is	that	methamphetamine	manufacture	is	reportedly	taking	place	in	Poland,	with	one	
illicit	laboratory	dismantled	in	2007	and	another	in	2009.51	
24.6%	of	patients	admitted	to	drug	treatment	report	using	amphetamine	as	their	primary	drug	of	use.	The	most	recent	
data	indicate	a	fall	in	the	purity	of	amphetamine	(24%	in	2009).
45	 Norway,	2011.
46	 Norway,	2010.
47	 Norway,	2010.
48	 The	 amphetamine	 powder	 often	 contains	mixtures	 of	 amphetamine	 sulphates	 and	 different	 additives	 (e.g.	 glucose,	 caffeine,	 painkillers)	which	 contain	
20-30%	of	pure	drug.
49	 UNODC,	2011a.
50	 Poland,	2010.
51	 Poland,	2011.
norway: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
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POLAND  BaLtic states / ESTONIA
BaLtic states
estonia
Illicit	ATS	manufacture	takes	place	in	Estonia,	where	several	laboratories	are	detected	each	year	with	annual	seizures	of	
about	50-55kg	of	amphetamine.	The	main	ATS	manufactured	is	amphetamine	using	P-2-P	as	the	main	precursor	chemi-
cal	which	is	smuggled	mainly	from	the	Russian	Federation.	Amphetamine	is	then	trafficked	from	Estonia	to	Nordic	coun-
tries	and	to	the	Russian	Federation.	
In	2008,	a	significant	single	seizure	of	38kg	of	methamphetamine	was	made,	 indicating	the	possible	expansion	of	the	
drug	to	the	Estonian	market.	However,	practically	no	seizures	of	methamphetamine	were	reported	in	the	following	year	
(0.02kg).	Estonia	reports	that	methamphetamine	is	being	manufactured	in	the	country,	most	 likely	from	P-2-P	sourced	
from	outside	the	EU.52	
The	illicit	manufacture	of	ecstasy	has	also	been	detected	in	Estonia	but	quality	of	the	ecstasy	is	low.	In	2008,	1,841	litres	
of	 safrole	 (a	precursor	 for	 the	manufacture	of	ecstasy)	were	 confiscated	 in	Estonia;	 almost	97%	of	global	 seizures	of	
safrole	in	2008.53	Between	1	kg	to	12	kg	of	ecstasy	are	seized	each	year	(2005-2009).
At	1%,	the	annual	prevalence	rate	of	amphetamines	in	Estonia	remains	high	for	Europe	as	does	the	annual	prevalence	
rate	for	ecstasy	(1.2%).	The	major	ATS	used	is	amphetamine,	with	methamphetamine	use	not	being	common	or	wide-
spread.	Injecting	of	amphetamines	is	an	increasing	problem	in	Estonia,	as	a	recent	study	of	injecting	drug	users	in	two	
cities	 found	 amphetamine	 injecting	 to	 be	 quite	widespread.	A	 third	 of	 injecting	 users	 surveyed	 in	 Tallinn	 considered	
amphetamine	to	be	their	primary	drug,	while	more	than	two-thirds	of	prison	inmates	reported	using	amphetamine	while	
incarcerated	in	2006	and	2008.54	One	notable	development	in	amphetamine	use	was	that	the	annual	prevalence	rate	for	
women	increased	sharply	from	1.5%	in	2003	to	2.7%	in	2008,	while	the	rate	for	men	in	the	same	age	group	decreased	
significantly,	from	9.3%	to	4.6%.
52	 EMCDDA,	2010b.
53	 Estonia,	2010.
54	 EMCDDA,	2010b.
poland: seized amphetamine laboratories, 2003-2009
Source: UNODC ARQ/DELTA
poland: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
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estonia: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
Lithuania
Lithuania	has	been	playing	an	 increasingly	prominent	 role	
in	the	illicit	manufacture	and	trafficking	of	ATS	in	Europe	in	
recent	years.	Like	Estonia,	Lithuania	reports	that	manufac-
ture	of	methamphetamine	is	taking	place,	most	likely	from	
P-2-P	 sourced	 from	outside	 the	 EU,	 in	 contrast	 to	 central	
European	methamphetamine	manufacturing	methods	(e.g.	
Czech	Republic)	which	use	ephedrine	and	pseudoephedrine	
as	precursors.55	In	2009,	an	illegal	methamphetamine	labo-
ratory	of	medium	capacity	was	detected	in	the	Alytus	dis-
trict56	 (southern	Lithuania).	Manufacture	of	amphetamine	
is	also	being	reported,	and	the	substances	are	destined	for	
markets	 in	 other	 European	 countries.	 Ecstasy	 shipments	
transit	the	country	and	are	trafficked	eastwards	to	destina-
tions	such	as	Belarus	and	the	Russian	Federation.	
Lithuanian	 organized	 crime	groups	 are	 believed	 to	 play	 a	
significant	role	 in	the	supply	and	trafficking	of	ATS	to	the	
Russian	 Federation,	 Belarus,	 Scandinavia	 and	 the	 Baltic	
States.57	 Lithuania’s	 geographical	 location	 leaves	 it	well-
placed	to	serve	as	a	transit	country	for	ATS	trafficking	from	
both	East	to	West	and	West	to	East.	ATS	smuggling	from	
Lithuania	to	Belarus	(and	vice	versa)	appears	to	be	a	well-
established	route	for	trafficking	ATS	and	their	precursors.
55	 EMCDDA,	2010b.
56	 Lithuania,	2011.
57	 Europol,	2011a.
Lithuania: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
Latvia: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
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  eastern anD soutH-east europe / BULGARIA
Amphetamines	and	ecstasy	use	are	reportedly	on	the	rise.	The	annual	prevalence	rate	of	ecstasy	is	estimated	at	1%	(up	
from	0.4%	 in	2004),	while	 last	 year	use	of	amphetamines	more	 than	doubled	 from	0.3%	 in	2004	 to	0.7%	 in	2008.	
Country	analysis	suggests	that	methamphetamine	is	used	more	than	amphetamine,	although	distributors	often	describe	
the	drug	they	are	selling	as	‘amphetamine’	regardless	of	whether	it	is	amphetamine	or	methamphetamine.58
Latvia
Latvia	is	mainly	used	as	a	transit	country	for	transporting	drugs	to	its	neighbouring	countries.	According	to	the	EMCDDA,	
synthetic	drugs	are	brought	into	Latvia	from	Estonia,	Poland,	the	Netherlands	and	Germany.59	ATS	(as	well	as	synthetic	
cannabinoids)60	are	among	the	most	frequently	used	drugs	in	Latvia.61	As	with	other	Baltic	and	Nordic	countries,	meth-
amphetamine	has	recently	appeared	on	the	drug	market	where	 it	seems	to	be	partially	replacing	amphetamine.	Latvia	
reports	a	very	high	proportion	of	drug-related	offences	related	to	methamphetamine	(33%).62
ATS	 seizures	 remain	 fairly	 small.	Between	2007	and	2009,	 there	was	a	notable	 increase	 in	 the	number	of	 seizures	of	
methamphetamine	and	a	corresponding	decrease	in	the	number	of	seizures	of	amphetamine	and	ecstasy	pills	(although	
seizures	of	all	three	were	low	in	2009).	The	quality	of	methamphetamine	was	reportedly	three	times	higher	in	2008	than	
in	2007.63	
At	1.5%,	Latvia	has	a	particularly	high	ecstasy	annual	prevalence	rate	for	Europe	(more	than	double	the	average),	with	
the	annual	prevalence	rate	of	amphetamines	(0.9%)	also	being	considerably	higher	than	the	European	average.	In	2008,	
amphetamines	accounted	for	26%	of	the	most	commonly	used	primary	substances	by	first-time	clients	in	treatment	in	
Latvia;	second	only	to	heroin	(34%).64
eastern anD soutH-east europe
Bulgaria
Bulgaria	continues	to	be	associated	with	the	manufacture	of	tabletted	amphetamine	(Captagon)65	for	markets	in	the	Near	
and	Middle	East,	with	the	detection	of	three	illicit	amphetamine-manufacturing	laboratories	being	reported	in	2009	–	the	
most	laboratories	reported	since	2006	(also	three)	–	and	three	in	2010.66	No	illicit	methamphetamine	laboratories	had	
been	 reported	 since	 2001	 but	 in	 2010,	 two	mobile	methamphetamine	 laboratories	were	 seized.	Organized	 criminal	
groups	operate	in	Bulgaria,	manufacturing,	tabletting	and	trafficking	amphetamine	out	of	the	country	to	the	Near	and	
Middle	East.	Apart	from	Bulgarian	citizens,	national	authorities	have	identified	the	involvement	of	nationals	from	Lebanon,	
the	Syrian	Arab	Republic,	 the	 Islamic	Republic	of	 Iran,	Serbia	and	Turkey.	Ephedrine,	a	precursor	chemical	used	 in	 the	
manufacture	of	methamphetamine,	was	recently	identified	as	the	most	frequently	smuggled	precursor	chemical	in	Bul-
garia.67
Following	high	amphetamine	seizures	in	2004	(1.45	mt)	and	2005	(1.1	mt),	the	quantity	of	seized	amphetamine	has	been	
falling,	most	notably	in	2007	when	seizures	fell	to	less	than	a	quarter	of	the	2006	total.	National	authorities	point	to	a	
significant	reduction	in	the	trafficking	of	amphetamine	directed	to	Turkey	and	Middle	Eastern	countries	in	2007.	While	
2008	saw	a	considerable	increase	in	amphetamine	seizures,	they	remained	far	below	the	number	of	seizures	during	the	
period	2004-2006	and	they	fell	again	in	2009.	Bulgarian	authorities	attribute	this	decline	to	a	decline	in	illicit	domestic	
manufacture	and	a	shift	towards	amphetamine	manufacture	 in	the	Middle	East.	Since	2004,	authorities	have	reported	
sizeable	annual	seizures	of	ecstasy	of	up	to	80kg.
In	2009,	it	was	reported	that	the	number	of	young	people	using	amphetamines	and	ecstasy	was	increasing	–	between	
2007	and	2008,	the	reported	annual	prevalence	rate	of	amphetamines	use	doubled,	from	0.5%	to	1%	of	the	population.	
The	annual	prevalence	rate	for	ecstasy	also	rose	from	0.5%	in	2005	to	0.7%	in	2008.
58	 Europol,	2011a.
59	 EMCDDA,	2010c.
60	 Synthetic	cannabinoids	such	as	‘spice’	are	frequently	sold	on	the	internet	and	in	specialized	shops	as	a	smoking	mixture.	The	psychoactive	constituents	are	
synthetic	additives	such	as	the	cannabinoid	receptor	agonist	JWH-018	that	mimic	the	effects	of	tetrahydrocannabinol	(THC)	in	cannabis.
61	 Latvia,	2010.
62	 EMCDDA	2010a.	
63	 EMCDDA	2010a.
64	 The	treatment	data	collection	system	in	Latvia	does	not	distinguish	between	methamphetamine	or	amphetamine	use.	(Latvia,	2010).
65	 Captagon	was	originally	the	trade	name	for	fenethylline,	a	synthetic	stimulant.	Analysis	of	seized	Captagon	pills	show	that	most	contain	amphetamine	and	
other	ingredients	such	as	caffeine	and	theophylline.
66	 UNODC,	2011c.
67	 Bulgaria,	2010.
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Bulgaria: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
turkey: seizures of captagon pills, 2005-2009
Source: UNODC ARQ/DELTA; Turkey, 2011
turkey: captagon trafficking routes 
Source: Turkey, 2011 
Note: The boundaries and names shown and the designations used 
on this map do not imply official endorsement or acceptance by the 
United Nations. 
turkey: seizures of ecstasy, 2005-2009
Source: Turkey, 2011
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eastern anD soutH-east europe / TURKEy / SERBIA
turkey
Illicit	laboratory	activity	concerning	the	manufacture	of	Captagon	continues	to	be	reported	by	Turkey,	though	it	appears	
to	have	decreased	significantly.	Following	the	record	seizure	of	12	illicit	amphetamine	(Captagon)	laboratories	in	2006,	
only	one	laboratory	was	reported	in	2009.	The	laboratory,	which	was	described	by	Turkish	authorities	as	a	pill	pressing	
facility,	was	located	in	an	industrial	facility	in	Istanbul,	and	was	seized	in	February	2009	along	with	over	2	million	Capta-
gon	pills,	press	moulds	and	pill	making	machines.
Seizures	of	Captagon	 in	Turkey	declined	sharply	between	2006	and	2009,	 from	almost	20	million	pills	 in	2006	to	2.8	
million	pills	in	200968.	Further	decreases	were	reported	for	2010,	which	might	point	to	a	decline	of	illicit	manufacture	in	
the	country.	A	recent	report	by	the	Turkish	National	Police	concluded	that	criminal	organizations	have	shifted	Captagon	
manufacture	from	South	East	Europe	to	countries	closer	to	the	Captagon	market	in	the	Near	East	and	Middle	East,	such	
as	the	Syrian	Arab	Republic.69	Captagon	is	not	widely	used	in	Turkey.	Turkey	remains	a	key	transit	country	for	the	traf-
ficking	of	Captagon,	which	Turkish	authorities	claim	is	now	smuggled	into	Turkey	from	the	Syrian	Arab	Republic	and	then	
shipped	to	Middle	Eastern	and	Arabian	countries,	particularly	Saudi	Arabia.70	
Turkey	 continues	 to	be	a	destination	 country	 for	 ecstasy	 trafficked	 from	Western	Europe.	 Ecstasy	 seizures	 showed	an	
upward	trend	until	2005	when	they	began	to	decline	sharply.	Despite	decreasing	to	a	quarter	of	the	total	number	of	pills	
seized	in	2005,	in	2009,	Turkey	recorded	the	largest	ecstasy	seizure	in	Europe	(432,513	pills).	In	2008,	ecstasy	seizures	
took	place	in	65	out	of	81	provinces,	showing	that	ecstasy	is	widely	available	in	the	country.71	Preliminary	figures	for	2010	
indicate	a	sharp	increase	in	ecstasy	seizures.
In	 recent	 years,	many	pills	 sold	 as	 ecstasy	 have	been	 found	 to	 contain	McPP	 (meta-Chlorophenylpiperazine)72	 or	 BZP	
(1-Benzyl	piperazine)	as	an	active	ingredient	instead	of	MDMA.	Research	suggests	this	may	explain	a	possible	reduction	
in	demand	for	ecstasy,	which	could	in	turn	account	for	the	decline	in	seizures	since	2005.73
Methamphetamine	was	seized	in	Turkey	for	the	first	time	in	2009.	Methamphetamine	is	being	smuggled	overland	from	
the	Islamic	Republic	of	Iran	into	Turkey	then	trafficked	by	air	to	East	and	South-East	Asian	countries	such	as	Japan,	Malay-
sia,	Indonesia	and	South	Korea.74	
serbia
Evidence	of	ATS	manufacture	first	emerged	in	Serbia	in	2007,	with	the	discovery	of	an	illicit	amphetamine	laboratory	in	
the	Belgrade	suburb	of	Krnjaca.	In	2008,	another	laboratory	was	reported.	ATS	and	their	precursors	are	smuggled	into	
Serbia	through	the	Balkan	Route,	from	western	Europe.	In	2009,	almost	2	tons	of	phenylacetic	acid	–	a	precursor	of	the	
substance	P-2-P	used	in	the	manufacture	of	amphetamines	–	were	seized	in	Serbia.	Two	large	illicit	amphetamine	labo-
ratories	were	reportedly	seized	in	Serbia	in	2010.	Bulgarian	nationals	were	arrested	for	participating	in	the	manufacturing	
process.75
precursor chemical seizures & trafficking
ephedrine and pseudoephedrine
While	seizures	of	ephedrine	and	pseudoephedrine	remain	low	in	Europe,	these	precursor	chemicals	are	being	transshipped	
through	 Europe	with	 increasing	 frequency;	 often	 via	Amsterdam,	 Brussels,	 Frankfurt,	 London	 and	 Paris,	 destined	 for	
Mexico.	 In	2006-07	 the	Netherlands	 reported	an	attempted	diversion	of	more	 than	200	 tons	of	ephedrine	and	pseu-
doephedrine	to	Europol,	while	German	authorities	confiscated	14.5	tons	of	ephedrine	and	more	than	1.6	million	pseu-
doephedrine	pills	 in	2008.76	In	2010,	the	International	Narcotics	Control	Board	warned	that	pills	containing	ephedrine	
and	pseudoephedrine,	 increasingly	used	 to	produce	methamphetamine	 in	 Europe	 (and	elsewhere)	 are	probably	being	
underreported.
68	 Turkey,	2011.
69	 Turkey,	2011.
70	 72%	of	the	Captagon	seized	in	2008	(2,145,000)	were	brought	to	Turkey	from	Syria	through	hiding	in	legal	cargo	and	seized	in	Adana	on	its	way	to	Saudi	
Arabia.	This	highlights	Turkey‘s	position	as	a	transit	country	with	regard	to	Captagon	(Turkey,	2010).
71	 Turkey,	2010.
72	 A	recreational	drug	and	stimulant	of	the	piperazine	class.
73	 Turkey,	2010.
74	 Turkey,	2011.
75	 UNODC,	2011d.	
76	 EMCDDA	and	Europol,	2009.
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europe: seizures of ephedrine (kg), 2009
Source: INCB – Seizures of substances in Tables I and II of the 1988 
Convention as reported to the International Narcotics Control Board, 
2005-2009
europe: seizures of p-2-p (litres), 2009
Source: INCB – Seizures of substances in Tables I and II of the 1988 
Convention as reported to the International Narcotics Control Board, 
2005-2009
europe: seizures of substances required for the  
manufacture of amphetamines-group substances, 
2005-2009
Source: INCB – Seizures of substances in Tables I and II of the 1988 
Convention as reported to the International Narcotics Control Board, 
2005-2009
europe: seizures of substances required for the  
manufacture of ecstasy-group substances, 2005-2009
Source: INCB – Seizures of substances in Tables I and II of the 1988 
Convention as reported to the International Narcotics Control Board, 
2005-2009
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europe
P-2-P 
The	Russian	Federation	is	said	to	be	the	main	source	of	P-2-P	used	in	the	illicit	manufacture	of	amphetamines	in	Europe.	
In	2009,	the	Russian	Federation	reported	a	seizure	of	1,731	litres	of	P-2-P	–	amounting	to	70%	of	European	seizures	and	
about	 one	 third	 of	 that	 year’s	 global	 seizures	 –	while	 in	August	 2010,	 the	 International	Narcotics	Control	 Board	was	
informed	of	a	seizure	of	5,000	 litres	of	P-2-P	 in	Belgium,	a	volume	that	matched	the	global	 total	seized	 in	2009.77	A	
relatively	new	trend	in	P-2-P	trafficking	is	the	‘masking’	of	the	chemical	(normally	found	in	liquid	form)	as	a	powder	known	
as	P-2-P	bisulphate	prior	to	it	being	trafficked	into	Europe.	
Phenylacetic acid
In	some	European	countries	where	illicit	amphetamine	manufacture	has	been	identified,	such	as	Poland,	P-2-P	is	manu-
factured	from	so-called	‘pre-precursors’	such	as	phenylacetic	acid	and	benzyl	cyanide.78	In	2009,	1.9	tons	of	phenylacetic	
acid	were	seized	in	Serbia,	accounting	for	the	vast	majority	of	global	seizures	that	year.	Increasing	seizures	of	phenylace-
tic	acid	indicate	that	those	involved	in	illicit	ATS	activity	may	be	increasingly	using	this	substance	due	to	tighter	controls	
of	traditional	precursors	(such	as	ephedrine,	pseudoephedrine	and	P-2-P).79
3,4-mdP-2-P and safrole
Precursors	for	ecstasy-group	substances	 include	safrole	(including	in	the	form	of	safrole-rich	oils),	 isosafrole,	piperonal,	
and	3,4-MDP-2-P,	which	are	all	controlled	in	Table	1	of	the	1988	Convention.	Reported	global	seizures	of	these	precursors	
have	strongly	declined,	reflecting	the	declining	availability	of	ecstasy	in	Europe,	one	of	the	main	markets	for	the	substance.	
Seizures	of	3,4-MDP-2-P	in	Europe	have	been	practically	non-existent	since	2007,	while	the	seizures	of	safrole-rich	oil	have	
increased	since	that	time.	In	2009,	European	seizures	(954	litres)	accounted	for	over	90%	of	global	seizures	of	safrole,	
most	of	it	in	Lithuania	(929	litres).	Smaller	amounts	of	safrole	were	confiscated	in	the	Netherlands	(20	litres)	and	the	UK	
(5	litres).	In	2008,	Europe	accounted	for	almost	100%	of	the	global	total	(of	which	1,841	litres	were	seized	in	Estonia).	
77	 INCB,	2011b.	Significant	recent	seizures	of	P-2-P	have	also	been	made	in	Bulgaria,	Estonia,	Germany	,	Lithuania,	Netherlands,	Poland	and	Slovakia.
78	 EMCDDA,	2010b.	
79	 INCB,	2011a.
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regional overview
The	quality	and	availability	of	information	on	ATS	trends	including	illicit	manufacture,	trafficking	and	domestic	use	remains	
scarce	for	most	of	Africa	but	the	limited	data	that	is	available	points	to	an	increase	in	all	these	areas,	particularly	traffick-
ing.	South	Africa	reports	most	illicit	ATS	laboratories	and	illicit	methamphetamine	manufacture	has	been	on	the	rise	in	
that	country	since	2004.	In	North	Africa,	Egypt	has	a	history	of	some	stimulant	manufacture,	possibly	methamphetamine	
in	a	form	known	locally	as	Maxiton Forte1	prior	to	2000	as	well	as	one	reported	case	of	ecstasy	manufacture	in	2004.	
The	most	recent	indication	of	illicit	ATS	manufacture	was	received	in	the	form	of	an	illicit	methamphetamine	manufactur-
ing	laboratory	in	Alexandria	which	was	discovered	and	dismantled	by	Egyptian	authorities	in	April	2010.	In	addition,	the	
World	Customs	Organization	reported	a	 large	seizure	of	1.3	million	ecstasy	pills	 in	Saudi	Arabia	 in	2009	from	a	vessel	
originating	in	Egypt,	demonstrating	Egypt’s	potentially	significant	role	as	a	departure	country	for	ATS	shipments	to	the	
Middle	East.2	
Evidence	of	methamphetamine	manufacture	emerged	in	June	2011,	with	the	detection	of	a	methamphetamine	laboratory	
in	Lagos,	Nigeria.	Other	indications	that	ATS	manufacture	has	spread	to	West	Africa	include	the	discovery	of	evidence	of	
intended	ATS	manufacture	in	Guinea	in	July	2009.	In	2010,	the	United	States	Government	indicted	members	of	a	large	
international	cocaine	trafficking	organization	for,	inter alia,	the	intent	to	establish	a	clandestine	laboratory	in	Liberia	for	
the	large-scale	manufacture	of	methamphetamine.3	
ATS	seizures	reported	to	UNODC	since	2008	continue	to	be	small.	The	largest	seizures	are	reported	from	South	Africa	
(principally	methamphetamine	and	methcathinone),	Nigeria	and	Burkina	Faso,	with	smaller	quantities	of	ATS	reported	by	
Côte	 d’Ivoire,	 Egypt,	Guinea,	Morocco,	Niger,	 Swaziland	 and	 Zambia	 since	 2005.	 Reported	 seizures	 of	 ecstasy-group	
substances	have	remained	low	(below	10kg)	since	2006.	
The	annual	prevalence	of	amphetamines-group	substances	in	Africa	is	estimated	to	be	between	1.2	and	8	million	people,	
with	the	highest	annual	prevalence	rates	being	reported	from	South	Africa.	Nigeria,	Burkina	Faso,	Côte	d’Ivoire,	Egypt,	
Ghana,	Kenya,	Senegal,	Sierra	Leone	and	several	other	African	countries	have	reported	ATS	use	in	recent	years.	Use	of	
methaqualone,	a	sedative-hypnotic,	continues	to	be	widespread	in	South	Africa.	
1	 Maxiton	Forte	is	a	trade	name	for	a	pharmaceutical	preparation	containing	dexamphetamine,	which	is	no	longer	manufactured.
2	 The	seizure	was	made	by	Saudi	Arabian	Customs	at	Dhuba	seaport.	The	drugs	had	been	concealed	on	board	 the	vessel	which	arrived	 from	Egypt	 (WCO,	
2010).	
3	 UNODC,	2010b.	
measure DruG Group 2005 2006 2007* 2008 2009
Laboratory  
(#)
Methamphetamine 
Amphetamine 
Other synthetic/combined stimulants 
Ecstasy-group substances
11 
- 
28 
-
17 
- 
18 
-
12 
- 
10 
-
20 
- 
- 
-
10 
- 
6 
-
total 39 35 22 20 16
Seizures  
(kg)
Methamphetamine
Amphetamine
Non-specified amphetamines
Ecstasy-group substances
-
0.04
2,084.8
3.7
9.1
8.4
833.1
74.5
13.4
5.4
701.8
9.2
-
47.3
3,445.0
0.1
37.0
50.3
11.0
-
total 2,088.5 925.1 729.8 3,492.4 98.3
Annual Prevalence 
(15-64)
Amphetamines-group substances
Ecstasy-group substances
 0.4%
 0.04%
 0.4%
  0.04%
0,55%
0.25%
0,6%
0.25%
 0.8%
0.2%
* From 2007 onwards, reported prevalence percentage is based on midpoint of range.  
- Not reported. 
Source: UNODC ARQ/DELTA
africa: ats laboratories, seizures, and annual prevalence rates (2005-2009)
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Trafficking routes of methamphetamine in Africa
Source: UNODC, 2011a 
Note: The boundaries and names shown and the designations used 
on this map do not imply official endorsement or acceptance by the 
United Nations. Lines represent origin and intended destination, not 
necessarily exact route, and include completed or stopped traffick-
ing attempts. Modes of transport include by air, sea, overland, or 
any combination thereof.
Since 2006, fears have been growing that African countries are being used as trans-shipment points for shipments of 
precursor chemicals such as ephedrine and pseudoephedrine, the main chemicals used in the manufacture of ATS such 
as methamphetamine and methcathinone from Asia. The final destination of these chemicals are countries in Central and 
North America, and to a lesser extent, South Africa. 
In 2008, INCB identified Africa as the region with the greatest number of diversions or attempted diversions of ATS pre-
cursor chemicals. Target countries of such diversions in recent years include Botswana, the Democratic Republic of the 
Congo, Ethiopia, Nigeria, Togo, Uganda, the United Republic of Tanzania and Zambia. However, despite the high number 
of attempted diversions of ephedrine and pseudoephedrine to or through Africa, hardly any seizures of these precursors 
have been reported by African countries. Between 2003 and 2008, ephedrine and pseudoephedrine seizures totaled 242 
kg, with South Africa reporting most of these seizures.4 
Since 2008, perhaps due to strengthened controls in certain countries, notably South Africa, and intensified screening by 
authorities of exporting countries of shipments of precursors destined for Africa, the mass smuggling of those substances 
(often in the form of pharmaceutical preparations) through Africa appears to have declined. The absence of attempted 
diversions and seizures of precursors does not necessarily point to a decline in illicit ATS manufacture and trafficking but 
highlights the flexibility with which criminal organizations operate as traffickers continue to search for alternative traffick-
ing routes as well as substitute substances to use in the manufacture of ATS in response to stringent precursor controls 
and law enforcement legislation.
West and Central Africa
Since 2004, criminal organizations have been using West Africa as a transit area for smuggling cocaine from South 
America to Europe and North America, exploiting the region’s many vulnerabilities to their advantage. There is growing 
evidence to suggest that criminal organizations involved in trafficking ATS, particularly methamphetamine, now exploit 
the region in a similar way to cocaine traffickers and look to avoid effective law enforcement to traffic ATS to other parts 
of the world, primarily East Asia. 
4 For instance, between 2000 and 2008, ephedrine and pseudoephedrine seizures in Africa totalled only 242 kg, with South Africa accounting for most of 
those seizures (INCB 2009a).
Seizures of methamphetamine in Japan by African 
country of origin, 2008-2010
Source: JCITAC, 2010
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Prior	to	2008,	no	cases	of	methamphetamine	trafficking	from	Africa	to	East	Asia	had	been	reported.	However,	following	
a	small	number	of	reported	cases	in	2008,	2009	saw	both	the	number	of	seizures	and	quantities	destined	for	East	Asia	
originating	in	Africa,	including	West	African	countries	such	as	Benin,	Cameroon,	Côte	d’Ivoire,	Ghana,	Guinea,	Senegal	
and	Nigeria	more	than	triple.	The	most	common	trafficking	destinations	have	been	Japan,	followed	by	the	Republic	of	
Korea,	with	more	recent	reports	emerging	from	Malaysia	and	Thailand.	In	2009,	Japanese	Customs	reported	that	stimu-
lants	from	Nigeria,	Uganda,	Kenya,	Lesotho	and	other	African	countries	had	been	intercepted	for	the	first	time.	In	2009,	
only	7.4%	of	seizures	of	methamphetamine	trafficked	to	Japan	were	estimated	to	have	originated	in	Africa;	by	mid-2010,	
this	proportion	had	risen	to	36%.	Such	trafficking	cases	are	typically	multi-kilo,	transported	by	air	hidden	in	luggage	and	
typical	of	methods	employed	by	West	African	syndicates	for	other	drugs.	Couriers	transit	via	West	Asia,	East	Africa	and	
Europe.5
In	2008,	almost	90%	of	global	seizures	of	non-specified	amphetamines	were	recorded	in	West	and	Central	Africa,	due	
in	 large	part	 to	the	significant	seizure	reported	by	Burkina	Faso	that	year	 (3,403	kg	–	reported	as	 ‘médicaments	de	 la	
rue’).6	The	unknown	nature	of	the	drugs	seized	highlights	the	need	for	a	better	understanding	of	the	nature	of	drugs	in	
the	illicit	market,	particularly	in	this	vulnerable	region,	as	well	as	the	urgent	need	for	more	complete	and	timely	data	in	
order	to	stem	the	growing	danger	of	the	region	falling	prey	to	organized	crime	groups	 involved	 in	the	trafficking	and	
manufacture	of	ATS.	
nigeria
Nigeria	is	increasingly	at	risk	of	being	exploited	as	a	traffick-
ing	 and	 potential	manufacturing	 hub	 for	methampheta-
mine.
Seizure	reports	from	Nigeria	have	strongly	fluctuated	over	
the	 past	 five	 years.	 In	 2007,	Nigeria	 reported	 seizures	 of	
530	 kg	 of	 unspecified	 psychotropic	 substances,	while	 in	
2009,	seizures	of	712	kg	of	psychotropic	substances	were	
recorded.	According	to	reports	from	the	NDLEA,	ATS,	prin-
cipally	methamphetamine,	are	being	trafficked	with	increas-
ing	frequency	and	 in	comparable	amounts	to	other	drugs	
such	as	heroin	and	cannabis.	Between	January	and	Decem-
ber	2010,	74.8	kg	of	amphetamines	were	seized	at	Lagos	
airport,	making	up	almost	one-fifth	of	the	total	quantity	of	
drugs	seized	at	that	location.7	
The	number	of	major	 seizure	 cases	of	methamphetamine	
smuggling	 by	Nigerian	 nationals	 intercepted	 by	 Japanese	
custom	officials	has	risen	sharply	since	2009.	From	January	
to	 June	 2010,	 cases	 of	methamphetamine	 trafficking	 by	
Nigerian	males	represented	a	significant	proportion	(21%)	
of	24	major	seizure	cases.8	From	2008	to	2010,	Japanese	Customs	reported	a	total	of	16	kg	of	seized	methamphetamine	
found	to	have	originated	in	Nigeria.	A	significant	number	of	multi-kilo	cases	of	the	drug	originating	in	South	Africa,	Benin,	
Cameroon	and	Senegal	emerged	in	the	same	period.	
south africa
ATS	such	as	methamphetamine	(known	as	tik),	methcathinone	(known	as	cat)	and	ecstasy	continue	to	pose	major	threats	
to	South	Africa.	Methamphetamine	and	methcathinone	as	well	as	methaqualone,	a	sedative	hypnotic,	are	manufactured	
in	the	country	for	local	use.	Most	ATS	laboratories	are	small-scale	operations,	often	located	in	residential	areas.	
Illicit	manufacture	of	methcathinone	was	first	reported	in	2002.	Historically,	most	methcathinone	laboratories	were	seized	
in	the	Gauteng	Province	in	the	northeast	of	South	Africa	(93%	in	2002).	Since	2004,	methamphetamine	manufacture	
has	become	more	prominent,	as	reflected	by	the	growing	seizures	of	the	drug,	as	well	as	the	growing	number	of	clan-
destine	laboratories	found	to	be	manufacturing	methamphetamine.	In	2007,	the	number	of	methamphetamine	labora-
tories	seized	outpaced	those	of	methcathinone	for	the	first	time	and	that	trend	continued	through	2009.	
5	 UNODC,	2010b.
6	 There	have	been	recent	unconfirmed	reports	of	mobile	amphetamine	laboratories	in	Burkina	Faso	run	by	Nigerian	criminals	but	none	have	been	discovered	
to	date	(INCSR,	2011).
7	 NDLEA,	2011.
8	 71%	of	the	cases	appearing	on	this	list	concern	methamphetamine	trafficking	(Japan	Customs,	2010).
In June 2011, the National Drug Law Enforcement 
Agency of Nigeria (NDLEA) seized an illicit meth-
amphetamine laboratory on the outshirts of Lagos 
‒ the first evidence of methamphetamine manu-
facture in Nigeria. The laboratory had an estimated 
capacity of 160 kg - 200 kg of crystalline metham-
phetamine per week.
Source: NDLEA Official Communication, 2011
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south africa: seizures of illicit methamphetamine and 
methcathinone laboratories, 2005-2009
* No laboratory seizures were reported to UNODC in 2008 – however 
seizures of 20 clandestine laboratories manufacturing methampheta-
mine were reported by a government source. 
Source: UNODC/ARQ DELTA
south africa: number of import and export  
notifications of precursor chemicals, 2005-2010
Source: South African Police Service Reports 2006-2010
south africa: methamphetamine as primary  
substance of abuse: Western cape,* 2003-2010
* From 2007, figures are for the whole Western Cape which includes 
Cape Town, Atlantis and Worcester. Up until 2007, figures denote the 
percentage of users in Cape Town alone.
Source: SACENDU, 2010
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Since	2006,	there	has	been	a	marked	decrease	in	the	total	number	of	reported	ATS	laboratories.	In	2007,	22	ATS	labora-
tories	were	dismantled,	compared	to	35	in	2006.	In	2008,	the	total	number	of	ATS-related	clandestine	laboratories	declined	
further,	with	a	total	number	of	20	clandestine	laboratories	reported	–	a	figure	which	remained	stable	through	2009.	
The	declining	number	of	seized	methamphetamine	laboratories	is	inconsistent	with	the	amounts	of	methamphetamine	
seized.	In	2009,	for	example,	while	37	kg	of	methamphetamine	were	seized	in	South	Africa,	the	largest	amount	ever,	the	
number	of	reported	laboratories	was	only	half	as	high	as	in	2008.
South	Africa	is	a	significant	importer	of	ephedrine	and	pseudoephedrine,	the	main	precursor	chemicals	used	in	the	illicit	
manufacture	of	methamphetamine	and	methcathinone.	The	South	African	Government	continues	to	strengthen	legisla-
tion	and	reporting	measures	to	prevent	chemical	diversion.	Ephedrine,	pseudoephedine	and	norephedrine	can	only	be	
imported	or	exported	with	special	permits	and	the	prescription	and	distribution	of	pharmaceutical	preparations	containing	
ephedrine	and	pseudoephedrine	are	strictly	controlled.
The	number	of	 import	and	export	notifications	of	precursor	chemicals	has	seen	a	sharp	 increase	since	2005,	with	397	
import	notifications	reported	in	2009/2010	(compared	to	226	in	2005/2006)	and	1,805	export	notifications	in	2009/2010	
(compared	to	735	in	2005/2006).9	A	direct	result	of	such	measures	appears	to	be	the	decline	in	the	number	of	identified	
and	attempted	diversions/attempted	diversions	of	ephedrine	and	pseudoephedrine.	No	seizures	of	ephedrine,	norephe-
drine	or	pseudoephedrine	have	been	reported	from	South	Africa	since	2006.	
The	decline	in	the	total	amount	of	ephedrine	and	pseudoephedrine	involved	in	identified	attempts	at	diverting	to	Africa	
in	general	could	be	due	to	a	number	of	factors,	which	may	 include	traffickers	placing	orders	for	smaller	shipments	of	
ephedrine	and	pseudoephedrine	to	avoid	suspicion	by	national	authorities.	Organized	crime	groups	reportedly	have	also	
shown	a	renewed	interest	in	norephedrine,	a	precursor	for	amphetamine	manufacture,	as	a	potential	alternative	to	ephe-
drine	and	pseudoephedrine.10	While	there	have	been	no	reports	of	seizures	of	norephedrine	 in	South	Africa,	 in	2009,	
Australian	authorities	intercepted	22.8	kg	of	the	substance,	concealed	in	machinery,	which	had	originated	in	South	Afri-
ca.11	Furthermore,	in	2007,	South	Africa	informed	INCB	of	attempts	to	produce	ephedrine	from	N-methyl-DL-alanine,	a	
non-scheduled	substance.	
South	Africa’s	excellent	financial,	transportation	(including	direct	air	links	with	South	America,	Asia	and	Europe)	and	com-
munications	facilities	provide	crime	syndicates	with	ample	opportunities	for	 regional	and	 international	 trafficking	 in	all	
forms,	including	ATS.	All	these	factors	make	South	Africa	an	attractive	 location	for	drug	traffickers	to	warehouse	their	
stocks	before	shipping	them	on	to	other	countries.	South	Africa	is	used	as	a	transhipment	point	for	precursor	chemicals	
and	ATS.	The	Australian	Crime	Commission	listed	South	Africa	and	Zambia	among	the	main	points	of	embarkation	for	
ATS	shipments	seized	in	Australia.	Detections	from	these	two	countries	accounted	for	about	20%	of	the	total	amount	of	
ATS	detected	at	the	Australian	border	in	2008/2009.12
The	past	decade	has	witnessed	a	steady	increase	in	ATS	use	in	South	Africa,	largely	driven	by	the	sharply	increasing	level	
of	methamphetamine	use	in	the	Western	Cape	Province	and	more	specifically,	Cape	Town.	High	use	rates	of	metham-
phetamine	have	remained	relatively	stable	in	the	Western	Cape	Province	since	2006,	with	about	one	third	of	drug	users	
reporting	the	drug	as	their	primary	drug	of	abuse	and	two	thirds	of	drug	users	reporting	it	as	a	primary	or	secondary	drug	
of	abuse.	Use	of	methamphetamine	appears	to	be	spreading	to	Pretoria	and	Port	Elizabeth.13	
The	percentage	of	drug	treatment	patients	 in	the	Gauteng	Province	(in	the	northeast	of	the	country),	reporting	meth-
cathinone	 as	 their	 primary	 or	 secondary	 drug	of	 abuse,	 high	 in	 comparison	with	 other	 sites	 in	 South	Africa,	 remains	
comparatively	stable	at	4%.14	Few	patients	in	other	drug	treatment	sites	across	the	country	report	using	this	drug.	
Ecstasy	use	is	low	across	South	Africa,	with	between	1%	and	4%	of	people	attending	specialist	substance	abuse	treat-
ment	facilities	in	South	Africa	reporting	the	drug	as	a	primary	or	secondary	substance	of	abuse.15	While	smaller	amounts	
of	ecstasy	were	seized	from	2001-2007,	no	seizures	of	ecstasy	were	reported	in	South	Africa	for	2008	or	2009.	
ATS	use	is	likely	a	contributing	factor	to	increasing	drug-related	crime	rates	in	South	Africa.	Research	by	the	Institute	for	
Security	Studies	has	linked	the	increase	in	crime	to	the	higher	volume	of	illicit	drugs	in	the	market,	highlighting	the	growth	
of	the	drug	scene	since	the	appearance	of	methamphetamine	on	the	illicit	market.16
9	 SAPS,	2006-2010.
10	 INCB,	2010b.
11	 INCB,	2010b.
12	 Methamphetamine	was	detected	on	27	March	2009	 in	 large	metal	 rollers,	consigned	as	air	cargo	from	South	Africa	 to	Sydney,	while	amphetamine	was	
detected	on	26	August	2008	in	plastic	bottles	in	parcel	post	from	Zambia	to	Sydney	(ACC,	2010).
13	 INCSR	2008	–	2011.
14	 SACENDU,	2010.
15	 SACENDU,	2010.
16	 ISS	Africa,	2010.	
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metHaQuaLone
South Africa is possibly the world’s largest 
consumer of methaqualone (known as man-
drax). Methaqualone is a sedative-hypnotic 
often smoked in combination with cannabis 
(a form of drug abuse known as the “white 
pipe”) and is smuggled into South Africa from 
China, India transiting countries such as Mo-
zambique, Swaziland and Zimbabwe. Meth-
aqualone is illicitly manufactured in South 
Africa (four laboratories were seized in 2009). 
Illicit methaqualone manufacture reportedly 
also takes place in clandestine laboratories 
in Mozambique, suggesting a desire to avoid 
better policed South African air and sea ports, 
as well as suggesting that the risk of detection 
may well be lower in neighbouring countries.
Source: UNODC ARQ/DELTA
south africa: reported seizures of methaqualone (kg),  
2005-2009
159
773
93
1,586
828
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
2005 2006 2007 2008 2009
Se
iz
u
re
s 
o
f 
m
et
h
aq
u
al
o
n
e 
(k
g
 e
q
u
iv
al
en
ts
)
nortH america
75
regional overview
North	America	continues	to	be	a	significant	market	for	ATS,	particularly	methamphetamine	and	ecstasy.	With	an	estimated	
3.5	million	people	who	had	used	amphetamines-group	substances	at	 least	once	 in	the	previous	year,	the	region	has	a	
prevalence	rate	of	1.1%	of	the	population	aged	15	to	64.
The	number	of	reported	laboratory	incidents	in	North	America	has	increased	slightly	since	2006,	from	8,218	to	9,641	in	
2009	(+17%),	after	experiencing	declines	in	2007	and	2008.	Over	the	past	five	years,	Mexico	has	become	an	important	
manufacturing	location,	primarily	for	methamphetamine.	In	2009,	Mexico	reported	the	dismantling	of	191	laboratories,	
up	from	21	in	2008	and	the	upward	trend	appears	to	have	continued	in	2010.	Since	2008,	Canada	has	emerged	as	a	
location	for	ecstasy,	with	12	ecstasy	laboratories	being	seized	in	2009.	
Methamphetamine	seizures	in	North	America	remain	high,	due	to	continued	high	seizures	in	the	United	States	as	well	as	
sharp	increases	in	methamphetamine	seizures	in	Mexico	in	2009	and	2010.	Seizures	of	ecstasy	also	increased	significantly	
in	the	USA	in	2009	in	contrast	to	Canada	where	they	declined	for	the	second	consecutive	year.
canada
Canada	continues	to	be	a	significant	source	for	ATS	manufacture	and	trafficking,	principally	for	ecstasy-group	substances	
but	 also	methamphetamine.	 Illicit	manufacture	 of	 amphetamine	was	 reported	 in	 2008	 for	 the	 first	 time	 in	 about	 a	
decade.	
Organized	crime	groups	in	Canada	are	the	main	source	of	ecstasy	on	the	North	American	market	and	the	primary	market	
for	ecstasy	manufactured	in	Canada	is	the	USA.	Canadian	police	reported	that	smuggling	of	ecstasy	across	the	border	
into	the	USA	increased	significantly	between	2008	and	2009,	with	smuggling	activity	being	reported	from	the	provinces	
of	British	Colombia,	Ontario	and	Quebec;	a	trend	which	continued	from	previous	years.1	
Over	the	last	decade	there	has	been	a	sharp	increase	in	the	illicit	manufacture	and	trafficking	of	both	ecstasy	and	meth-
amphetamine	in	Canada.	While	the	number	of	illicit	laboratories	detected	in	Canada	remained	stable	from	2006	to	2009	
(at	between	30	and	40	per	year),	there	are	indications	that	illicit	ATS	activity	in	the	country	is	on	the	increase,	driven	by	
1	 RCMP,	2010.
north america: ats laboratories, seizures and annual prevalence rates, 2005-2009
measure DruG Group 2005 2006 2007* 2008 2009
Laboratory 
(#)
Methamphetamine
Amphetamine
Combined amphetamines
Ecstasy-group substances
13,052
9
-
37
8,218
29
-
35
6,138
3
-
27
7,259
3
4
14
9,641
-
-
12
total 13,098 8,282 6,168 7,280 9,653
Seizures 
(kg)
Methamphetamine
Amphetamine
Non-specified amphetamines
Ecstasy-group substances
7,207.3
57.2
157.8
2,227.1
7,810.4
38.6
1,377.5
3,008.0
6,837.2
45.4
163.9
3,981.1
8,087.0
428.4
35.5
3,279.5
15,592.5**
182.8
0.6
3,816.3
total 9,649.4 12,234.5 11,027.7 11,830.4 19,592.2
Annual Prevalence 
(15-64)
Amphetamines-group substances
Ecstasy-group substances
1.3%
0.8%
1.3%
0.8%
1.3%
0.9%
1.05%
0.8%
1.1%
1.1%
* From 2007 onwards, reported prevalence percentage is based on midpoint of range. ** Cuarto Informe de Ejecución, 2011; NDIC, 2010b. 
- Not reported. 
Source: UNODC ARQ/DELTA
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canada: seized ats laboratories, 2005-2009
Source: UNODC ARQ/ DELTA
expanding	international	markets	and	the	growing	involve-
ment	of	organized	crime	groups.
ATS	laboratories	seized	in	Canada	are	typically	large	indus-
trial-style	facilities	run	by	organized	crime	groups,	primarily	
with	links	to	East	Asia.	Canada	continues	to	strengthen	ATS	
legislation	 and	precursor	 control	measures	 to	 address	 the	
issue.
In	2009,	two	thirds	of	the	 laboratories	seized	were	meth-
amphetamine	 laboratories	 while	 one	 third	was	 for	 the	
manufacture	of	ecstasy.	The	number	of	methamphetamine	
laboratories	 seized	 in	Canada	more	 than	 tripled	 between	
2008	and	2009,	from	7	to	23.	
Increases	 in	 the	manufacture	 of	 ecstasy	 in	 Canada	 have	
coincided	with	 a	 reported	 decline	 in	manufacture	 of	 the	
drug	 in	 Europe	 (mainly	 the	 Netherlands	 and	 Belgium),	
driven	in	part	by	larger	demand	for	ecstasy	in	North	Amer-
ica.	Crime	networks	with	 links	to	East	Asia,	primarily	situ-
ated	in	British	Columbia	and	Ontario,	continued	to	dominate	
the	 Canadian	 illicit	 ATS	 drug	 trade	 in	 2009.	 Organized	
crime	 groups	with	 links	 to	 Asia	 (Viet	 Nam),	 South	 Asia	
(India),	and	Eastern	Europe	were	identified	in	2009	as	con-
tinuing	 and	 emerging	 players	 in	 the	 domestic	 synthetic	
drug	landscape.	Mexican	crime	groups	operating	in	Quebec	
were	 also	 identified	 as	 being	 involved	 in	 the	 illegal	 ATS	
drugs	trade	in	Canada.
The	 shortage	 of	 ecstasy	 precursors	 such	 as	 3,4-MDP-2-P	
canada: seizures of ats, 2005-2009
Source: UNODC ARQ/ DELTA
canada: past year ats use, 2004-2009
* No data was provided for crystalline methamphetamine use in the 
2004 survey. 
Source: health Canada, 2009
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reported	from	Europe	in	2008	and	2009	appears	not	to	have	affected	ecstasy	manufacture	in	Canada.	In	Europe,	effective	
precursor	controls	curtailed	the	availability	of	 the	precursor	used	 in	 the	manufacture	of	ecstasy.	This	had	resulted	 in	a	
significant	decline	in	the	number	of	seizures	of	laboratories	as	well	as	seizures	of	ecstasy,	storage	and	dump	sites	related	
to	large-scale	ecstasy	manufacture.2
A	recent	trend	is	the	increasing	use	of	BZP	to	manufacture	pills	falsely	sold	as	ecstasy.	In	2009,	BZP	was	available	in	large	
supply	and	a	strong	increase	in	cross-border	smuggling	of	BZP	pills	from	Canada	to	the	USA	was	noted.3
Organized	crime	groups	based	in	Canada	continue	to	manufacture	methamphetamine	for	both	the	domestic	and	global	
markets.	While	domestic	demand	for	methamphetamine	in	Canada	is	reportedly	stable,	illicit	manufacture	of	the	drug	in	
Canada	is	on	the	rise	driven	by	expanding	international	demand.	Methamphetamine	is	increasingly	being	trafficked	out-
side	the	region	to	destinations	such	as	Japan	and	Australia.	Seizures	of	illicit	methamphetamine	laboratories	more	than	
tripled	between	2008	and	2009,	from	7	in	2008	to	23	in	2009.	Methamphetamine	manufacture	in	Canada	takes	place	
in	urban	areas,	primarily	Vancouver,	the	greater	Toronto	area	and	the	Montreal	region.
The	rate	of	cross-border	methamphetamine	trafficking	from	or	to	Canada	and	the	USA	continues	to	be	low	compared	to	
cross-border	ecstasy	trafficking.	The	vast	majority	of	methamphetamine	seized	in	Canada	originates	from	domestic	labo-
ratories.	However,	a	slight	increase	was	noted	in	the	number	of	methamphetamine	shipments	intercepted	in	Canada	(both	
to	and	from	the	USA)	in	2009.4
While	there	was	a	significant	decline	in	the	total	amount	of	ecstasy-group	substances	seized	in	Canada	between	2007	
and	2009,	several	new	trends	were	noted	in	2009,	including	increased	incidences	of	powder	ecstasy	shipments	destined	
for	foreign	countries,	indicating	the	expansion	of	international	markets	for	Canadian-manufactured	ecstasy.	
The	Pacific	region,	specifically	British	Colombia,	is	the	primary	smuggling	corridor	for	ecstasy	trafficking	from	Canada	to	
the	USA,	as	well	as	appearing	to	be	the	main	site	of	illicit	manufacture	in	the	country.	In	2009,	a	record	amount	of	2.6	
million	units	of	ecstasy	were	seized	in	the	region.	Cross-border	smuggling	activity	was	noted	in	other	provinces,	such	as	
Manitoba,	which	appears	to	have	become	an	important	transit	point	for	inter-provincial	trafficking.	An	increase	in	domes-
tic	trafficking	was	also	noted	in	2009,	reflected	by	significant	seizures	in	regions	which	had	previously	reported	only	small	
amounts.
Ecstasy	is	also	trafficked	to	countries	in	Asia	and	Oceania.	Shipments	from	Canada	destined	for	the	Philippines	were	first	
noted	in	2008,	and	continued	to	be	detected	in	2009.	Mexico	and	Jamaica	were	also	identified	as	destinations	for	ecstasy.	
While	ecstasy	trafficked	across	the	border	to	the	USA	is	mainly	smuggled	via	land	transport,	shipments	destined	for	Asia	
usually	consist	of	smaller	quantities	trafficked	via	postal/courier	services	and	airline	passenger	luggage.5	
Estimates	of	the	annual	prevalence	rate	of	ecstasy	use	among	the	population	aged	15-64	in	Canada	declined	significantly	
in	2009,	to	1.1%,	down	from	1.7%	in	2008.	The	annual	prevalence	among	young	people,	aged	15-19,	was	3%	in	2009.6	
The	highest	rates	of	ecstasy	use	are	reported	from	the	provinces	of	Saskatchewan	(1.6%	in	2009)	and	British	Colombia	
(1.3%	in	2009).7
The	 2008	 British	Colombia	Adolescent	 Health	 Survey	 reported	 that	 the	 percentage	 of	 students	who	 had	 ever	 used	
ampheta	mines	(including	crystalline	methamphetamine)	decreased	between	1998	and	2008.	In	the	same	survey,	7%	of	
students	reported	they	had	used	ecstasy	and	2%	reported	that	they	had	used	crystal	methamphetamine.8
Following	increases	of	ATS	use	between	2004	and	2008,	the	Canadian	Alcohol	and	Drug	Use	Monitoring	survey	9	also	
showed	a	 sharp	decline	 in	past	 year	use	of	ecstasy	and	amphetamine	between	2008	and	2009,	as	well	as	an	overall	
decline	since	the	comparable	Canadian	Addiction	Survey	(CAS)	carried	out	in	2004.
2	 RCMP,	2010.
3	 RCMP,	2010.	
4	 RCMP,	2010.	In	the	Annual	Reports	Questionnaire	for	2009,	Canada	reports	the	seizure	of	20kg	of	methamphetamine	transported	from	Mexico	to	British	
Columbia	via	the	USA.
5	 RCMP,	2010.
6	 UNODC,	2011a.
7	 Health	Canada,	2009.
8	 McCreary	Centre	Society,	2009.	
9	 In	2008	and	2009,	over	13,000	Canadian	nationals	aged	15	and	older	took	part	 in	the	survey	which	was	based	on	the	previously	carried	out	 ‘Canadian	
Addiction	Survey’	(CAS).
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mexico: seizures of methamphetamine laboratories 
and methamphetamine, 2001-2009
* Cuarto Informe de Ejecución, 2011 
Source: UNODC DELTA
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Precursor	chemicals	 for	 the	manufacture	of	ATS	are	smuggled	 into	Canada	primarily	 from	 India	and	China,	with	 large	
amounts	of	P-2-P	and	significant	quantities	of	ephedrine	being	seized	each	year.10	2009	saw	the	resurgence	of	several	
unique	synthetic	drug	manufacturing	methods	which	required	the	acquisition	of	new	or	historically	used	chemicals.	Saf-
role,	for	example,	a	chemical	previously	used	in	older	manufacturing	methods	for	ecstasy,	appeared	to	make	a	comeback	
in	2009.11	In	addition,	phenylacetylcarbinol	(L-PAC)	emerged.	L-PAC	is	a	chemical	used	solely	to	produce	ephedrine	which	
has	only	been	used	by	the	pharmaceutical	 industry	 in	the	past.	This	 is	evidence	of	organized	crime	groups	diversifying	
their	methods	of	obtaining	ephedrine	for	the	illicit	manufacture	of	methamphetamine.12	
mexico
Since	the	mid-2000s,	Mexico	has	emerged	as	an	important	source	of	methamphetamine	to	the	USA,	following	strength-
ened	enforcement	and	precursor	 control	measures	 in	 the	USA.	Strong	 increases	 in	 the	 illicit	manufacture	of	metham-
phetamine	were	reported	from	2008	to	2009.	In	2009,	Mexico	reported	191	methamphetamine	laboratories,	up	from	21	
in	2008.	Most	laboratories	were	discovered	in	the	central	Pacific	region	(in	particular,	the	states	of	Michoacan,	Jalisco	and	
Sinaloa).	 Between	2007	 and	2009,	 seizures	 of	methamphetamine	by	United	 States	 authorities	 along	 the	border	with	
Mexico	increased	by	279%,	as	the	total	for	2009	amounted	to	5,197	kg	(compared	with	1,860	kg	in	2007).	
The	Government	of	Mexico	has	made	numerous	efforts	to	stem	the	trafficking	of	precursor	chemicals	to	the	country	to	
reduce	illicit	manufacture	of	methamphetamine.	Restrictions	over	the	import	of	pseudoephedrine	and	ephedrine	resulted	
in	lower	levels	of	methamphetamine	manufacture	in	2007	and	2008.	The	Government	of	Mexico	announced	a	prohibition	
on	pseudoephedrine	and	ephedrine	imports	into	Mexico	for	2008	and	a	ban	on	the	use	of	both	chemicals	in	Mexico	by	
2009.	Since	that	time,	reports	of	illicit	methamphetamine	laboratories	have	been	increasing	in	Central	America	and	South	
America.	
Due	to	the	stricter	controls	over	ephedrine	and	pseudoephedrine,	traffickers	have	resorted	to	alternative	methods	for	the	
manufacture	of	methamphetamine.	Such	techniques	either	synthesize	these	chemicals	from	others	more	easily	available	
or	bypass	their	use	entirely.	One	example	is	the	1-phenyl-2-propanone	(P-2-P)	method,	or	its	pre-precursor,	phenylacetic	
acid.	The	product	obtained	from	the	use	of	phenylacetic	acid	or	P-2-P	is	a	less	potent	racemic	‘d/l	methamphetamine’.	
The	 loss	 in	potency	of	this	product	can	be	compensated	by	higher	purity	 levels.	There	have	also	been	 indications	that	
traffickers	have	added	an	additional	purification	step	to	obtain	the	traditional	‘d-methamphetamine.’	
Mexico	made	 large	seizures	of	phenylacetic	acid	 (31	mt)	 in	2009,	which	can	be	used	to	obtain	P-2-P,	as	well	as	other	
closely	related	chemicals,	including	some	which	are	not	under	international	control	(such	as	esters	of	phenylacetic	acid	in	
2008	and	phenylacetyl	amide	in	2009).	In	2010	and	2011,	Mexican	authorities	continued	to	make	seizures	of	esters	of	
phenylacetic	acid.
In	Mexico,	while	there	has	been	no	update	in	the	annual	prevalence	of	amphetamines-group	substance	use	since	the	last	
household	 survey	 in	 2008,	 the	 expert	 perception	 in	 2009	 indicates	 stable	 trends	 for	 amphetamines	 use	 but	 a	 great	
increase	in	the	use	of	methamphetamine	over	the	past	year.	In	2009,	among	school	students	aged	12-19	in	Mexico,	the	
reported	lifetime	prevalence	of	amphetamine	and	methamphetamine	use	was	1.9%	and	0.7%	respectively.	In	previous	
years,	however,	the	lifetime	prevalence	among	youth	aged	12-17	was	reported.	
united states of america
Methamphetamine	laboratory	incidents	in	the	USA	rose	for	the	second	consecutive	year,	from	6,099	in	2007	to	9,427	in	
2009.	This	is	a	54%	increase	in	a	period	of	two	years.	There	is	a	growing	prevalence	of	small-scale	(‘one-pot’,	‘shake	and	
bake’)	laboratories.	
‘One-pot’	 is	a	variation	of	the	 lithium	ammonia	method	of	manufacture.	 Instead	of	manufacturing	methamphetamine	
through	a	series	of	sequential	steps,	the	one-pot	method	is	concluded	in	a	single	reaction	vessel	and	all	ingredients	are	
mixed	together	at	the	outset.	The	mixture	is	left	to	react,	naturally	producing	the	necessary	ammonia,	which	then	reacts	
with	the	lithium	metal	to	convert	the	pseudoephedrine	into	methamphetamine.13	
The	availability	of	domestically	manufactured	methamphetamine	has	increased.	Seizures	of	methamphetamine	increased	
to	7.5	mt	in	2009,	compared	to	7.4	mt	in	2008.	Methamphetamine	is	also	reportedly	at	its	purest	level	since	2005.	
	
10	 For	example,	Canadian	authorities	reported	the	seizure	of	over	6	tons	of	P-2-P	in	Vancouver	and	550kg	of	ephedrine	in	late	2010	(UNODC,	2011c).	
11	 RCMP,	2010.
12	 RCMP,	2010.
13	 NDIC,	2010b.
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The	main	source	for	the	manufacture	of	methamphetamine	
is	the	diversion	of	over-the-counter	pharmaceutical	prepa-
rations	containing	pseudoephedrine.	Such	preparations	are	
often	 obtained	 by	 ‘smurfing’14	 and	 several	 states	 in	 the	
USA	have	made	efforts	to	address	the	issue	by	establishing	
control	measures	and	restrictions	on	the	sale	of	pharmaceu-
tical	 preparations	 containing	 these	 precursors.	 Prior	 to	
1976,	prescriptions	were	required	federally	for	all	prepara-
tions	containing	pseudoephedrine.
Methamphetamine	 availability	 in	 the	 USA	 seems	 to	 be	
closely	related	to	methamphetamine	manufacturing	trends	
in	Mexico,	where,	following	precursor	restrictions	in	2007,	
manufacture	seems	to	have	rebounded	based	on	the	seized	
manufacturing	 facilities	using	non-ephedrine-based	meth-
ods.	 Seizures	of	methamphetamine	 increased	 significantly	
in	Mexico	 from	 some	 340	 kg	 in	 2008	 to	 8	mt	 in	 2009.	
Criminal	 organizations	 from	Mexico	do	not	only	organize	
trafficking	of	methamphetamine	into	the	USA	but	have	also	
established	their	own	operations	in	the	USA,	mainly	in	the	
state	of	California.	
Seizures	 of	 ecstasy	 are	 at	 a	 five-year	 high	 in	 the	USA.	 In	
2009,	3,411	kg	were	reported	seized,	a	15%	increase	com-
pared	to	2008.	With	a	total	of	114	manufacturing	facilities	
14	 Smurfing	 is	 a	method	 used	 by	 some	methamphetamine	 traffickers	 to	
acquire	large	quantities	of	precursor	chemicals	by	purchasing	quantities	at	
or	below	the	legal	threshold	from	multiple	retail	locations.	Traffickers	often	
enlist	the	assistance	of	several	friends	or	associates	in	these	operations.
usa: methamphetamine seizures along the  
southwest border, in kilograms, 2005-2009
*Partial-year data. 
Source: NDIC, 2010b
usa: annual prevalence of stimulants and metham-
phetamine use in the population aged 12 and older, 
2005-2009
Source: SAMhSA, 2010a
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usa: methamphetamine-related treatment 
admissions,	2004-2008*
* Treatment Episode Data Set (TEDS) is an admission-based system, 
the admissions do not represent individuals, hence one person 
admitted twice over a year is counted as two admissions. 
Source: SAMhSA, 2010b
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being	dismantled	from	2000	to	200915,	illicit	ecstasy	manufacture	in	the	USA	appears	to	be	limited.	Most	seized	facilities	
were	small	in	scale.	Ecstasy	is	predominantly	trafficked	into	the	USA	from	Canada,	where	Asian	transnational	organized	
crime	groups	are	believed	to	be	responsible	for	the	expansion	of	trafficking	to	the	USA.
In	2009,	the	annual	prevalence	rate	of	amphetamines-group	substances	was	reported	as	0.5%	of	the	population	aged	
12-64,	an	increase	compared	to	0.3	in	2008.	The	number	of	methamphetamine-related	treatment	admissions	showed	a	
decline	in	2007	and	2008,	although	there	are	indications	that	they	increased	in	2009.
For	2008,	a	total	of	1,900,000	substance	abuse	treatment	admissions	aged	12	and	older	were	reported	by	48	States,	the	
District	of	Columbia,	and	Puerto	Rico.16	Out	of	the	total	admissions,	7.2%	(121,485)	were	methamphetamine-related.17
Methamphetamine-related	treatment	admissions	peaked	in	2005,	when	they	reached	70	per	100,000,	and	subsequently	
declined	every	year	through	2008.
The	distribution,	sale	and	use	of	unregulated	synthetic	stimulants	marketed	‘bath	salts’	is	a	cause	for	concern	in	the	USA.	
Preliminary	 data	 from	 the	American	Association	 of	 Poison	Control	 Centers	 showed	 that	 number	 of	 calls	 related	 to	
exposures	to	‘bath	salts’	increased	from	303	in	2010	to	3,740	in	2011	(as	at	30	June	2011).	Most	‘bath	salts’	are	believed	
to	contain	MDPV	or	mephedrone.
15	 There	were	no	reports	of	ecstasy-group	manufacturing	facilities	in	2008	and	2009.
16	 Alaska	and	Georgia	did	not	report	admissions	for	2008.
17	 SAMSHA,	2010b.
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regional overview         
Drug	control	efforts	in	South	America,	Central	America	and	the	Caribbean	have	traditionally	focused	mostly	on	cocaine	
and	its	derivatives	and	cannabis.	Illicit	manufacturing,	trafficking	and	use	of	ATS	have	not	been	perceived	as	a	significant	
threat.	ATS	awareness	tends	to	be	low,	and	lack	of	data	on	the	illicit	manufacture,	trafficking	and	use	of	ATS	is	one	of	
the	main	challenges	in	assessing	the	situation	in	these	subregions.	Close	proximity	to	major	ATS	markets	(such	as	North	
America)	render	countries	in	these	regions	vulnerable	to	the	risk	of	being	used	as	manufacturing	bases	and	transit	points	
for	the	illicit	transhipment	of	ATS	as	drug	traffickers	increasingly	look	to	avoid	the	ever-stricter	controls	enforced	in	North	
America,	particularly	with	regard	to	precursor	chemicals	used	in	the	manufacture	of	ATS.	
Illicit	manufacture	of	ATS	has	recently	emerged	in	countries	in	Central	and	South	America	which	had	little	or	no	previous	
history	of	reported	manufacture,	such	as	Argentina,	Belize,	Brazil,	Guatemala,	Nicaragua	and	Suriname.	A	record	high	of	
six	laboratories	was	reported	from	the	region	in	2009,	including	two	methamphetamine	laboratories	in	Brazil	and	Nica-
ragua,	one	ecstasy	laboratory	in	Brazil	and	three	combined	amphetamine	and	ecstasy	group	laboratories	in	Guatemala.	
ATS	seizures	in	the	region	fluctuated	between	2003	and	2009,	reaching	a	peak	of	622	kg	in	2007,	largely	due	to	the	high	
quantity	of	amphetamine	seizures	reported	that	year	by	Colombia	(490	kg),	dropping	to	88	kg	in	2008	and	increasing	
again	to	243	kg	in	2009.	Amphetamine	and	ecstasy-group	substances	have	dominated	ATS	seizures,	with	only	two	sig-
nificant	 seizures	 of	methamphetamine	being	 reported	by	Argentina	 (20.2kg)	 and	 the	Dominican	Republic	 (10.2kg)	 in	
2008.	In	2009,	most	ATS	seizures	in	the	region	concerned	amphetamine.
Concern	over	rising	levels	of	use	of	synthetic	drugs	such	as	ecstasy	among	South	American	youths	has	been	growing	in	
recent	years.	Use	of	amphetamines-group	substances	in	South	America	is	close	to	the	world	average,	with	0.5	to	0.7%	
of	the	population	aged	15-64	reporting	having	used	the	drug	at	least	once	a	year.	Brazil,	the	Bolivarian	Republic	of	Ven-
ezuela	and	Argentina	report	the	highest	prevalence	rates	of	amphetamines	use	in	South	America.	
Some	countries	in	Central	America	have	comparatively	high	prevalence	rates	of	amphetamines-group	substance	use,	with	
El	Salvador	(3.3%),	Belize	(1.4%)	and	Costa	Rica	(1.3%)	reporting	the	highest	annual	prevalence	rates	among	the	general	
population.	Numerous	studies	carried	out	among	various	segments	of	general	population	show	that	the	use	of	pharma-
south america, central america and caribbean: ats laboratories, seizures and annual prevalence rates 2005-2009
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south america, central america and the caribbean: ats seizures, 2003-2009
Source: UNODC ARQ/DELTA
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ceutical	 preparations	 containing	 stimulant	 substances	 is	
widespread	in	the	region.
For	ecstasy	use,	 the	highest	annual	prevalence	rate	 in	the	
region	was	reported	from	Argentina	(0.5%).	Several	coun-
tries	in	the	region,	for	example,	El	Salvador,	Peru	and	Trini-
dad	 and	 Tobago	 reported	 a	 perceived	 increase	 in	 ecstasy	
use	 in	 2009.	A	 recent	 national	 survey	 conducted	 among	
university	students	in	Brazil	2009	showed	an	annual	preva-
lence	of	3.1%.	
An	epidemiological	 study	on	ATS	use	among	22,000	 stu-
dents	from	Bolivia,	Colombia,	Ecuador	and	Peru	carried	out	
in	2009	showed	a	high	rate	of	past	12	month	use	of	syn-
thetic	drugs	in	Colombia	(1.6%).	The	most	frequently	used	
drug	in	Colombia	was	found	to	be	ecstasy,	although	use	of	
LSD	was	also	prevalent.	
Ephedrine	and	pseudoephedrine,	the	main	precursors	used	
in	 the	 illicit	manufacture	 of	methamphetamine,	 are	 rou-
tinely	seized	in	countries	in	Central	and	South	America.	In	
the	 Caribbean,	 only	 the	 Dominican	 Republic	 has	 been	
reporting	seizures.	Seizures	of	ephedrine,	in	particular,	have	
shown	 an	 increasing	 trend.	While	 no	 or	 insignificant	 sei-
zures	of	ephedrine	were	reported	in	2005	and	2006,	quan-
tities	have	 increased	significantly	since	then,	 to	almost	12	
tons	in	2009.	
In	 2009,	Argentinian	 authorities	 seized	 a	 total	 of	 almost	
10.5	mt	of	ephedrine,	accounting	for	about	25%	of	global	
seizures.	 Although	manufacture	 in	 Argentina	 cannot	 be	
ruled	out,	it	is	likely	that	the	large	quantity	of	this	precursor	
chemical	was	 intended	 for	other	destinations,	 possibly	Mexico.1	 Seizures	of	 ephedrine	destined	 for	Mexico	were	 also	
reported	by	Paraguay	and	Chile	in	2009.	Chile	reported	total	ephedrine	seizures	of	almost	1.2	mt	in	2009.2	In	July	2010,	
Guatemalan	police	reportedly	seized	over	half	a	million	capsules	containing	ephedrine	close	to	the	Honduran	border.3
Seizures	of	pseudoephedrine	have	also	been	 increasing	 since	2005,	with	 large	quantities	being	confiscated	 in	Central	
American	countries	in	recent	years.
Between	the	second	half	of	2009	and	the	first	half	of	2010,	authorities	in	El	Salvador	reportedly	confiscated	over	42	mt	
of	 pseudoephedrine.4	 Significant	 seizures	were	 also	 reported	 from	Belize,	Guatemala,	 Honduras	 and	 the	Dominican	
Republic.5	 In	Belize,	pseudoephedrine	 is	 reportedly	 combined	with	 cocaine	and	cannabis	 into	packaged	 shipments	 for	
onward	transit.	In	2009,	423	kg	of	pseudoephedrine	were	seized	in	Belize.	In	addition,	more	than	40	mt	of	phenylacetic	
acid,	 a	 chemical	used	 in	 the	manufacture	of	methamphetamine,	were	 reportedly	 seized	by	Belize	Customs	officials	 in	
2010.
Along	with	Mexico,	countries	in	Central	America	and	the	Caribbean	such	as	Belize,	the	Dominican	Republic	and	Jamaica	
were	identified	as	destination	countries	for	suspicious	shipments	of	ephedrine	and	pseudoephedrine	in	2009.	Illicit	ship-
ments	of	ATS	precursors	have	also	transited	Panama.	European	countries	such	as	the	Netherlands,	Spain,	Germany	and	
the	United	Kingdom	are	also	used	as	transit	points	for	precursors	destined	for	the	region.
Many	countries	in	the	region	have	recently	strengthened	legislation	to	prohibit	the	import	of	pseudoephedrine	and	ephe-
drine	in	an	attempt	to	prevent	illicit	ATS	activity	occurring	on	their	territories.	
Between	2007	and	2009,	 several	 countries	 in	 the	 region	 reported	 seizures	of	pharmaceutical	 preparations	 containing	
1	 UNODC,	2009b.
2	 INCB,	2011b.
3	 UNODC,	2010b.
4	 UNODC,	2010b.
5	 UNODC,	2010b.
south and central america: seizures of ephedrine, 
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south america, central america and the caribbean: 
seizures of pharmaceutical preparations containing 
pseudoephedrine, 2007-2009
Source: OAS/CICAD/MEM, 2011
Brazil: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
Brazil: use of ecstasy-group substances and  
amphetamines-group substances among  
undergraduates, 2010
Source: SENAD, 2010
argentina: trends in lifetime use of ecstasy (%)  
among students
Source: OAS/CICAD/MEM, 1999-2009
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pseudoephedrine	(in	pill	and	capsule	form),	with	quantities	
totaling	over	19	million	pills	or	capsules.6	
Norephedrine,	a	precursor	used	in	the	illicit	manufacture	of	
amphetamine,	was	reported	seized	in	2009	in	Costa	Rica,	
totaling	30	kg	and	allegedly	destined	for	Mexico.	The	pre-
cursor	 had	 entered	 the	 country	 through	 Panama	 but	 its	
origin	was	unknown.7
soutH america
Brazil
Recent	reports	indicate	that	illicit	ATS	manufacture	is	taking	
place	in	Brazil.	Brazilian	authorities	seized	ecstasy	laborato-
ries	 in	 2008	 and	2009	 as	well	 as	 one	methamphetamine	
laboratory	in	2009.	In	2010,	Brazil	seized	2,740	ecstasy	pills	
and	5,910	units	of	methamphetamine.
Reports	point	to	a	continuous	air	passenger	and	cargo	flow	
of	 the	 drugs	 from	 Europe	 to	 Brazil.	 In	 2009,	 the	 Federal	
Police	 of	 Brazil	 reportedly	 dismantled	 a	 significant	 drug	
courier	 organization	 that	 transported	 cocaine	 to	 Europe	
and	ecstasy	and	LSD	to	Brazil.	
In	Brazil,	a	2009	survey	among	undergraduates	 in	 the	27	
state	capitals	in	Brazil	revealed	that	lifetime	use	of	ecstasy	
was	7.5%,	while	use	within	the	past	12	months	and	past	
30	days	was	reported	as	3%	and	2%	respectively.	The	same	
survey	 reported	 a	 2%	 lifetime	 rate	 of	 amphetamines	 use	
and	about	1%	for	use	in	the	past	12	months	and	30	days.	
Nearly	4%	of	amphetamine	users	were	classified	as	being	
at	moderate	risk	of	drug	dependence,	second	only	to	can-
nabis	users	(7.8%).8	
argentina
ATS	 seizures	 in	 Argentina	 have	 fluctuated	 over	 the	 past	
seven	 years.	 In	 2009,	 seizures	 of	 ecstasy	 pills	 increased	
more	 than	 10	 fold,	 from	 11,072	 in	 2008	 to	 136,550	 in	
2009.	Methamphetamine	both	in	powdered	form	as	well	as	
methamphetamine	pills	are	seized	regularly.	In	2008,	Argen-
tina	reported	the	seizure	of	one	ecstasy	laboratory.	
chile
No	illicit	ATS	laboratories	have	been	reported	to	UNODC	to	
date,	but	 in	2009	Chile	 reported	 the	 seizure	of	one	 illicit	
laboratory	 manufacturing	 the	 hallucinogen	 mescaline.	
Ephedrine	has	been	trafficked	from	Chile	to	Mexico	for	the	
illicit	manufacture	of	methamphetamine.	Reported	seizures	
of	 ecstasy	pills	 in	Chile	 showed	a	decline	of	 almost	40%	
from	 4,153	 in	 2006	 to	 2,590	 in	 2008,	with	 no	 seizures	
being	reported	in	2009.
6	 OAS/CICAD/MEM,	2011.
7	 INCB,	2011a
8	 SENAD,	2010.
argentina: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
chile: trends in lifetime use of ecstasy (%) among  
students, 2001-2009
Source: OAS/CICAD/MEM, 1999-2009
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south america: seizures of ecstasy, 2005-2009*
* Where years are missing, it indicates that no reports were received.
Source: OAS/CICAD/MEM, 1999-2009
central america and the caribbean: seizures of ecstasy, 2005-2009*
* Where years are missing, it indicates that no reports were received.
Source: OAS/CICAD/MEM, 1999-2009
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colombia
Colombia	 seized	 126,573	 ATS	 pills	 in	 2009,	 including	
23,477	ecstasy	pills.	 In	addition,	a	shipment	of	15	million	
ecstasy	 pills	 seized	 in	 Poland	 and	 intended	 for	Colombia	
suggested	that	Colombian	syndicates	were	accepting	pay-
ment	for	cocaine	in	the	form	of	ecstasy	pills	illicitly	manu-
factured	in	Europe.9
centraL america anD  
tHe cariBBean
Following	stricter	legislative	and	control	measures	in	North	
American	countries,	there	is	concern	that	illicit	ATS	manu-
facture	might	 shift	 towards	 countries	 in	Central	America.	
Several	 countries	 in	 Central	 America	 have	 reported	 inci-
dents	related	to	illicit	ATS	manufacture.	Guatemala	reported	
the	 seizure	 of	 one	ATS	 laboratory	 in	 2008	 and	 three	 in	
2009,	as	well	as	the	seizure	of	12	mt	of	pseudoephedrine	
in	 2009.	 In	 2008,	Honduran	 authorities	 dismantled	 some	
establishments	 used	 for	 extracting	 pseudoephedrine.	 In	
Nicaragua,	 police	 discovered	 a	 laboratory	manufacturing	
illicit	synthetic	drugs	 in	February	2010,	and	seized	a	small	
quantity	 of	 amphetamine.10	 Central	 American	 countries	
accounted	for	two	thirds	of	illicit	ATS	laboratories	seized	in	
the	region	in	2009.
Smaller	 quantities	 of	ATS	 seizures	 have	 been	 reported	 by	
several	countries	in	the	region.	In	2009,	small	quantities	of	
amphetamine-type	 stimulants	 were	 seized	 in	 Bahamas	
(ecstasy),	Costa	Rica	(methamphetamine	and	ecstasy),	Chile	
(amphetamine	and	ecstasy),	Cuba	(methamphetamine	and	unspecified	ATS)	and	El	Salvador	(amphetamine).	Significant	
quantities	of	ecstasy	have	been	seized	in	the	Dominican	Republic	but	these	declined	in	2009.	
Dominican republic
In	the	Dominican	Republic	–	for	years	an	important	transshipment	location	for	ecstasy	–	seizures	of	ecstasy	pills	fell	from	
20,861	units	in	2007	to	17,885	in	2008	and	10,166	in	2009.	The	country	reported	its	first	significant	seizure	of	amphet-
amine	in	2009	(102.3kg).	Following	a	significant	seizure	of	methamphetamine	in	2008,	no	further	seizures	of	the	drug	
were	reported	in	2009.
Pseudoephedrine,	mostly	in	the	form	of	pharmaceutical	preparations,	has	been	routinely	seized.	In	August	2009,	author-
ities	in	the	Dominican	Republic	intercepted	more	than	409,000	pseudoephedrine	pills	in	a	shipment	en	route	to	Guate-
mala	 and	 originating	 in	 Bangladesh.11	 In	 December	 2008,	 authorities	 arrested	 three	men	 in	 connection	with	 the	
trafficking	of	nearly	800,000	pseudoephedrine	pills	falsely	labelled	as	vitamins	and	destined	for	Honduras.
9	 UNODC,	2010f.
10	 UNODC,	2010a.
11	 UNODC,	2009b.
Dominican republic: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
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The	starting	materials	or	precursors	that	are	used	in	illicit	ATS	manufacture	provide	an	invaluable	source	of	information	
that	assists	in	the	operation	of	law	enforcement	authorities	in	Member	States.	The	changing	trends	in	the	use	of	precur-
sor	chemicals	as	well	as	the	trends	in	their	licit	trade	and	diversions,	seizures	and	trafficking	allow	an	insight	into	the	global	
nature	of	the	illicit	manufacture	and,	ultimately,	the	use	of	ATS.	This	chapter	outlines	the	changing	ATS	trends,	examines	
the	 key	 starting	materials,	 discusses	 current	manufacturing	methods	 and	 the	 available	 end	products	 in	 illicit	markets.	
Specifically,	the	chapter	looks	at	ephedrine	and	pseudoephedrine	as	well	as	1-phenyl-2-propanone	(P-2-P),	phenylacetic	
acid	and	emerging	trends	related	to	these	substances.	With	regard	to	precursors	of	ecstasy-group	substances,	trends	and	
developments	 focus	 on	 safrole	 (including	 safrole-rich	 oils),	 isosafrole,	 piperonal	 and	 3,4-methylenedioxyphenyl-2-pro-
panone	(3,4-MDP-2-P),	all	of	which	are	under	international	control.	Special	attention	is	given	to	developments	in	the	use	
of	non-controlled	substances.
precursor trends
Illicit	ATS	manufacture	requires	several	chemicals	but	is,	to	a	certain	extent,	highly	flexible.	As	a	result	of	the	strengthen-
ing	 of	 controls	 on	 the	 trafficking	 of	 the	most	 commonly	 used	 precursors,	 illicit	manufacturers	 have	 changed	 their	
approach.	This	can	range	from	using	alternate	types	of	precursors	and	chemically	modified	precursors	not	under	interna-
tional	control	to	the	development	of	more	complex	diversion	routes	in	the	illicit	manufacture	and	trafficking	of	ATS.
There	are	a	number	of	measures	in	place	that	allow	the	monitoring	of	the	international	trade	in	precursor	materials	as	
well	as	the	reporting	of	suspicious	shipments	and	seizures.	These	measures	have	been	implemented	by	Member	States,	
often	in	cooperation	with	INCB,	including	seizure	data	reported	by	Governments	and	Pre-export	Notifications	(PEN),	an	
online	system	which	facilitates	the	reporting	of	monitoring	of	international	trade	in	precursors.
One	example	of	a	successful	precursor	control	 initiative	is	Project	Prism,	an	international	operation	initially	designed	to	
address	the	diversion	of	bulk	chemicals	such	as	ephedrine	and	pseudoephedrine	used	in	the	illicit	ATS	manufacture.	From	
2002	to	2010,	the	operation	resulted	in	the	investigation	of	suspicious	shipments	and	the	seizure	of	66.5	mt	of	precursors	
intended	for	the	illicit	manufacture	of	ATS.	Project	Prism	was	extended	in	2008	to	include	pharmaceutical	preparations	
containing	ephedrine	and	pseudoephedrine.
sources of precursors
The	main	source	of	precursor	chemicals	 for	 illicit	ATS	manufacture	 is	 their	diversion	from	licit	markets	or	trade	routes.	
While	not	a	reflection	of	illicit	trafficking,	information	on	importing	and	exporting	countries	of	precursors	allows	a	view	
of	global	trade	routes	and	thus	possible	routes	that	could	be	targeted	for	diversion	by	traffickers.	Data	from	INCB	and	
the	Global	Trade	Atlas	illustrate	import	and	export	trends	for	the	main	countries	involved	in	the	trade	of	ephedrine	and	
pseudoephedrine.	
In	2009,	 India,	Germany,	the	USA,	Singapore	and	Taiwan	Province	of	China	were	the	top	exporters	of	ephedrine	with	
India	responsible	for	63%	(88,416	kg)	of	global	trade.	The	major	importing	countries	of	ephedrine	in	2009	were	Egypt	
and	Nigeria.	Imports	of	ephedrine	into	Egypt	have	shown	an	increasing	trend:	none	were	reported	before	2008	to	7,258	
kg	in	2008	and	64,763	kg	in	2009.	India	reported	50%	(533,838	kg)	of	global	exports	of	pseudoephedrine	in	2009;	the	
other	main	exporters	were	Germany,	Taiwan	Province	of	China,	Singapore	and	Switzerland.	The	USA	was	 the	 leading	
importer	of	pseudoephedrine	(186,099	kg)	in	2009,	followed	by	Singapore	and	Taiwan	Province	of	China.	Under	the	PEN	
system,	ephedrine	and	pseudoephedrine	shipments	were	reported	by	34	countries	exporting	to	125	countries	 in	2009	
and	46	countries	exporting	to	146	countries	in	2010.	
With	regard	to	the	legitimate	trade	of	other	ATS	precursors,	there	have	been	some	notable	trends	from	2008	to	2010.	
According	to	INCB,	P-2-P	is	mainly	exported	to	two	countries	in	West	Asia	which	were	responsible	for	75%	and	95%	of	
total	exports	in	2008	and	2009,	respectively.	The	main	importer	of	phenylacetic	acid	from	2008	to	2010	was	Mexico	with	
2,472	mt	in	2009	and	132	mt	in	2010.	The	legitimate	trade	of	the	ecstasy-group	precursor	safrole	has	shifted	towards	
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precursor seizures
Precursor seizure data are typically used to illustrate 
that illicit manufacture is taking place in a given 
country or region. It is, however, important to rec-
ognize that seizure data can only provide a partial 
(and qualitative) picture of precursor availability. 
Diversions and stopped shipments following regula-
tory interventions are not included in the traditional 
seizure statistics; neither are domestic diversions, 
followed by onward smuggling. This applies also to 
diversions of pharmaceutical preparations contain-
ing controlled precursors (e.g. ephedrine and pseu-
doephedrine), including the numerous small-scale 
diversions or purchases of over-the-counter prepara-
tions, which provide the raw material for the thou-
sands of clandestine methamphetamine laboratories 
seized in the USA and Oceania. Finally, substitute 
chemicals and pre-precursors not under interna-
tional control are not widely recorded, although the 
number of reported seizures is on the increase.
In general, precursor seizure successes may be ac-
counted for by better focus and/or capacity of law 
enforcement authorities and better regulatory con-
trol, possibly related to greater awareness of the ATS 
problem as a whole. Varying law enforcement strate-
gies in different countries may also account for differ-
ences in reported precursor seizures and the extent 
of illicit activity.
Precursor seizure statistics therefore tend to show 
more the impact from national and regional ini-
tiatives, major seizures, and the qualitative devel-
opment of local drug markets, versus providing a 
quantitative measure of precursor availability. Some 
recent examples of qualitative changes include:
•• The more frequent use of different forms of con-
trolled precursors in clandestine ATS manufacture, 
including,
– pharmaceutical preparations containing 
ephedrine and pseudoephedrine
– natural raw materials such as safrole-rich oils 
(containing ecstasy-group precursors) 
•• The appearance of a number of substitute chemi-
cals of controlled precursors, including methyl, 
ethyl, isobutyl, amyl esters of phenylacetic acid 
(precursor of P-2-P), and the methyl glycidate de-
rivative of the ecstasy-group precursor 3,4-methyl-
enedioxyphenyl-2-propanone (3,4-MDP-2-P)
•• The impact of chemical controls in an increasing 
number of traditional transit countries is forcing 
the establishment of new trafficking regions that 
are less well prepared (e.g. Africa), as evidenced 
by increasing reports of diversion and smuggling in 
countries of those regions.
Global seizures of methamphetamine precursors, 
2005-2009
Source: INCB, 2009b, 2010b and 2011b
Global seizures of 1-phenyl-2-propanone(p-2-p) 
(Litres) and phenylacetic acid (kg)
Source: INCB, 2009b, 2010b and 2011b
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sassafras	oil	and	other	safrole-rich	oils.	In	2010,	39	shipments	of	101,840	litres	of	safrole-rich	oils	were	recorded,	com-
pared	to	185	litres	in	2008.
Precursors for methamphetamine and amphetamine
Methamphetamine precursors: ephedrine and pseudoephedrine
Ephedrine	and	pseudoephedrine	are	the	main	precursors	for	methamphetamine	and	can	be	converted	to	the	drug	by	a	
number	 of	 relatively	 simple	 reductive	 synthetic	methods.	 Both	 substances,	 in	 their	 bulk	 form,	 are	 under	 international	
control	and	are	also	precursors	for	the	stimulant	methcathinone,	synthesized	through	a	simple	oxidation	process.
Global	seizures	of	ATS	precursors	have	fluctuated	significantly,	continuing	the	trend	seen	from	2001	to	2006.	In	2007,	
23	countries	 seized	21.8	mt	of	ephedrine	with	 the	 top	 three	being	Panama	 (10	mt),	 followed	by	China	 (5.8	mt)	and	
Mexico	(3.7	mt).	These	totals	decreased	in	2008	with	23	countries	reporting	seizures	of	18.2	mt	and	Mexico	reporting	
the	most	seizures	of	2.8	mt.	There	was	an	increase	in	total	global	seizures	in	2009	to	41.9	mt	and	China	accounted	for	
65	%	of	seizures	with	28	mt	of	ephedrine.	The	amounts	of	pseudoephedrine	seized	from	2007	to	2009	decreased	with	
15	countries	reporting	the	seizure	of	25.3	tons	 in	2007;	most	of	the	substance	being	seized	by	Mexico	(12.2	mt).	For	
Mexico,	the	decrease	to	5.1	mt	in	2008	and	7.2	mt	in	2009	coincides	with	strenghtened	Governmental	monitoring	of	
shipments	of	bulk	ephedrine	and	pseudoephedrine	and	the	resulting	increase	in	the	complexity	of	diversion	routes	used	
by	traffickers.	The	decline	may	also	be	attributed	to	the	continuing	trend	in	the	shift	in	metamphetamine	precursors	away	
from	bulk	raw	materials	to	pharmaceutical	preparations	containing	ephedrine	and	pseudoephedrine,	which	are	not	sub-
ject	to	similar	international	controls.	
However,	there	has	been	a	significant	increase	in	the	monitoring	of	the	shipment	of	pharmaceutical	preparations	contain-
ing	ephedrine	and	pseudoephedrine	and	a	number	of	countries	have	introduced	stricter	control	measures	in	recent	years.	
The	success	of	these	measures	is	evidenced	by	the	increased	percentage	of	methamphetamine	precursor	seizures	reported	
to	the	INCB	that	contain	pharmaceutical	preparations.	Of	the	35	cases	reported	under	Operation Crystal Flow	in	2007,	
11%	concerned	pharmaceutical	preparations	containing	ephedrine	and	pseudoephedrine.	This	percentage	increased	to	
67%	of	reported	cases	in	2009	and	2010,	providing	further	evidence	of	this	shifting	trend	in	the	identity	of	precursors.	
In	2007,	19	kg	of	pharmaceutical	preparations	containing	ephedrine	were	seized	and	this	increased	to	861	kg	in	2008	
and	2.9	mt	in	2009.	Similarly,	seizures	of	pseudoephedrine	preparations	increased.	While	the	total	amount	seized	in	2007	
was	395	kg,	a	single	notable	seizure	of	3,768	kg	was	reported	for	Mexico	alone	in	2008	and	Thailand	seized	over	700,000	
pills	 containing	 pseudoephedrine	 in	 two	 separate	 instances.	 This	 upward	 trend	 continued	 in	 2009	with	 12	 countries	
reporting	seizures	of	pseudoephedrine	preparations	with	a	total	weight	of	1,075	kg.	 In	addition,	 large	seizures	of	pills	
containing	pseudoephedrine	were	again	reported	by	Thailand	(1.7	million	pills)	and	Cambodia	(13	million	pills).
Further	evidence	of	the	effect	of	tightening	controls	on	ephedrine	and	pseudoephedrine	is	provided	by	recent	increases	
in	seizures	of	an	alternative	precursor,	norephedrine.	Global	seizures	of	norephedrine	have	increased	from	8	kg	in	2005-
2006	to	1,575	kg	over	the	2007-2009	period.	Another	instance	of	the	changing	patterns	in	illicit	trafficking	can	be	seen	
in	the	case	of	the	naturally	occuring	plant,	ephedra,	a	source	of	both	ephedrine	and	pseudoephedrine.	In	2005/06,	almost	
900	mt	of	this	precursor	were	seized.	However,	the	amounts	seized	have	decreased	dramatically	in	recent	years	to	2,265kg	
in	2009	and	3,645kg	in	2010.
Amphetamine and methamphetamine precursors: 1-Phenyl-2-propanone(P-2-P) and phenylacetic acid
The	internationally	controlled	substances	1-Phenyl-2-propanone	(P-2-P),	also	known	as	Benzyl	methyl	ketone	(BMK),	and	
its	precursor	phenylacetic	acid	can	be	used	for	the	synthesis	of	both	amphetamine	and	metamphetamine.	Reported	sei-
zures	of	P-2-P	in	the	period	2007-2010	increased	from	836	litres	in	2007,	to	5,619	litres	in	2008	and	decreased	to	4,885	
litres	in	2009.	Most	P-2-P	seizures	in	2009	were	made	in	Europe,	with	both	the	Russian	Federation	and	Lithuania	report-
ing	 significant	 seizures.	Belgium	 reported	a	 seizure	of	5,000	 litres	of	P-2-P	 in	2010.	 In	2009,	China	also	 reported	 the	
destruction	of	8.7	mt	of	P-2-P	that	had	been	accumulated	over	a	number	of	years.	
Seizures	of	phenylacetic	acid	have	 increased	over	the	same	period:	 from	159	kg	 in	2007	to	over	41	mt	 in	2009,	with	
Mexico	 (30.6	mt),	China	 (8.5	mt)	and	Serbia	 (1.9	mt)	accounting	 for	most	of	 recent	 seizures.	 Following	strengthened	
controls	by	Mexico	over	phenylacetic	acid	and	its	salts	and	derivatives	in	2010,	seizures	of	esters	of	phenylacetic	acid	have	
been	reported	more	frequently,	including	one	shipment	of	45	mt	of	ethyl	phenyl	acetate	in	Belize.	These	substances	can	
be	 easily	 converted	 to	 phenylacetic	 acid	 and	 as	 such,	 these	 and	other	 possible	 “masked”	precursors	 are	 expected	 to	
appear	more	frequently	 in	 future	seizures.The	 investigation	and	analysis	of	chemicals	seized	during	the	dismantling	of	
illicit	laboratories	provides	a	crucial	early	indicator	into	the	latest	trends	in	illicit	manufacture.
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Global seizures of ecstasy-group precursors,  
2005-2009 
Source: UNODC calculations based on INCB data taken from  
INCB, 2009b, 2010b and 2011b
Precursors for ecstasy group substances: 3,4-MDP-2-P, safrole, isosafrole, piperonal
The	main	 ecstasy-group	 substances	 are	 3,4-methylenedioxymethamphetamine	 (MDMA),	 and	 its	 analogues,	 including	
3,4-methylenedioxyamphetamine	 (MDA)	and	3,4-methylenedioxyethylamphetamine	 (MDE).	 The	precursors	 for	ecstasy-
group	substances	include	safrole	(including	in	the	form	of	safrole	rich	oils),	isosafrole,	piperonal,	and	3,4-methylenediox-
yphenyl-2-propanone	(3,4-MDP-2-P;	piperonyl	methyl	ketone	(PMK))	which	are	all	under	international	control.
There	were	fluctuations	in	the	seizures	of	precursors	for	ecstasy-group	substances	from	2007	to	2009.	Notable	seizures	
of	a	single	substance	 include	 the	45,970	 litres	of	 safrole	 reported	by	Thailand	 in	2007-2008.	 In	general,	 the	 reported	
quantities	of	seized	precursors	do	not	reflect	the	corresponding	amounts	of	MDMA	pill	seizures	and	this	is	attributed	to	
the	probable	synthesis	of	the	main	precursor	3,4-MDP-2-P	in	illicit	laboratories.	In	2008,	four	countries	reported	stopped	
shipments	of	1,904	litres	of	safrole,	mostly	in	the	form	of	safrole-rich	oils,	with	Estonian	authorities	responsible	for	over	
96%	of	seizures.	It	is	noteworthy	that	Cambodia	separately	reported	the	seizure	of	5.2	mt	of	sassafras	oil	in	2009	and	
the	destruction	of	13,600	litres	of	seized	safrole-rich	oils	in	2010.	
Piperonal	is	produced	from	safrole/isosafrole	and	is	a	known	precursor	of	3,4-MDP-2-P.	It	is	an	aromatic	aldehyde	used	
mostly	in	the	perfume	and	fragrance	industry	and	licit	trade	in	piperonal	totaled	2,123	mt	in	2009-2010.	While	seizures	
of	piperonal	fluctuated	from	2005	to	2010,	it	should	be	noted	that	6,300	kg	seized	in	2009	represented	the	highest	total	
seizure	of	any	ecstasy-group	substance	precursor	in	that	year.	
non-scheduled substances used in the illicit manufacture of ats
From	2007	to	2010,	there	was	an	increase	in	the	number	of	seizures	of	non-scheduled	substances	that	could	be	used	as	
alternate	precursors	of	ATS.	Mexico	reported	seizures	of	significant	amounts	of	methyl,	ethyl,	isobutyl	and	amyl	esters	of	
phenylacetic	acid	in	2008.	L-PAC,	a	substance	used	in	the	industrial-scale	synthesis	of	ephedrine,	was	detected	in	2008	and	
2009	in	Canada	and	Mexico.	The	chemical	masking	of	precursors	continued	as	evidenced	by	seizures	of	the	non-scheduled	
bisulfite	adduct	of	P-2-P	in	2009	and	also	by	further	seizures	of	methyl	3-[3’4’-(methylenedioxy)phenyl]-2-methyl	glycidate	
(MMDMG)	in	2010.	MMDMG,	which	was	first	seen	in	Australia	in	2004,	is	a	non-controlled	chemical,	which	is	made	from	
piperonal	and	a	precursor	of	3,4-MDP-2-P.	The	increase	in	seizures	of	these	non-controlled	‘pre-precursor’	substances	reflects	
the	response	of	drug	traffickers	to	the	tighter	controls	placed	on	the	traditional	ATS	precursors.
Global seizures of ats precursors, 2007-2009 
Source: UNODC calculations based on INCB data taken from 
INCB, 2009b, 2010b and 2011b
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precursor trenDs 
trafficking trends
Trafficking	routes	for	the	precursors	of	ATS	have	become	more	complex.	In	addition	to	trafficking	precursor	chemicals	in	
bulk,	traffickers	are	increasingly	targeting	pharmaceutical	preparations	containing	ephedrine	and	pseudoephedrine.	This	
is	evidenced	by	increased	seizures	in	Europe	of	pills	in	transit.	For	example,	authorities	in	the	Netherlands	seized	11	million	
pseudoephedrine	pills	in	transit	from	Viet	Nam	to	Guatemala.	Similarly,	other	European	countries	including	France	as	well	
as	the	United	Kingdom	and	the	USA	seized	shipments	of	preparations	in	transit	from	Asian	countries	destined	for	South	
and	Central	America.	
Other	examples	of	the	increasing	complexity	of	trafficking	in	precursors	include	the	increasing	use	of	masked	precursors	
not	under	international	control	and	the	creation	of	new	trafficking	routes	as	a	result	of	increased	controls	on	precursors.	
For	example,	as	a	result	of	the	restrictions	on	ephedrine	and	pseudoephedrine	put	in	place	by	Mexican	authorities	in	2008	
and	2009,	there	has	been	an	increase	in	manufacturing	and	trafficking	in	countries	in	Central	and	South	America.	The	
main	precursor	of	ecstasy-group	substances,	3,4-methylenedioxyphenyl-2-propanone	(3,4-MDP-P-2-P),	 is	mostly	manu-
factured	 in	 illicit	 laboratories	 as	evidenced	by	decreased	 levels	of	 seizures	 in	 recent	 years.	As	a	 result,	 there	has	been	
increased	trafficking	in	precursors	of	3,4-MDP-P-2-P	such	as	piperonal	and	safrole-rich	oils	and	increased	manufacture	of	
ecstasy-group	substances	in	regions	of	Asia	where	these	starting	materials	are	produced.

manufacturinG metHoDs
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The	practical	information	for	manufacturing	ATS	is	widely	available	as	several	synthetic	routes	for	ATS	are	described	not	
only	in	the	scientific	literature	but	also	on	the	Internet.	The	structural	similarity	between	most	types	of	ATS	makes	it	pos-
sible	 for	manufacturers	 to	 easily	 adapt	methods	 used	 to	manufacture,	 for	 example,	 amphetamine	 to	make	metham-
phetamine.	
Central	 to	 the	 variety	 of	 synthetic	 routes	 that	 can	 be	 used	 for	 the	manufacture	 of	 ATS	 is	 a	 chemical	 reductive	
transformation*1	of	the	precursor	or	intermediate	molecule.	This	reduction	can	be	facilitated	by	a	range	of	chemicals.	The	
use	of	these	chemicals	depends	on	the	availability	of	the	necessary	chemicals	and	equipment,	the	desired	product	and	
the	skills	of	the	operator	-	thus	providing	manufacturers	with	a	degree	of	flexibility.	The	chemicals	used	include	organic	
solvents	such	as	acetone	or	ether,	various	reducing	agents	such	as	hypophosphorous	acid/iodine	and	other	chemicals	used	
for	purification	and	crystallization.	While	some	of	the	chemicals	required	are	difficult	to	obtain	on	the	open	market,	others	
can	be	obtained	from	commercially	available	materials	e.g.	ammonia	and	lithium	strips	from	batteries	can	be	used	for	the	
manufacture	 of	methamphetamine.	 In	 general,	 for	methamphetamine/amphetamine	 syntheses,	 there	 are	 additional	
requirements	depending	on	whether	ephedrine/pseudoephedrine	or	phenyl-2-propanone	(P-2-P)/phenylacetic	acid	(PA)	is	
the	precursor	used.	For	example,	using	either	P-2-P	or	PA	for	ATS	produces	a	mixture	of	isomers	(called	d	and	l),	which	
requires	an	extra	purification	step	to	make	a	product	with	the	same	potency	as	that	obtained	using	ephedrine	or	pseu-
doephedrine.
1	 Methcathinone	is	synthesized	from	ephedrine/pseudoephedrine	using	a	simple	oxidation	process.
most commonly used manufacturing methods and their yields
enD proDuct
precursor  
(1 KG or 1 Lt.)
syntHesis metHoD (metHoD) practicaL yieLD
Amphetamine P-2-P (lt.) Ammonium formate (Leuckart) 55%
Amphetamine P-2-P (lt.) Formamide (Leuckart) 67%
d,l-Methamphetamine P-2-P (lt.) Formic acid (Leuckart) 60%
d-Methamphetamine Pseudo/ ephedrine (kg) Red phosphorus / iodine 47%
d-Methamphetamine Pseudo/ ephedrine (kg) Red phosphorus / hydriodic acid 54%
d-Methamphetamine Pseudo/ ephedrine (kg) Lithium / ammonia (‘Birch’) 55%
d-Methamphetamine Pseudo/ ephedrine (kg) hypophosphorous acid / iodine 76%
d-Methamphetamine Pseudo/ ephedrine (kg) Thionyl chloride (Emde) 70%
Methcathinone Pseudo/ ephedrine (kg) Potassium permanganate 50%
MDA Sassafras oil* (lt.) hydrogen peroxide/ sodium cyanoborohydride 12%
MDA 3,4-MDP-2-P (lt.) Sodium cyanoborohydride 37%
MDA Piperonal Nitroethane 41%
MDMA Sassafras oil* (lt.) hydrogen peroxide/ aluminium amalgam 31%
MDMA Sassafras oil* (lt.) hydrobromic acid 48%
MDMA 3,4-MDP-2-P (lt.) Formic acid (Leuckart) 66%
MDMA Sassafras oil* (lt.) Methyl nitrite/ aluminium amalgam (Wacker) 68%
MDMA 3,4-MDP-2-P (lt.) Aluminium amalgam (reductive amination) 95%
* at 75% safrole. 
Source: Royal Canadian Mounted Police and health Canada; Suravina, L. G. and Voronenko, L. A. (1994). Forensics Investigation of Narcotic and Drastic 
Substances Obtained from Ephedra Grass Using home Production Methods. Ministry of Justice of the Republic of Kazakhstan, Kazakhs Scientific 
Research Institute; DEA, Methamphetamine Synthesis #7 (1997).
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The	most	common	synthetic	methods	used	for	the	manufacture	of	ATS	are	shown	below.	The	three	most	common	meth-
ods	used	 in	Europe	as	 reported	by	 the	EMCDDA	 in	2009	are	 the	 lithium-ammonia,	hypophosphorous	acid/iodine	and	
hydroiodic	acid/red	phosphorus	methods.	All	these	methods	necessitate	the	use	of	ephedrine	and	pseudoephedrine	pre-
cursors	and	are	1-step	synthetic	methods.	Two	other	less	commonly	detected	methods	in	Europe	are	the	Leuckart	and	
reductive	amination	method.
As	can	be	seen	from	the	table,	the	efficiency	of	the	transformation	from	precursor	to	product	(practical	yield)	varies	sig-
nificantly	depending	on	the	method	used.	There	is	an	inherent	difference	in	yields	based	solely	on	the	different	reagents	
used.	The	manufacture	of	ATS	under	improvised	clandestine	laboratory	conditions	by	operators	of	varying	skills	results	in	
even	 greater	 yield	 variation.	However,	 it	 is	 to	 be	 expected	 that	 yields	within	 a	 particular	 clandestine	 laboratory	may	
increase	over	time	as	a	result	of	improved	manufacturing	methods	and	skill	of	the	operators,	and	increased	sophistication	
of	laboratories.	While	the	choice	of	method	is	largely	determined	by	the	availability	of	precursors	and	other	reagents	and	
chemicals,	the	scale	of	the	illicit	laboratory	also	limits	the	use	of	certain	synthetic	routes.	
regional trends in ats manufacture and products
There	are	regional	preferences	for	the	use	of	certain	synthetic	methods	for	the	manufacture	of	ATS	substances.	In	Aus-
tralia,	methamphetamine	synthesis	involving	the	reaction	of	pseudoephedrine	with	hypophosphorous	acid/iodine	was	the	
preferred	method	in	38%	of	laboratories	in	2009-10,	although	the	Birch	method	(dissolving	metal	reduction	using	lithium/
sodium	and	anhydrous	ammonia)	was	the	predominant	method	in	Western	Australia	where	97	of	112	Australian	labora-
tories	using	this	method	were	located.	Also	of	note	in	Australia	over	the	period	2009-10	was	the	increase	in	the	number	
of	laboratories	using	the	red	phosphorus	route	in	the	synthesis	of	methamphetamine	-	from	16	laboratories	in	2008-09	
to	51	laboratories	in	2009-10.	In	New	Zealand,	where	135	clandestine	laboratories	involved	in	the	manufacture	of	ATS	
were	detected	in	2009,	the	most	commonly	detected	chemicals	indicated	a	preference	for	the	red	phosphorus	route	for	
methamphetamine	synthesis.
In	Europe,	the	use	of	the	hydroiodic	acid/red	phosphorus	method	for	the	manufacture	of	methamphetamine	was	reported	
mainly	in	the	Czech	Republic,	Slovak	Republic,	Germany	and	the	Netherlands,	while	methamphetamine	seized	in	Lithua-
nia	was	shown	to	have	been	produced	using	P-2-P	as	a	precursor.	An	alternate	amphetamine	manufacturing	method	was	
detected	in	a	clandestine	laboratory	in	Hungary	in	2009	involving	the	use	of	the	non-controlled	substances	benzaldehyde	
safrole-rich oils*
Safrole-rich oils are the main raw materials for the manufacture of safrole for commercial purposes. They are 
marketed worldwide in large quantities as starting materials for the fragrance and pesticide industries. 
There are a number of safrole-rich plant species that constitute the starting materials for the extraction of saf-
role; they are found in North America, South America, East Asia and South-East Asia. Safrole can be present in 
their essential oils at concentration levels of more than 90%. 
Safrole-rich oil tree species grow naturally and/or are cultivated for commercial purposes. To produce the oil, the 
trees are typically felled and the oil distilled from the timber, the root and stump. Oil yields from the distillation 
process typically range between 1% and 3.5%. however, many of these operations remain unregulated and as a 
consequence, there are not only concerns from the point of view of diversion into illicit drug manufacture, but 
also concerning environmental aspects, ecology systems and forestry. 
A recent survey in six countries in East and 
South-East Asia found 361 plants that con-
tain essential oils rich in safrole, most of 
which were of the Cinnamomum species. 
Other plant species rich in safrole include 
the North American Sassafras albidum 
(~80% safrole) and the Brazilian Ocotea pre-
tiosa (~80% safrole) and Piper hispidinervum 
(~90% safrole). 
The reported global licit trade of safrole-rich oils for 
2009-2010 was estimated at 101,840 litres.
* Safrole-rich oils are defined as “any mixtures or natural products containing safrole present in such a way that it can be used or recovered by 
readily applicable means” (INCB, 2011b).
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and	nitroethane	as	precursors.	In	general,	ATS	manufacture	
in	the	Czech	Republic	is	carried	out	in	smaller-scale	labora-
tories	compared	to	the	larger	industrial-type	facilities	used	
for	ATS	manufacture	in	parts	of	Asia.
In	North	America,	large	numbers	of	illicit	laboratories	were	
detected	 in	2009	 including	9,420	 in	 the	USA	and	191	 in	
Mexico.	Most	of	 the	 laboratories	 in	 the	United	States	are	
small-scale	laboratories,	where	operators	are	noted	to	often	
purchase	 pharmaceutical	 preparations	 containing	 ephe-
drine/pseudoephedrine	 in	 small	 quantities	 from	multiple	
retail	outlets.	The	number	of	laboratories	detected	in	Mexico	
increased	from	21	in	2008	to	191	in	2009	and	the	range	of	
chemicals	seized	indicated	the	use	of	a	variety	of	synthetic	
routes.	 The	 chemicals	 seized	 included	 over	 30,000	 kg	 of	
phenylacetic	 acid,	 its	 sodium	 salt	 and	 the	 pre-precursor	
phenylacetamide.	Tartaric	acid,	which	is	used	to	purify	the	
crude	products	of	ATS	synthesis	using	P-2-P/PA	as	precur-
sors,	was	also	seized.
In	2009,	Canada	reported	the	discovery	of	novel	synthetic	
methods	in	a	number	of	illicit	laboratories.	These	included	
the	discovery	of	drums	of	l-PAC,	a	precursor	of	ephedrine,	
suspended	 in	 toluene.	 In	 another	 laboratory	 producing	
ecstasy,	 chemicals	 associated	with	 the	Wacker	 oxidation	
synthetic	process,	a	method	not	recently	found	in	Canada,	
were	detected.	
ats products
ATS	are	available	in	a	range	of	forms	(e.g.liquid,	crystalline,	powder)	and	the	purities	of	the	substances	can	vary	signifi-
cantly	from	one	country	to	the	next.	It	is	difficult	to	accurately	estimate	the	content	and	purity	of	substances	seized	as	
both	these	factors	can	vary	depending	on	the	degree	of	adulteration	which	is	related	to	the	point	of	seizure	(customs	or	
illicit	 laboratory	or	final	street	product).	However,	 it	 is	possible	to	discern	certain	trends	in	content/purity	from	data	on	
regional	preferences.	While	ecstasy-group	substances	remain	a	global	phenomenon,	the	popularity	of	amphetamine	and	
methamphetamine	use	varies	regionally	with	amphetamine	being	most	common	in	Europe	and	West	Asia	and	with	meth-
amphetamine	the	ATS	of	choice	in	North	America	and	East	Asia.	
For	amphetamine,	100%	of	all	manufacturing	sites	discovered	in	2009	were	discovered	in	Europe	and	98.7%	of	global	
seizures	were	in	the	Near	and	Middle	East/South-West	Asia	and	Europe.	Amphetamine	in	the	Near	and	Middle	East/South-
West	Asia	continues	to	take	the	form	of	pills	known	as	Captagon	which	contain	amphetamine	and	other	components	
such	as	caffeine.	The	source	of	these	pills	remains	unknown.	
Amphetamine	purity	in	Europe	varies	from	less	than	10	%	to	25%	depending	on	whether	the	samples	are	seized	before	
or	after	adulteration.	For	example,	 in	the	UK,	the	purity	of	amphetamine	seized	at	points	of	entry	to	the	country	was	
17-21%	and	while	this	indicates	a	large	amount	of	adulteration,	the	purity	of	retail	samples	in	the	UK	was	in	the	range	
1-6%	with	caffeine	making	up	over	80%	of	the	content.2	It	is	also	noteworthy	that	the	amphetamine	products	seized	at	
points	of	entry	to	the	UK	were	not	in	the	form	of	powders	but	rather	as	pastes	contaminated	with	chemicals	from	the	
manufacture	process.
Methamphetamine	is	a	colourless	oil	 in	its	free-base	form,	but	is	commonly	commercially	available	as	its	hydrochloride	
salt	which	is	a	white	or	off-white	powder,	depending	on	purity	and	quality.	The	pure	crystalline	salt	form	takes	the	appear-
ance	of	crystals	and	has	a	number	of	common	names	including	“glass”	and	“Ice”.	Methamphetamine	purities	in	Europe	
in	2008	ranged	from	22	to	80%	with	Belgium	(80%)	reporting	the	highest	levels,	followed	by	the	Czech	Republic	and	
Slovakia	both	reporting	purities	of	64%.	The	high	purity	of	methamphetamine	compared	to	amphetamine	is	a	direct	result	
2	 SOCA,	2011.
This figure shows the molecular structures of methamphetamine (1), 
amphetamine (2) and their main precursor substances, pseudoephe-
drine (A), ephedrine (B), phenyl-2-propanone (P-2-P)(C) and pheny-
lacetic acid (D). The arrows indicate the flexibility of the ATS 
manufacturing process and illustrate the similarities of the precur-
sors and relative simplicity of the transformations required to con-
vert precursor to product.
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of	the	crystalline	nature	of	the	product.	In	the	United	States,	purities	of	methamphetamine	in	2006	and	2007	were	55%	
and	52%	respectively	after	a	high	of	78%	the	previous	year.3	Within	the	Asian	market	and	indeed	globally,	the	increasing	
use	of	methamphetamine	can	be	related	to	two	product-related	factors:	 the	 increased	potency	of	crystalline	metham-
phetamine	and	the	comparatively	low	cost	of	methamphetamine	in	pill	form.
With	regard	to	the	nature	of	the	products	of	ecstasy-group	substances,	they	are	available	as	powders	but	generally	take	
the	form	of	pills	containing	the	active	substance	as	its	hydrochloride	or	phosphate	salt	plus	bulking	agents	or	adulterants.	
Purities	of	ecstasy	in	Europe	declined	in	2008	and	2009,	but	preliminary	data	for	2010	showed	an	increase	in	purity	in	
2010.	Pills	sold	as	ecstasy	commonly	contain	amounts	of	piperazines,	ketamine	or	mephedrone.	Substances	detected	in	
pills	sold	as	ecstasy	in	Australia	2009	contained	methamphetamine,	BZP	and	TFMPP.
3	 NDIC,	2010.
unregulated products sold in ats markets
Several unregulated substances have appeared in established ATS markets at an unprecedented pace, as manu-
facturers and traffickers exploit the lack of controls. These substances often have chemical and/or pharmaco-
logical properties and effects similar to a known illicit substance. As these substances are not controlled by the 
United Nations international drug control treaties, they are marketed as “legal highs”. Substances are frequently 
labelled “plant food”, “bath salts”, “incense” or “scented sachets”. They are often sold in online shops: the EM-
CDDA found that the number of online shops selling such substances increased from 170 to 277 from 2010 to 
2011.
piperazines are often sold on illicit markets as ‘ecstasy’ and they may also be included as adulterants in pills. Pip-
erazines are typically taken orally, but can also be smoked or snorted. The most commonly reported piperazine 
is benzylpiperazine (BZP), others include 1-(3-chlorophenyl)piperazine (mCPP) and 1-(3-trifluoromethyl-phenyl)
piperazine (TFMPP).
Ketamine1 is often sold as ‘ecstasy’ or ‘amphetamine’ in the form of a bottled liquid or as a whitish powder. Its 
use has been reported in Asia, Americas, Europe and Oceania and it is under national control in several countries. 
synthetic cathinones are analogues to, or derivatives of, the internationally controlled substance cathinone, 
one of the psychoactive substances in the khat plant. Some of the most widespread synthetic cathinones are: 
mephedrone, methylenedioxypyrovalerone (MDPV- “bath salt”), methedrone, 4-fluoromethcathinone, 3-fluor-
omethcathinone, methylone. Some of the synthetic cathinones like mephedrone are under national control in 
several countries, particularly in Europe. 
synthetic cannabinoids are typically synthetic cannabinoid receptor agonists that function similar to delta-9-
tetrahydrocannabinol (ThC), the principal psychoactive component in cannabis. In 2008, several synthetic can-
nabinoids were detected in herbal smoking blends (e.g. ‘spice’, ’yucatan fire’) and include homologues of the 
nonclassical cannabinoid CP-47,4972 and the aminoalkylindole JWh-018 [e.g. JWh-122], which are potent can-
nabimimetics. 
Plants with psychoactive properties sold in ATS market include:
Kratom (Mitragyna speciosa) - a plant indigeneous to South-East Asia that contains the alkaloid mitra-
gynine. The most frequent mode of administration is making tea out of the dried leaves. It is a control-
led substance in several Asian and European countries.
Salvia divinorum - a plant which contains the hallucinogen salvinorin A. The substance is administered 
by chewing the fresh leaves or by drinking the juices of freshly crushed leaves.
1	 Chemically:	(±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone.
2	 Auwärter,	V.,	et	al.,	'Spice'	and	other	herbal	blends:	harmless	incense	or	cannabinoid	designer	drugs?	J	Mass	Spectrom,	2009.	44(5):	p.	832-7.
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Analysing	ATS	markets	and	developing	an	evidence	base	for	action	against	ATS	requires	accurate,	comparable	and	timely	
data.	Changes	in	ATS	drug	markets	-	the	specific	substance	and	form,	their	manufacture,	trafficking	and	use	-	occur	very	
rapidly,	and	there	are	clear	indications	that	they	are	expanding	in	developing	regions	of	the	world,	the	same	regions	where	
data	 and	understanding	are	most	 limited.	 The	 less	data	 are	 available,	 the	greater	 the	 reliance	upon	assumptions	 and	
generalization	which	can	lead	to	inaccurate	estimates	that	allow	the	problem	to	proliferate.	While	some	progress	has	been	
made	in	the	availability	of	ATS-related	data	in	some	regions	of	the	world,	lack	of	robust	information	on	the	illicit	manu-
facture,	trafficking	and	use	of	ATS	remains	a	significant	challenge	to	Member	States	and	the	international	community	in	
designing	effective	policy	and	programme	interventions.	
To	develop	an	accurate	and	comprehensive	picture	of	the	global	ATS	situation	requires	data	from	Member	States.	Data	
are	utilized	from	a	variety	of	sources	including:	the	UNODC	Annual	Reports	Questionnaire	(ARQ);	technical	reports	from	
the	International	Narcotics	Control	Board	(INCB);	Government	reports	and	reports	from	intergovernmental	organizations	
such	as	ICPO/Interpol,	the	World	Customs	Organization,	regional	organizations	such	as	the	European	Monitoring	Centre	
on	Drugs	and	Drug	Addiction	(EMCDDA),	Europol	as	well	as	regional	data	collection	mechanisms	such	as	the	Drug	Abuse	
Information	Network	for	Asia	and	the	Pacific	(DAINAP)	managed	by	the	Global	Synthetics	Monitoring:	Analyses,	Reporting	
and	Trends	(SMART)	Programme.
Pursuant	 to	 the	 provisions	 of	 the	United	Nations	 drug	 control	Conventions,	 the	 1961	 Single	Convention	 on	Narcotic	
Drugs,	the	1971	Convention	on	Psychotropic	Substances	and	the	1988	United	Nations	Convention	Against	Illicit	Traffic	
in	Narcotic	Drugs	and	Psychotropic	Substances,	Member	States	are	formally	required	to	provide	national	drug	control-
related	information	to	the	Secretary-General	of	the	United	Nations.	The	Commission	on	Narcotic	Drugs,	the	principal	drug	
policy	making	body	in	the	United	Nations,	developed	the	Annual	Reports	Questionnaire	(ARQ)	to	collect	such	informa-
tion.	
For	the	purposes	of	assessing	the	ATS	situation,	the	questionnaire	on	drug	use	and	the	questionnaire	on	the	illicit	supply	
of	drugs	are	most	relevant.	
The	ARQ	is	sent	out	by	UNODC	to	194	States	and	15	territories	to	gather	standardized	information	on	the	drug	control	
situation	and	received	107	replies	 to	 its	questionnaire	on	drug	abuse	and	106	replies	 to	 its	questionnaire	on	the	 illicit	
supply	of	drugs	relating	to	2009.	The	proportion	of	questionnaires	that	were	returned	by	region	in	2009	and	2010	for	
the	reporting	year	2009	were:	Europe	(80%	demand	and	88%	supply),	Asia	(64%	and	62%),	Americas	(59%	and	53%);	
Africa	 (27%	and	25%)	and	Oceania	 (12%	for	both	demand	and	supply).1	There	are	Member	States	and	regions	 that	
consistently	provide	either	no	data	or	 incomplete	data	 (i.e.,	 they	provide	 less	 than	50%	of	 the	minimum	critical	data	
necessary	in	the	ARQ)	largely	as	a	result	of	a	lack	of	infrastructure	to	generate,	manage,	analyse,	and	report	drug	infor-
mation.
These	are	also	regions	with	relatively	limited	resources	and	capacity	and	where	there	are	concerns	about	expansion	of	the	
ATS	problem.	For	example,	there	is	irregular	and/or	incomplete	reporting	in	parts	of	East	and	South-East	Asia,	South	Asia,	
the	Near	and	Middle	East,	subregions	within	the	Americas,	much	of	Africa	and	most	island	nations	of	Oceania.	
challenges in analysing ats data
seizure data
Global	 seizures	 of	ATS	 end-products	 are	 based	 largely	 on	 available	 data	 from	Member	 States.	 Seizure	 totals	 compile	
reported	seizures	weights	in	mass	(gram	or	kilogram),	volume	(ml/	lt.)	or	“units”	(e.g.,	pills,	ampoules,	doses,	etc.)	and	
convert	them	into	standardized	kilogram	equivalents.	
1	 More	questionnaires	are	returned	and	data	are	more	complete	for	illicit	supply	of	drugs,	because	data	reflect	law	enforcement	reporting	which	are	generally	
more	readily	available.
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arQ responses by member state, by completeness: 
Drug Demand
Source: UNODC ARQ
Many	Member	States	do	not	have	the	capacity	to	carry	out	forensic	work	and	profiling	on	seizures.	Therefore,	analysis	of	
seizure	data	 requires	many	assumptions	 to	be	made.	One	of	 the	assumptions	 is	 that	 seizures	were	 in	 fact	 tested	and	
properly	identified	-	versus	‘assumed	to	be	a	certain	substance’,	as	is	often	the	case.	There	is	also	little	information	on	the	
active	ingredient	of	ATS	seizures.	Pills	sold	as	ecstasy	may	not	always	contain	MDMA	but	amphetamine,	ketamine,	mephe-
drone	or	other	substances.	There	is	also	little	knowledge	about	the	amount	of	active	ingredient.	
Like	most	markets,	the	ATS	market	is	dynamic	and	constantly	changes.	The	end	product	that	is	sold	to	the	user,	often	
undergoes	 significant	 changes	 in	 terms	 of	 active	 ingredient	 and	 shape.	 Laboratory	 analysis	 of	 seized	 ecstasy	 pills	 in	
Canada,	for	example,	found	that	between	2001	and	2007	the	MDMA	content	declined	precipitously	from	69%	to	only	
3%,	with	concurrent	increases	in	the	proportion	of	methamphetamine	and	other	active	ingredients.	Similar	changes	are	
also	reported	from	other	regions,	e.g.	Europe.	
precursor seizures
As	discussed	previously,	there	is	mounting	evidence	that	ATS	manufacture,	specifically	methamphetamine,	is	occurring	via	
diverted	 pharmaceutical	 preparations	 and	other	 chemicals	 not	 under	 international	 control.	 For	 example,	 based	on	 an	
initial	 2007	 snapshot,	 pharmaceutical	 preparations	 accounted	 for	 a	 significant	proportion	of	 seized	pseudoephedrine.	
Additionally,	increased	utilization	of	Pre-Export	Notifications	(PEN)	has	quite	probably	stopped	or	suspended	some	diver-
sions	 and	 suspected	 shipments	 from	getting	 into	 the	 illicit	market,	 thus	 contributing	 to	 lower	 total	 seizure	 amounts.	
Precursors	that	are	diverted	from	national	distribution	channels	(i.e.,	domestic	diversions	within	a	country)	are	also	not	
reported.	The	lack	of	data	on	the	extent	of	domestic	diversions	most	likely	results	in	an	underestimation	of	the	precursors	
available	for	illicit	manufacture.
The	assumptions	related	to	manufacture	also	do	not	account	for	 improvements	 in	manufacturing	methods	or	regional	
variations	in	clandestine	conversion	ratios	(yields).	For	example,	in	2001,	Canada	reported	average	clandestine	laboratory	
yields	 for	 pseudoephedrine-based	methamphetamine	 of	 50%,	 and	 38%	 for	 sassafras	 oil-based	MDMA.2	 By	 2006,	
reported	yields	had	increased	substantially	to	71%	and	80%,	respectively.	These	increases	were	likely	due	to	changes	in	
manufacturing	methods,	 greater	 operator	 skills	 and/or	 greater	 laboratory	 sophistication.	Additionally,	 there	 are	 some	
2	 UNODC,	2003.
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variations	within	regions	even	when	using	similar	manufacturing	methods;	the	difference	between	Slovakia	and	the	Czech	
Republic	for	reported	yields	for	methamphetamine	using	the	same	precursors	was	14%	in	2009.
consumption estimates
One	of	the	main	challenges	in	assessing	the	demand	for	ATS	is	the	fact	that	countries	with	significant	populations	have	
little	if	any	national	household	survey	estimates	of	annual	drug	prevalence	or	other	types	of	estimates	(e.g.	national	school	
surveys)	that	could	be	extrapolated	into	national	or	regional	estimates.	Moreover,	existing	surveys	often	vary	substantially	
in	 their	 quality	 and	 timeliness.	 For	 example,	 the	World Drug Report 2008	 reported	amphetamine and ecstasy-group 
prevalence	estimates	 for	166	 countries	 and	 regions,3	with	an	average	estimate	 that	was	3.3	 years	old	at	 the	 time	of	
publication.	In	the	World	Drug	Report	2011	the	number	of	countries	and	regions	has	decreased	to	120,	with	the	data	
being	4.6	years	old	on	average.	While	some	improvements	have	been	seen,	other	regions	still	fall	far	behind.	
Most	ATS	estimates	have	been	 submitted	 from	Europe	 (87%),	 followed	by	 the	Americas	 (72%),	Asia	 (46%),	Oceania	
(25%)	and	Africa	(16%).	However,	even	though	72%	of	countries	in	the	Americas	have	reported	ATS	estimates,	these	
are	on	average	5.1	years	old,	only	slightly	more	recent	than	estimates	from	Africa	(5.2	years	old	on	average).	Countries	
in	the	Near	and	Middle	East,	where	most	of	the	world’s	amphetamine	is	seized,	have	some	of	the	oldest	prevalence	esti-
mates	available,	even	dating	back	to	2001.	
There	are	several	subregions	(e.g.,	East	and	South-East	Asia,	the	Near	and	Middle	East,	etc.)	which	encompass	multiple	
countries	where	household	 surveys	or	other	prevalence	estimates	are	outdated,	 lacking	 in	 completeness	or	quality,	or	
simply	do	not	exist.
price and purity data
Price	and	purity	data,	if	properly	collected	and	reported	can	be	useful	indicators	of	market	trends.	Short-term	changes	in	
the	market	are	often	first	reflected	in	purity	changes.	However,	particularly	where	ATS	are	concerned,	reporting	on	these	
indicators	is	not	consistent	and	there	are	several	difficulties	in	calculating	global	average	prices	since	ATS	prices	-	like	illicit	
drug	prices	in	general	-	differ	strongly	within	countries	as	well	as	across	countries	and	regions.	Additionally,	on	only	very	
few	occasions	are	the	corresponding	price	and	purity	data	sets	available.	All	of	this	is	because	many	Member	States	do	
not	have	-	as	yet	-	reliable	monitoring	systems	to	register	price	and	purity	data	that	would	be	required	for	market	value	
estimates	as	well	for	understanding	the	behaviour	of	drug	markets	and	the	impact	of	supply	and	demand	interventions.	
The	above	methodological	and	other	characteristics	of	the	ATS	market,	such	as	the	speed	and	flexibility	with	which	pat-
terns	of	manufacture,	trafficking	and	use	are	shifting,	coupled	with	the	lack	of	data	from	significant	geographic	regions,	
create	a	series	of	challenges	related	to	assessing	the	ATS	situation.	The	absence	of	accurate	and	timely	data	in	turn	poses	
a	 challenge	 to	Member	 States’	 law	enforcement,	 judicial,	 prison	and	health	 care	 systems,	which	need	 information	 to	
respond	adequately	to	the	current	ATS	situation	and	prevent	its	future	spread.	
3	 For	example,	regions	include	Scotland,	Northern	Ireland,	Gibraltar,	Taiwan	(Province	of	China)	and	Hong	Kong	(SAR	of	China).	
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After	cannabis,	ATS	are	the	second	most	widely	used	drugs	and	the	number	of	ATS	users	has	stabilized	at	high	levels:	
UNODC	estimates	that	the	annual	prevalence	for	amphetamines-group	substances	ranged	between	0.3%	and	1.3%	in	
2009,	 or	 some	14	 to	 57	million	 people	 aged	15-64.	 For	 the	 ecstasy	 group,	 global	 annual	 prevalence	 is	 estimated	 at	
between	0.2%	and	0.6%	of	the	population	aged	15-64,	or	some	11	to	28	million	past-year	users.	The	scale	of	the	prob-
lem	is	underreported,	as	some	large	countries	such	as	China	or	India	have	never	conducted	a	nationally	representative	
survey	to	collect	data	on	ATS	use.	
The	report	has	shown	that	the	ATS	problem	keeps	spreading	to	new	regions	and	countries	not	previously	affected	by	the	
phenomenon.	 It	 is	a	dynamic	problem	characterized	by	 rapid	changes	 in	 regional	 trends	 in	 the	 levels	of	manufacture,	
trafficking	and	use.	And	it	is	a	complex	problem,	with	a	great	variety	of	substances	sold	in	a	number	of	different	forms-	
as	powders,	pills	or	high	purity	crystals.
Due	to	the	complexity	and	dynamic	nature	of	the	ATS	phenomenon,	the	capacity	to	monitor	the	illicit	manufacture,	traf-
ficking	and	use	of	ATS	is	a	sizeable	and	often	enormous	challenge	for	many	Governments.	Attention	to	the	ATS	problem	
remains	uneven	across	the	world.	Functional	drug	monitoring	systems	that	provide	data	on	all	aspects	of	the	phenomenon	
are	few	and	far	between,	and,	to	a	large	extent,	located	in	developed	countries.1	Australia	and	New	Zealand	have	estab-
lished	extensive	monitoring	mechanisms	to	gauge	the	phenomenon.	In	Canada	and	the	USA,	attention	to	ATS	use	and	
its	consequences	has	renewed	interest	in	better	monitoring	the	problem.	The	European	Monitoring	Centre	on	Drugs	and	
Drug	Addiction	has	a	system	for	monitoring	drug	markets	and	the	emergence	of	new	psychoactive	substances.	
In	East	and	South-East	Asia	‒	a	region	confronted	with	a	significant	methamphetamine	problem	as	well	as	use	of	ecstasy	
and	manufacture,	 trafficking	and	use	of	other	synthetic	substances	such	as	ketamine	–	a	monitoring	system	has	been	
established,	with	the	assistance	of	the	UNODC	Global	Synthetics	Monitoring:	Analyses,	Reporting	and	Trends	Programme	
(SMART).	The	extension	of	Global	SMART	to	Latin	America	in	2010	is	expected	to	further	strengthen	monitoring	efforts	
of	Governments	in	that	region	to	assess	the	extent,	patterns	and	trends	of	the	ATS	problem.	
There	is	a	need,	however,	to	establish	and	further	develop	ways	to	assess	the	ATS	situation	in	other	regions.	In	the	Near	
and	Middle	East,	the	region	with	the	highest	seizures	of	amphetamines,	there	is	a	strong	need	to	broaden	the	information	
and	knowledge	base.	Data	on	ATS	use	are	almost	non-existent	and	little	is	known	about	the	origin	of	the	pills	which	are	
seized	in	large	quantities	in	most	countries	in	the	region.	Africa,	increasingly	associated	with	trafficking	of	precursors	and	
expanding	ATS	manufacturing	capacity,	is	another	region	which	would	benefit	from	investment	into	drug-related	prob-
lems.	At	present,	few	countries	in	Africa	(South	Africa	being	the	notable	exception)	have	drug	use	monitoring	systems.	
Most	Pacific	Island	States	and	territories	lack	infrastructure	to	collect	and	provide	information	on	ATS	yet	are	increasingly	
associated	with	trafficking	of	precursors	and	the	transit	of	ATS.	Unfortunately,	worsening	ATS	problems	often	coincide	
with	lack	of	infrastructure,	resources	and	experience	with	ATS	markets.	
It	has	often	been	observed	that	criminal	organizations	target	vulnerable	countries	close	to	developed	markets	for	 illicit	
manufacture	operations	or	to	transit	ATS.	The	growth	in	illicit	activity	in	these	locations	is	reflected	in	increasing	seizures	
as	well	as	levels	of	use,	the	latter	being	a	result	of	the	spill-over	of	ATS	to	previously	unaffected	regions	and	countries.
The	exact	relationship	between	‘supply-push’	and	‘demand-pull’	factors	remains	unclear,	and	many	of	the	recent	trends	
are	 not	 understood	well	 enough	 or	 quickly	 enough	 to	 enable	 the	 design	 of	 the	 required	 strategic	 interventions	 and	
responses	 by	 national	 law	 enforcement,	 judicial,	 regulatory	 and	health	 care	 systems.	Developing	 an	 evidence	base	 of	
actionable	information	to	counter	the	challenge	of	ATS	relies	on	a	variety	of	comparable	and	timely	data	but	despite	many	
efforts	made	by	Governments,	data	gaps	remain.	While	data	and	other	intelligence	on	the	size	and	sophistication	of	illicit	
ATS	laboratories	or	forensic	profiles	of	the	substances	sold	in	illicit	ATS	markets	exist	in	some	countries,	such	information	
1	 There	is	no	established	convention	for	the	designation	of	“developed”	and	“developing”	countries	or	areas	in	the	United	Nations	system.	See	United	Nations	
Standard	country	or	Area	Codes	for	Statistical	Use.	Series	M,	No.	49,	Rev.	4	(United	Nations	publication,	Sales	No.	M.98.XVII.9).	Therefore,	for	the	purposes	
of	this	analysis,	“developed	countries”	are	the	member	countries	of	the	Organisation	for	Economic	Co-operation	and	Development	(OECD).
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is	often	not	comparable	between	countries	and	regions	or	between	years.	As	shown	above,	data	on	ATS	use	is	elusive	
for	some	of	the	largest	countries	in	the	world.	Other	gaps	are	specific	to	certain	regions	or	countries.
next steps
Addressing	the	problem	requires,	first	and	foremost,	a	better	understanding	of	the	ATS	phenomenon	at	the	global	level	
and	in	selected	key	regions	which	are	particularly	vulnerable	to	the	ATS	phenomenon.	Such	an	evidence	base	will	provide	
a	foundation	for	improved	understanding	and	effective	assessment	of	the	ATS	situation	and	the	patterns	and	distribution	
of	their	use.	Data	will	also	be	useful	to	Governments	in	planning	effective	operational	interventions	and	other	responses	
to	the	ATS	problem.	
A	wide	range	of	targeted	practical	measures	is	required.	Action	will	include	strategies	to	raise	awareness	of	ATS	manu-
facture,	 trafficking	 and	 use	 among	 law	 enforcement,	 health	 and	 regulatory	 authorities	 as	well	 as	 the	 general	 public;	
advancing	the	systematic	collection	of	data	on	ATS	use,	the	diversion	of	precursors	and	preparations	containing	ATS	and	
using	the	data	 in	 implementing	appropriate	 responses	 to	 the	problem;	assessing	the	health,	safety	and	environmental	
implications	related	to	illicit	manufacture;	and	developing	and	implementing	measures	to	address	the	demand	and	provide	
treatment	services	for	ATS	users.	
The	 international	community	has	recognized,	most	notably	 in	the	1998	UNGASS	Action Plan on ATS	as	well	as	 in	the	
Political	Declaration	and	Plan	of	Action	on	 International	Cooperation	 towards	an	 Integrated	and	Balanced	Strategy	 to	
Counter	the	World	Drug	Problem	adopted	in	2008,	that	ATS	continue	to	pose	a	serious	and	constantly	evolving	challenge	
to	 international	drug	 control	 efforts,	 a	 challenge,	which	 threatens	 the	 security,	health	and	welfare	of	 the	population,	
especially	youth	and	has	called	on	Member	States	to	take	comprehensive	national,	regional	and	global	responses.	
To	properly	respond	to	the	ATS	problem,	further	investments	in	ATS	information	systems	that	provide	accurate,	timely	and	
actionable	information	with	detail	at	the	subregional	or	national	level,	remain	among	the	highest	priorities	for	action.
Emerging	ATS	markets	need	to	be	monitored	and	addressed	proactively	before	they	are	established	and	become	a	sig-
nificant	added	burden	to	national	health	and	justice	systems.	UNODC	will	continue	to	identify	and	communicate	informa-
tion	on	emerging	trends	to	assist	relevant	Government	authorities	in	their	understanding	of	the	ATS	market.
Illicit	ATS	manufacture	needs	to	be	targeted	at	the	origin	by	further	increasing	the	effectiveness	of	precursor	control.	Such	
efforts	should	also	include	preventing	the	diversion	of	preparations	containing	ATS	precursors	and	of	derivatives	specially	
designed	to	circumvent	existing	controls.
Finally,	it	is	evident	from	this	report	that	a	worsening	ATS	problem	is	correlated	with	a	lack	of	infrastructure	and	resources,	
and	priority	must	therefore	be	given	to	those	vulnerable	countries	and	subregions	where	ATS	are	spreading	most	rapidly	
and	where	data	are	known	to	be	lacking	or	insufficient.	
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